<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006875.pub3" GROUP_ID="COLOCA" ID="606007041616021964" MERGED_FROM="" MODIFIED="2016-12-09 09:35:50 +0000" MODIFIED_BY="Henning Keinke Andersen" REVIEW_NO="113" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2016-12-09 09:35:47 +0000" MODIFIED_BY="Henning Keinke Andersen">
<TITLE MODIFIED="2016-10-17 14:03:53 +0200" MODIFIED_BY="Anne Lawson">Second-line systemic therapy for metastatic colorectal cancer</TITLE>
<CONTACT MODIFIED="2016-12-09 09:35:47 +0000" MODIFIED_BY="Henning Keinke Andersen"><PERSON ID="FCEB45A182E26AA200DA2AF39360FFBF" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Simone</FIRST_NAME><LAST_NAME>Mocellin</LAST_NAME><POSITION>MD, PhD</POSITION><EMAIL_1>simone.mocellin@unipd.it</EMAIL_1><EMAIL_2>mocellins@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Surgery, Oncology and Gastroenterology</DEPARTMENT><ORGANISATION>University of Padova</ORGANISATION><ADDRESS_1>Via Giustiniani 2</ADDRESS_1><CITY>Padova</CITY><ZIP>35128</ZIP><REGION>Veneto</REGION><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>++ 0498211851</PHONE_1><FAX_1>++ 049 651891</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-12-09 09:35:47 +0000" MODIFIED_BY="Henning Keinke Andersen"><PERSON ID="FCEB45A182E26AA200DA2AF39360FFBF" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Simone</FIRST_NAME><LAST_NAME>Mocellin</LAST_NAME><POSITION>MD, PhD</POSITION><EMAIL_1>simone.mocellin@unipd.it</EMAIL_1><EMAIL_2>mocellins@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Surgery, Oncology and Gastroenterology</DEPARTMENT><ORGANISATION>University of Padova</ORGANISATION><ADDRESS_1>Via Giustiniani 2</ADDRESS_1><CITY>Padova</CITY><ZIP>35128</ZIP><REGION>Veneto</REGION><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>++ 0498211851</PHONE_1><FAX_1>++ 049 651891</FAX_1></ADDRESS></PERSON><PERSON ID="z1506221310203235005422994219551" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Zora</FIRST_NAME><LAST_NAME>Baretta</LAST_NAME><EMAIL_1>zora.baretta@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>U.O.C. di Oncologia ULSS5 Ovest Vicentino</DEPARTMENT><ORGANISATION>Ospedale di Montecchio</ORGANISATION><ADDRESS_1>Montecchio Maggiore</ADDRESS_1><CITY>Vicenza</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="AAD7845D82E26AA20130726F85E76FD4" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Marta</FIRST_NAME><LAST_NAME>Roqué i Figuls</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>mroque@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 171</ADDRESS_1><ADDRESS_2>Edifici Casa de Convalescència</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08041</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><PHONE_2>+34 935 537 808</PHONE_2><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="12177" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ivan</FIRST_NAME><LAST_NAME>Solà</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>isola@santpau.cat</EMAIL_1><EMAIL_2>ensayos@cochrane.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="4204409182E26AA201D1E765E27FF009" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marta</FIRST_NAME><LAST_NAME>Martin-Richard</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Oncologist</POSITION><EMAIL_1>MMartinRi@santpau.es</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Oncology</DEPARTMENT><ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08025</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34935565637</PHONE_1></ADDRESS></PERSON><PERSON ID="z1311201256043078176992859186081" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Sara</FIRST_NAME><LAST_NAME>Hallum</LAST_NAME><POSITION>Editorial Assistant</POSITION><EMAIL_1>sara.hallum@regionh.dk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Colorectal Cancer Group</DEPARTMENT><ORGANISATION>Cochrane</ORGANISATION><ADDRESS_1>23 Bispebjerg Bakke</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2400 NV</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35313731</PHONE_1></ADDRESS></PERSON><PERSON ID="D3B1F77E82E26AA200831C1940F4DA2E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xavier</FIRST_NAME><LAST_NAME>Bonfill Cosp</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>xbonfill@santpau.cat</EMAIL_1><EMAIL_2>director@cochrane.es, XBonfill@hsp.santpau.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret, 167</ADDRESS_1><ADDRESS_2>Pavilion 18 (D-13)</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 10</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 0</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-06-08 08:22:18 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="18" MONTH="5" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="5" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="5" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-11-07 11:26:41 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-11-07 11:26:41 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>New search performed and 27 new studies incorporated in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-23 10:31:51 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-11 11:53:58 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment: review finalised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-05 15:42:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR">
<DATE DAY="16" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Instituto de Salud Carlos III. PI04/2309</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-12-09 09:02:30 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-10-19 09:39:13 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-10-19 09:37:27 +0200" MODIFIED_BY="[Empty name]">Second-line therapy can increase survival of people with metastatic colorectal cancer who did not respond to a first treatment</TITLE>
<SUMMARY_BODY MODIFIED="2016-10-19 09:39:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>We reviewed the ability of chemotherapy drugs (medicines used to treat cancer) to reduce tumour size and improve survival in people with metastatic colorectal cancer who had not responded to a prior treatment. We also looked at the side effects caused by the different drug regimens.</P>
<P>
<B>Background</B>
</P>
<P>People with metastatic colorectal cancer (cancer that has spread to sites other than the colon) and whose disease had progressed despite one prior chemotherapy (first-line treatment) treatment, and who can be offered a second therapy (second-line treatment) with the aim of improving their poor outcome (prognosis). The treatment regimens compared were systemic (administered intravenously (through a vein)).</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence is current to May 2016. In this updated review, we identified 34 clinical trials that compared second-line therapy with either no chemotherapy (best supportive care) or an alternative second-line therapy, so addressing the issue of second-line therapy performance in people with metastatic colorectal cancer.</P>
<P>
<B>Main results</B>
</P>
<P>Available evidence seemed to support the use of second-line therapy because it improved survival expectations as compared to best supportive care, although this was reported in only one small trial and the result would need to be confirmed in further research. Moreover, we found that modern chemotherapy regimens were more effective than older ones that contained a drug called 5-fluorouracil, that combination chemotherapy was more effective than single agent chemotherapy and that targeted agents (so called 'smart drugs' that attack the cancer cells and do little damage to normal cells) increased the effectiveness of conventional chemotherapy. Generally, toxicity increased as effectiveness increased.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The main conclusions of this review were based on moderate to high quality evidence. When the quality of the evidence was considered low or moderate, this was generally due to inconsistency in the main results (i.e. the result for progression-free survival (time from the start of second-line treatment to progression of the cancer) was not confirmed by overall survival (time from the start of second-line treatment to death from any cause)) and the low numbers of participants included in the analyses. Nevertheless, it should be remembered that progression-free survival nowadays is considered a reliable surrogate of overall survival (which includes all deaths, not just cancer-related, and requires longer follow-up to obtain an accurate estimate) in the setting of second-line therapy for metastatic colorectal cancer. Most of the trials did not report quality of life, which prevented us formally investigating the balance between survival benefits provided by second-line systemic therapy and treatment-related toxicity.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-11-07 11:17:48 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-10-19 09:17:00 +0200" MODIFIED_BY="[Empty name]">
<P>The therapeutic management of people with metastatic colorectal cancer (CRC) who did not respond to first-line treatment represents a formidable challenge.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-10-19 09:17:04 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and toxicity of second-line systemic therapy in people with metastatic CRC.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-11-07 11:17:48 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 4), Ovid MEDLINE (1950 to May 2016), Ovid MEDLINE In-process &amp; Other Non-Indexed Citations (1946 to May 2016) and Ovid Embase (1974 to May 2016). There were no language or date of publication restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-10-19 09:17:26 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) assessing the efficacy (survival, tumour response) and toxicity (incidence of severe adverse effects (SAEs)) of second-line systemic therapy (single or combined treatment with any anticancer drug, at any dose and number of cycles) in people with metastatic CRC that progressed, recurred or did not respond to first-line systemic therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-10-19 09:20:37 +0200" MODIFIED_BY="[Empty name]">
<P>Authors performed a descriptive analysis of each included RCT in terms of primary (survival) and secondary (tumour response, toxicity) endpoints. In the light of the variety of drug regimens tested in the included trials, we could carry out meta-analysis considering classes of (rather than single) anticancer regimens; to this aim, we applied the random-effects model to pool the data. We used hazard ratios (HRs) and risk ratios (RRs) to describe the strength of the association for survival (overall (OS) and progression-free survival (PFS)) and dichotomous (overall response rate (ORR) and SAE rate) data, respectively, with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-10-19 09:23:53 +0200" MODIFIED_BY="[Empty name]">
<P>Thirty-four RCTs (enrolling 13,787 participants) fulfilled the eligibility criteria. Available evidence enabled us to address multiple clinical issues regarding the survival effects of second-line systemic therapy of people with metastatic CRC.<BR/>1. Chemotherapy (irinotecan) was more effective than best supportive care (HR for OS: 0.58, 95% CI 0.43 to 0.80; 1 RCT; moderate-quality evidence); 2. modern chemotherapy (FOLFOX (5-fluorouracil plus leucovorin plus oxaliplatin), irinotecan) is more effective than outdated chemotherapy (5-fluorouracil) (HR for PFS: 0.59, 95% CI 0.49 to 0.73; 2 RCTs; high-quality evidence) (HR for OS: 0.69, 95% CI 0.51 to 0.94; 1 RCT; moderate-quality evidence); 3. irinotecan-based combinations were more effective than irinotecan alone (HR for PFS: 0.68, 95% CI 0.60 to 0.76; 6 RCTs; moderate-quality evidence); 4. targeted agents improved the efficacy of conventional chemotherapy both when considered together (HR for OS: 0.84, 95% CI 0.77 to 0.91; 6 RCTs; high-quality evidence) and when bevacizumab was used alone (HR for PFS: 0.67, 95% CI 0.60 to 0.75; 4 RCTs; high-quality evidence).</P>
<P>With regard to secondary endpoints, tumour response rates generally paralleled the survival results; moreover, higher anticancer efficacy was generally associated with worse treatment-related toxicity, with the important exception of bevacizumab-containing regimens, where the addition of the targeted agent to chemotherapy did not result in a significant increase in the rate of SAE. Finally, we found that oral (instead of intravenous) fluoropyrimidines significantly reduced the incidence of adverse effects (without compromising efficacy) in people treated with oxaliplatin-based regimens.</P>
<P>We could not draw any conclusions on other debated aspects in this field of oncology, such as ranking of treatments (not all possible comparisons have been tested and many comparisons were based on single trials enrolling a small number of participants) and quality of life (virtually no data available).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-10-19 09:37:19 +0200" MODIFIED_BY="[Empty name]">
<P>Systemic therapy offers a survival benefit to people with metastatic CRC who did not respond to first-line treatment, especially when targeted agents are combined with conventional chemotherapeutic drugs. Further research is needed to define the optimal regimen and to identify people who most benefit from each treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-11-07 11:18:36 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-10-19 09:40:30 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-10-19 09:39:24 +0200" MODIFIED_BY="[Empty name]">
<P>Colorectal cancer (CRC) is one of the most common causes of cancer and cancer death worldwide and the third cause in Western countries (<LINK REF="REF-Ferlay-2015" TYPE="REFERENCE">Ferlay 2015</LINK>; <LINK REF="REF-Torre-2015" TYPE="REFERENCE">Torre 2015</LINK>). The World Health Organization (WHO) estimates that there are about one million cases annually worldwide, with almost 500,000 deaths (<LINK REF="REF-WHO-2003" TYPE="REFERENCE">WHO 2003</LINK>). About 50% of all newly diagnosed people have metastatic disease at presentation (so called synchronous metastasis) or will ultimately develop metastatic disease (metachronous metastasis), regardless of treatment (<LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>; <LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>; <LINK REF="REF-Saunders-2006" TYPE="REFERENCE">Saunders 2006</LINK>). Except for selected people with liver only resectable metastatic disease where radical surgery can be followed by long survival times (<LINK REF="REF-Adam-2012" TYPE="REFERENCE">Adam 2012</LINK>; <LINK REF="REF-Schmoll-2012" TYPE="REFERENCE">Schmoll 2012</LINK>), systemic treatment is the treatment of choice in metastatic disease since it has proved to be effective in prolonging survival (<LINK REF="REF-Best-2000" TYPE="REFERENCE">Best 2000</LINK>; <LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>; <LINK REF="REF-Gustavsson-2015" TYPE="REFERENCE">Gustavsson 2015</LINK>; <LINK REF="REF-Kirstein-2014" TYPE="REFERENCE">Kirstein 2014</LINK>; <LINK REF="REF-Schmoll-2012" TYPE="REFERENCE">Schmoll 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-10-19 09:40:02 +0200" MODIFIED_BY="[Empty name]">
<P>Until the introduction of irinotecan and oxaliplatin in 2000, standard first-line chemotherapy treatment for metastatic CRC was based on regimens containing 5-fluorouracil (5FU) and leucovorin. Currently, the combination regimens FOLFOX (5FU plus leucovorin plus oxaliplatin) and FOLFIRI (5FU plus leucovorin plus irinotecan) are considered standard therapies in first-line treatment (<LINK REF="REF-Grothey-2006" TYPE="REFERENCE">Grothey 2006</LINK>; <LINK REF="REF-NICE-2005" TYPE="REFERENCE">NICE 2005</LINK>). Moreover, so-called targeted therapies based on agents that selectively act on molecules that play a significant role in cancer progression (e.g. epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF)) have further improved life expectancy (<LINK REF="REF-Kirstein-2014" TYPE="REFERENCE">Kirstein 2014</LINK>; <LINK REF="REF-Marques-2014" TYPE="REFERENCE">Marques 2014</LINK>). However, most (if not all) people with metastatic disease will eventually present clinical failure (i.e. disease recurrence or progression) or lack of response to first-line treatment, thus becoming potential candidates for second-line systemic therapy (<LINK REF="REF-Arnold-2013" TYPE="REFERENCE">Arnold 2013</LINK>; <LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>; <LINK REF="REF-Goldberg-2006" TYPE="REFERENCE">Goldberg 2006</LINK>; <LINK REF="REF-Gustavsson-2015" TYPE="REFERENCE">Gustavsson 2015</LINK>; <LINK REF="REF-Kirstein-2014" TYPE="REFERENCE">Kirstein 2014</LINK>; <LINK REF="REF-Marques-2014" TYPE="REFERENCE">Marques 2014</LINK>; <LINK REF="REF-Rougier-2005" TYPE="REFERENCE">Rougier 2005</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2016-10-19 09:40:30 +0200" MODIFIED_BY="[Empty name]">
<P>The performance (i.e. efficacy and toxicity) of second-line systemic therapy is unclear. In particular, there is uncertainty about the efficacy of chemotherapy in this population (as compared to observation/best supportive care), the role of targeted agents (e.g. whether or not they increase the efficacy of conventional chemotherapy), the optimal regimen in terms of type and number of anticancer agents and the schedule of treatment delivery. The purpose of this systematic review was to summarize the available evidence on the performance of second-line systemic therapy in people with distant metastatic CRC.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-10-19 09:40:31 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and toxicity of second-line systemic therapy in people with metastatic CRC.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-11-07 11:18:11 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-11-07 11:18:03 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-10-19 09:40:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) in people with distant metastatic (or locally advanced unresectable) CRC, in which a second-line systemic therapy regimen is compared with placebo, best supportive care or another second-line systemic therapy regimen. Cluster-randomized trials and cross-over trials were not eligible.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-11-07 11:18:03 +0100" MODIFIED_BY="[Empty name]">
<P>People with distant metastatic or locally advanced unresectable CRC (that is, TNM stage IV disease) that had progressed, recurred or did not respond to first-line systemic therapy. People eligible for surgery (e.g. with resectable liver metastasis) were not included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-10-19 09:40:48 +0200" MODIFIED_BY="[Empty name]">
<P>Any second-line systemic therapy regimen (single agent or combinatory regimen). We considered the following comparisons:<BR/>
</P>
<UL>
<LI>second-line systemic therapy versus control (placebo or best supportive care);</LI>
<LI>comparisons of different second-line systemic therapy regimens.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-10-19 09:41:48 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-10-19 09:41:10 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Overall survival (OS, time from the start of second-line treatment to death by any cause).</LI>
<LI>Progression-free survival (PFS, time from the start of second-line treatment to disease progression).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-10-19 09:41:48 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Overall tumour response rate (ORR (complete and partial response), according to WHO (<LINK REF="REF-WHO-1979" TYPE="REFERENCE">WHO 1979</LINK>), or Response Evaluation Criteria In Solid Tumours (RECIST) criteria (<LINK REF="REF-Therasse-2000" TYPE="REFERENCE">Therasse 2000</LINK>)).</LI>
<LI>Severe adverse events (SAE, treatment-related grade 3 to 5 toxicity in Common Terminology Criteria for Adverse Events (CTCAE) (<LINK REF="REF-CTCAE" TYPE="REFERENCE">CTCAE</LINK>) scale, or equivalent).</LI>
<LI>Quality of life (QoL, as assessed by dedicated questionnaires such as the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-11-07 11:18:11 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-11-07 11:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted a comprehensive literature search to identify all published and unpublished RCTs applying no language or date of publication restrictions. We searched the following electronic databases:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 4) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>Ovid MEDLINE (1950 to May 2016) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>Ovid MEDLINE In-process &amp; Other Non-Indexed Citations (1946 to May 2016) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>); and</LI>
<LI>Ovid EMBASE (1974 to May 2016) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
<P>We applied a sensitivity- and precision maximizing search filter to the MEDLINE search strategy in accordance with recommendations from Chapter 6 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-10-19 09:42:41 +0200" MODIFIED_BY="[Empty name]">
<P>We checked the reference lists of relevant studies as well as those of both qualitative and quantitative reviews to identify additional trials.</P>
<P>Finally, we searched the following web-based electronic databases in May 2016: <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>; <A HREF="http://www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</A>; <A HREF="http://www.eortc.org/clinical-trials">www.eortc.org/clinical-trials</A>, and <A HREF="http://www.cancerresearchuk.org">www.cancerresearchuk.org</A>.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-10-19 09:49:01 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-10-19 09:43:00 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors (SM, ZB) independently screened the results of the bibliographic search, assessing studies against the inclusion criteria. We retrieved full copies of trial reports when necessary for a more thorough assessment. We resolved disagreements by discussion and consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-10-19 09:44:12 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors (SM, ZB) independently extracted the relevant data from the included trials. We resolved disagreements by discussion and consensus. We extracted information regarding trial quality, participants and disease features, study design and trial results. As regards trial findings, we retrieved and analyzed intention-to-treat data. For survival data, for each comparison we extracted the corresponding hazard ratio (HR) (and its 95% confidence interval (CI)) relative to the experimental versus control arm; when these summary data were not reported in the study article, we calculated them from Kaplan-Meier survival curves (if available) as per <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>. For dichotomous data (tumour response and toxicity), we extracted events and total number of participants from both experimental and control arm.</P>
<P>In order to evaluate whether the number of participants included in a trial (or meta-analysis of trials) was adequate to draw robust conclusions (i.e. based on adequately powered analyses) regarding the lack of difference between two treatments, we calculated that the minimum sample size needed to get an 80% statistical power (considering an alpha level of significance of 5%, a one-year survival rate in the control population of 20% and an expected HR of 0.75) was about 500.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-10-19 09:45:18 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors (SM, ZB) independently assessed the risk of bias according to the Cochrane 'Risk of bias' tool within the following domains (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<UL>
<LI>random allocation generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding of participants and personnel;</LI>
<LI>blinding of outcome assessment;</LI>
<LI>incomplete outcome data;</LI>
<LI>selective reporting bias; and</LI>
<LI>other biases (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</LI>
</UL>
<P>Criteria for judging as low, high or unclear risk of bias within each domain were classified based on the 'Risk of bias' assessment tool (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) from Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We summarized the risk of bias for each included study in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>We resolved any disagreements by discussion or by involving a third author.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-10-19 09:45:28 +0200" MODIFIED_BY="[Empty name]">
<P>For each included trial, we measured treatment effects with HR for survival (time-to-event) data and risk ratio (RR) for dichotomous variables (i.e. ORR and SAE rate). We presented each effect estimate with its 95% confidence intervals (CIs) as a measure of uncertainty.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-07-07 10:09:32 +0200" MODIFIED_BY="[Empty name]">
<P>We did not encounter unit of analysis issues (we chose to exclude cluster-randomized trials and cross-over trials).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-10-19 09:45:45 +0200" MODIFIED_BY="[Empty name]">
<P>The eligible articles did not report all outcomes of interest. We contacted the corresponding authors of these articles by email, but we could not retrieve the missing data either because the study had not been designed to collect those data or because we did not receive a reply. In case of dropouts, we considered the best-case and worse-case scenarios (for binary data only, as for time to event data this is unfeasible).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-10-19 09:46:42 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed the consistency of results (effect sizes) across studies using the I<SUP>2</SUP> statistic (which indicates the percentage of the variability in effect estimates because of true between-study variance rather than sampling error (within-study variance)). Heterogeneity was considered low, moderate or high for I<SUP>2</SUP> values of less than 25%, 26% to 50% or greater than 50%, respectively (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-10-19 09:47:37 +0200" MODIFIED_BY="[Empty name]">
<P>Funnel plot is usually utilized to detect the so-called 'small-study effect' (<LINK REF="REF-Sterne-2000" TYPE="REFERENCE">Sterne 2000</LINK>). Publication and selection biases in meta-analysis are more likely to affect small studies, which also tend to be of lower methodological quality: this may lead to a smaller study effect, where the smaller studies in a meta-analysis show larger treatment effects. Funnel plot asymmetry is formally investigated with the Egger linear regression approach: to be more conservative, usually this test is considered statistically significant when the P value is less than 0.1. However, since the test is poorly reliable (due to low power to detect bias, if present) when the number of trials is low (e.g. fewer than 10), we could not assess the small-study effect (all meta-analyses included fewer than 10 studies).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-10-19 09:48:12 +0200" MODIFIED_BY="[Empty name]">
<P>When possible (at least two RCTs available), we pooled summary data for survival (OS, PFS) and dichotomous outcomes (ORR, SAE rate) obtained from relevant trials by means of meta-analysis using the random-effects model (inverse variance method). Since the estimation of between-study variance can be inaccurate when the number of trials is small, we adopted a fixed-effect model when fewer than four trials were available. Otherwise, we reported summary data (HRs, RRs along with their 95% CI) of single RCTs.</P>
<P>For survival and toxicity data, a ratio lower than 1 favours the intervention, whereas for tumour response data a ratio greater than 1 favours the intervention.</P>
<P>Finally, we calculated the event rates in the control and experimental groups in order to provide readers with information on the absolute effect of treatment on participants' outcomes. In the light of the multiple comparisons we considered, we limited these calculations to the primary outcomes (OS and PFS), on which the main conclusions are based; since primary outcomes are based on survival data, the event rates were calculated as per <LINK REF="REF-Altman-1999" TYPE="REFERENCE">Altman 1999</LINK>.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-10-19 09:48:31 +0200" MODIFIED_BY="[Empty name]">
<P>We explored the potential sources of heterogeneity by means of subgroup analysis, which brings together RCTs more homogeneous by one or more features such as drug regimen (e.g. with or without targeted anticancer agents), study design (e.g. open label versus double blind), participants' characteristics (e.g. performance status, mean age) or disease characteristics (e.g. tumour stage). Testing the statistical difference between subgroups can be useful to identify regimens with better efficacy (or lower toxicity) or subsets of participants who benefit most from a given treatment. Unfortunately, the limited number of RCTs and the frequent lack of information on all these aspects did not allow us to perform all the planned subgroup analyses. Finally, sensitivity analysis was also carried out to investigate heterogeneity (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>).</P>
<P>Effect differences across subgroups were formally tested using the Cochrane Q-test for heterogeneity, as performed by the Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-10-19 09:49:01 +0200" MODIFIED_BY="[Empty name]">
<P>We used a sensitivity analysis to assess the impact of specific trials (e.g. those with doubts about the randomization process or those characterized by a high risk of bias) by excluding them from the meta-analysis (if at least two RCTs were available). This can help test the robustness of meta-analysis findings, especially in the presence of result uncertainty (e.g. in the presence of substantial between-study heterogeneity).</P>
<SUBSECTION>
<HEADING LEVEL="3">Evidence grading</HEADING>
<P>We used the GRADE system to grade the quality of evidence (regarding primary outcome, that is, survival) into four levels (<LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>).</P>
<TABLE COLS="2" ROWS="5">
<TR>
<TH VALIGN="TOP">
<P>
<B>Grade</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Definition</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>Further research is very unlikely to change our confidence in the estimate of effect</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Further research is likely to have an impact on our confidence in the estimate of effect and may change the estimate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Low</P>
</TD>
<TD VALIGN="TOP">
<P>Further research is very likely to have an important impact on our confidence on the estimate of effect and is likely to change the estimate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
<TD VALIGN="TOP">
<P>Any estimate of effect is very uncertain</P>
</TD>
</TR>
</TABLE>
<P>The quality of evidence can be downgraded by one (serious concern) or two (very serious concern) levels for the following reasons: risk of bias (see <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>), inconsistency (unexplained heterogeneity, inconsistency of results), indirectness (indirect population, intervention, control, outcomes), imprecision (wide CIs, single trial) and risk of publication bias. The quality can also be upgraded by one level due to large summary effect (we chose HR less than 0.6).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-11-07 11:18:30 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-10-19 10:05:28 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-10-19 09:49:22 +0200" MODIFIED_BY="[Empty name]">
<P>We identified 1826 records through the electronic searches of the Cochrane Library (279 records), MEDLINE (332 records), MEDLINE In-process &amp; Other Non-indexed citations (548 records) and Embase (667 records). We excluded 791 duplicates and 968 clearly irrelevant records through reading titles and abstracts. We retrieved the remaining 67 records for further assessment. Upon full-text reading, we excluded 41 studies for reasons listed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. We identified eight additional studies through scanning reference lists of the identified RCTs.</P>
<P>In total, 34 RCTs fulfilled the inclusion criteria. The study flow diagram is shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>A list of abbreviations used in the text are reported in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-10-19 09:52:45 +0200" MODIFIED_BY="[Empty name]">
<P>The main features of each of the 34 included trials (overall enrolling 13,787 participants; range: 55 to 1298; median: 247) are reported in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. One trial compared four arms (<LINK REF="STD-Bendell-2013_x005f_folfiri" TYPE="STUDY">Bendell 2013_folfiri</LINK>), four trials compared three arms (<LINK REF="STD-Cohn-2013_x005f_conat" TYPE="STUDY">Cohn 2013_conat</LINK>; <LINK REF="STD-_x00c9_lez-2015" TYPE="STUDY">Élez 2015</LINK>; <LINK REF="STD-O_x0027_Neil-2014" TYPE="STUDY">O'Neil 2014</LINK>; <LINK REF="STD-Rothenberg-2003_x005f_folfox" TYPE="STUDY">Rothenberg 2003_folfox</LINK>), and the remaining 27 trials compared two arms. Only one trial compared a second-line chemotherapy regimen with best supportive care (<LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>). The other included studies compared two or more different second-line treatments.</P>
<P>All trials were comparable in terms of baseline characteristics (all participants enrolled had metastatic CRC and had not responded to a first-line treatment), except for the first-line regimens that could be different. As regards outcomes, OS, PFS, ORR and SAE data were reported in 31, 31, 30 and 34 trials, respectively.</P>
<P>The drug regimens tested were heterogeneous. In particular, 17 different anticancer agents (alone or in combination) were tested: seven chemotherapy agents (5FU, oxaliplatin, irinotecan, mitomycin-C, raltitrexed, capecitabine, S-1) and 10 targeted agents (seven monoclonal antibodies: bevacizumab, cetuximab, panituzumab, abituzumab, conatumumab, ganitumab, ramucirumab; two small molecule inhibitors: vatalanib and gefitinib; and two recombinant blocking proteins: aflibercept and trebananib). The main features of these compounds are reported in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Two compounds (leucovorin and hyaluronan) utilized in some RCTs have no anticancer activity per se, but increase (leucovorin) or are supposed to increase (hyaluronan) the anticancer activity of chemotherapy agents.</P>
<P>The RCTs tested the following 25 drug combinations: 1. FOLFOX (5FU plus leucovorin plus oxaliplatin), 2. FOLFIRI (5FU plus leucovorin plus irinotecan), 3. IRIS (S-1 plus irinotecan), 4. XELOX (capecitabine plus oxaliplatin), 5. bevacizumab plus FOLFIRI, 6. bevacizumab plus FOLFOX, 7. cetuximab plus irinotecan, 8. panitumumab plus FOLFIRI, 9. panitumumab plus irinotecan, 10. panitumumab plus bevacizumab plus FOLFIRI, 11. axitinib plus FOLFOX, 12. axitinib plus FOLFIRI, 13. conatumumab plus FOLFIRI, 14. ganitumab plus FOLFIRI, 15. hyaluronan plus irinotecan, 16. oxaliplatin plus irinotecan, 17. linifanib plus FOLFOX, 18. ramucirumab plus FOLFIRI, 19. vatalanib plus FOLFOX, 20. aflibercept plus FOLFIRI, 21. gefitinib plus raltitrexed, 22. mitomycin plus oxaliplatin, 23. mitomycin plus irinotecan, 24) trebananib plus FOLFIRI and 25. abituzumab plus cetuximab plus irinotecan.</P>
<P>Only one trial used no anticancer treatment (best supportive care) as the control arm (the experimental arm was treatment with irinotecan) (<LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-10-19 10:05:28 +0200" MODIFIED_BY="[Empty name]">
<P>After reading the full text of 65 articles, we excluded 39 studies. Main reason for exclusion was that the trial did not focus on second-line therapy, rather the enrolment of people for first-line treatment or for third- or higher-line treatment.</P>
<P>Details regarding the reasons for exclusion of each study are reported in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-10-19 10:06:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> show the risk of bias across trials and for each trial, respectively; details are reported in the 'Risk of bias' tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. Considering the risk of single biases across trials, a high risk was present in a significant proportion (greater than 50%) of trials only for performance and detection bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). However, it should be noted that performance bias was unavoidable in some circumstances (e.g. chemotherapy compared to best supportive care); moreover, it is unlikely that this type of bias had a significant impact on the trial results and ultimately on the findings of the meta-analysis. While evaluating the risk of bias we did not find any difference between different outcomes; therefore, the risk assessment across domains is reported as a single assessment for all outcomes.</P>
<ALLOCATION MODIFIED="2016-10-19 10:06:05 +0200" MODIFIED_BY="[Empty name]">
<P>There was no high risk of selection bias, although the risk was unclear for about 50% of the trials (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-10-19 10:06:14 +0200" MODIFIED_BY="[Empty name]">
<P>There was high risk of bias in 22 open-label trials due to the lack of blinding (performance bias) intrinsic to the study design.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-10-19 10:06:51 +0200" MODIFIED_BY="[Empty name]">
<P>There was a high risk of attrition bias (incomplete outcome data) in only one study due to the following reasons: 1. for survival outcome, neither the arm the two withdrawn participants belonged to, nor the reasons for withdrawal were reported; and 2. for tumour response, "39 patients were evaluable for response", therefore 16 participants were not evaluable (<LINK REF="STD-Graeven-2007" TYPE="STUDY">Graeven 2007</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-10-19 10:06:53 +0200" MODIFIED_BY="[Empty name]">
<P>There was no high risk of reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-10-19 10:06:58 +0200" MODIFIED_BY="[Empty name]">
<P>There was no high risk of other bias (e.g. baseline imbalances between arms).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-11-07 11:18:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> shows a synopsis of the results (in terms of OS, PFS, ORR and SAEs) generated by each included trial.</P>
<P>The included RCTs rarely tested the same drugs or drug regimens. Therefore, the results of the 34 eligible trials could not be pooled. Nevertheless, the available evidence provided us with the opportunity to group (and meta-analyze) RCTs addressing the same clinical issue (e.g. does the addition of targeted agents improve the efficacy of conventional chemotherapy?), although - singularly taken - they tested drug regimens that were not always identical (e.g. different targeted agents or different chemotherapy drugs).</P>
<P>Due to space considerations and in order to ease the interpretation of the wealth of data reported in this review, we reported forest plots and 'Summary of findings' tables only for the primary outcome (survival) in case of clinical practice changing results (i.e. for the comparisons on which the main conclusions of this review are based).</P>
<P>Nine out of 34 studies (26%) formally addressed QoL with participant compliance being 50% to 60% (<LINK REF="STD-Clarke-2011" TYPE="STUDY">Clarke 2011</LINK>; <LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>; <LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>; <LINK REF="STD-Peeters-2010" TYPE="STUDY">Peeters 2010</LINK>; <LINK REF="STD-Price-2014" TYPE="STUDY">Price 2014</LINK>; <LINK REF="STD-Rougier-1998" TYPE="STUDY">Rougier 1998</LINK>; <LINK REF="STD-Seymour-2013" TYPE="STUDY">Seymour 2013</LINK>; <LINK REF="STD-Sobrero-2008" TYPE="STUDY">Sobrero 2008</LINK>; <LINK REF="STD-Tabernero-2015" TYPE="STUDY">Tabernero 2015</LINK>). Although most investigators used similar questionnaires, the (few) data could not be meta-analyzed since no article reported the actual scores (neither individual nor summary data). As regards single studies, six trials reported no significant differences in QoL (<LINK REF="STD-Clarke-2011" TYPE="STUDY">Clarke 2011</LINK>; <LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>; <LINK REF="STD-Peeters-2010" TYPE="STUDY">Peeters 2010</LINK>; <LINK REF="STD-Price-2014" TYPE="STUDY">Price 2014</LINK>; <LINK REF="STD-Rougier-1998" TYPE="STUDY">Rougier 1998</LINK>; <LINK REF="STD-Tabernero-2015" TYPE="STUDY">Tabernero 2015</LINK>). QoL was better in participants treated with irinotecan compared to those treated with best supportive care (<LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>), irinotecan plus panitumumab versus irinotecan alone (<LINK REF="STD-Seymour-2013" TYPE="STUDY">Seymour 2013</LINK>), and cetuximab plus irinotecan versus irinotecan alone (<LINK REF="STD-Sobrero-2008" TYPE="STUDY">Sobrero 2008</LINK>).</P>
<P>The available evidence enabled us to address the following clinical issues.</P>
<SUBSECTION>
<HEADING LEVEL="4">Modern chemotherapy regimens versus 5-fluorouracil</HEADING>
<P>Two RCTs (726 participants) compared 5FU (the first chemotherapeutic agent to be associated with survival advantage in first-line treatment of people with metastatic CRC) with three different chemotherapy regimens (including more modern drugs): FOLFOX (<LINK REF="STD-Rothenberg-2003_x005f_folfox" TYPE="STUDY">Rothenberg 2003_folfox</LINK>), oxaliplatin (<LINK REF="STD-Rothenberg-2003_x005f_oxa" TYPE="STUDY">Rothenberg 2003_oxa</LINK>), and irinotecan (<LINK REF="STD-Rougier-1998" TYPE="STUDY">Rougier 1998</LINK>).</P>
<P>Only one trial (167 participants) addressed OS and showed a significant advantage for participants treated with irinotecan (HR 0.69, 95% CI 0.51 to 0.94) (<LINK REF="STD-Rougier-1998" TYPE="STUDY">Rougier 1998</LINK>). Both trials reported PFS: considering the single comparisons, both FOLFOX and irinotecan were better than 5FU, whereas oxaliplatin was not. By pooling the PFS data of the three comparisons, regimens other than 5FU alone performed better than 5FU alone (HR 0.84, 95% CI 0.73 to 0.96) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), a finding characterized by a high between-study heterogeneity (I<SUP>2</SUP> = 91%) sustained by the poor activity of oxaliplatin alone. The 'leave-one-out' sensitivity analysis showed that heterogeneity reduced to 11% if the oxaliplatin versus 5FU comparison was excluded; in this case, FOLFOX and irinotecan showed a clinically relevant and statistically significant PFS advantage compared to 5FU in second-line therapy of metastatic CRC (HR 0.59, 95% CI 0.49 to 0.73). Based on the GRADE system, we rated this evidence as high (no reason for downgrading) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>For tumour response data, at meta-analysis, ORR was significantly higher for other chemotherapy regimens compared to 5FU (RR 2.96, 95% CI 1.66 to 5.27), although this finding was not supported by the oxaliplatin versus 5FU comparison. Finally, the SAE rate was higher in participants treated with modern chemotherapy regimens (RR 1.39, 95% CI 1.22 to 1.58).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Irinotecan plus other anticancer agents versus irinotecan</HEADING>
<P>Six trials assessed the effect of adding other anticancer agents (5FU, oxaliplatin, hyaluronan acid (a drug carrier), panitumumab, cetuximab) to irinotecan (2615 participants) (<LINK REF="STD-Clarke-2011" TYPE="STUDY">Clarke 2011</LINK>; <LINK REF="STD-Gibbs-2011" TYPE="STUDY">Gibbs 2011</LINK>; <LINK REF="STD-Graeven-2007" TYPE="STUDY">Graeven 2007</LINK>; <LINK REF="STD-Haller-2008" TYPE="STUDY">Haller 2008</LINK>; <LINK REF="STD-Seymour-2013" TYPE="STUDY">Seymour 2013</LINK>; <LINK REF="STD-Sobrero-2008" TYPE="STUDY">Sobrero 2008</LINK>).</P>
<P>Only one trial (627 participants) found a statistically significant advantage for both OS (HR 0.78, 95% CI 0.67 to 0.90) and PFS (HR 0.60, 95% CI 0.55 to 0.66), when irinotecan was combined with oxaliplatin (also known as IROX regimen) (<LINK REF="STD-Haller-2008" TYPE="STUDY">Haller 2008</LINK>). The grade of evidence was moderate (because there was only one study) (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>When the results of the six studies were pooled together, there was no OS advantage (HR 0.91, 95% CI 0.79 to 1.04), with a non-negligible between-study heterogeneity (I<SUP>2</SUP> = 42%). In contrast, there was both a PFS advantage (HR 0.68, 95% CI 0.60 to 0.76) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) and an ORR advantage (RR 2.87, 95% CI 2.10 to 3.93) for combination regimens, with no significant difference in terms of toxicity (RR 1.18, 95% CI 0.96 to 1.45); the grade of evidence was moderate (since the PFS findings were not confirmed by the OS data) (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>Since the between-study heterogeneity was moderate to high for all outcomes, we searched for more homogeneous results by subgroup analysis. Pooling the data of two trials (144 participants) comparing the same regimens (irinotecan versus FOLFIRI) found no OS, PFS, ORR or SAE differences (<LINK REF="STD-Clarke-2011" TYPE="STUDY">Clarke 2011</LINK>; <LINK REF="STD-Graeven-2007" TYPE="STUDY">Graeven 2007</LINK>).</P>
<P>Heterogeneity was drastically reduced (I<SUP>2</SUP> less than 25%) when we meta-analyzed the data of the two trials (1758 participants) testing the hypothesis that the addition of targeted agents (panitumumab, cetuximab) might enhance the therapeutic efficacy of irinotecan (<LINK REF="STD-Seymour-2013" TYPE="STUDY">Seymour 2013</LINK>; <LINK REF="STD-Sobrero-2008" TYPE="STUDY">Sobrero 2008</LINK>): both PFS (HR 0.71, 95% CI 0.64 to 0.79) and ORR (RR 3.38, 95% CI 2.52 to 4.53) were significantly better in the combination regimen; however, there was no significant OS difference (HR 0.99, 95% CI 0.88 to 1.10), and the rate of SAEs was significantly higher with the combination regimen (RR 1.44, 95% CI 1.31 to 1.59); the grade of evidence was moderate because the PFS findings were not confirmed by the OS data (<LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fractionated irinotecan versus single-dose irinotecan</HEADING>
<P>Three RCTs compared irinotecan administered as single dose (every three weeks) with that of irinotecan fractionated (with different schedules) (<LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>, 391 participants; <LINK REF="STD-Shoemaker-2004" TYPE="STUDY">Shoemaker 2004</LINK>, 85 participants; <LINK REF="STD-Tsavaris-2003" TYPE="STUDY">Tsavaris 2003</LINK>, 120 participants). There were no statistically significant differences in terms of OS (HR 0.86, 95% CI 0.71 to 1.05; 2 RCTs) (<LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>; <LINK REF="STD-Tsavaris-2003" TYPE="STUDY">Tsavaris 2003</LINK>), PFS (HR 0.90, 95% CI 0.71 to 1.14; 2 RCTs) (<LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>; <LINK REF="STD-Tsavaris-2003" TYPE="STUDY">Tsavaris 2003</LINK>), ORR (RR 0.83, 95% CI 0.45 to 1.53; 2 RCTs) (<LINK REF="STD-Shoemaker-2004" TYPE="STUDY">Shoemaker 2004;</LINK> <LINK REF="STD-Tsavaris-2003" TYPE="STUDY">Tsavaris 2003</LINK>), and SAE (RR 0.97, 95% CI 0.87 to 1.10; 3 RCTs) (<LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>; <LINK REF="STD-Shoemaker-2004" TYPE="STUDY">Shoemaker 2004</LINK>; <LINK REF="STD-Tsavaris-2003" TYPE="STUDY">Tsavaris 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bevacizumab plus chemotherapy versus chemotherapy</HEADING>
<P>Four RCTs (1723 participants) addressed the addition of bevacizumab to chemotherapy (oxaliplatin- or irinotecan-based regimens) (<LINK REF="STD-Bennouna-2013" TYPE="STUDY">Bennouna 2013</LINK>; <LINK REF="STD-Cao-2015" TYPE="STUDY">Cao 2015</LINK>; <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>; <LINK REF="STD-Masi-2015" TYPE="STUDY">Masi 2015</LINK>).</P>
<P>All four studies demonstrated a survival advantage for the combination arms, although this advantage was only statistically significant in two RCTs (<LINK REF="STD-Bennouna-2013" TYPE="STUDY">Bennouna 2013</LINK>; <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>). Pooling the OS data from all four studies showed that bevacizumab can lead to a survival advantage (HR 0.79, 95% CI 0.70 to 0.88) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), with no between-study heterogeneity (I<SUP>2</SUP> = 0%). The four single trials reported even better results for PFS, which was confirmed by meta-analysis (HR 0.67, 95% CI 0.60 to 0.75) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). Based on the GRADE system, we rated the evidence as high (no reason for downgrading) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>ORR data were in line with survival data as the response rates were higher in the bevacizumab-containing regimens (RR 1.72, 95% CI 1.23 to 2.43). Interestingly, the addition of bevacizumab did not significantly increase the risk of SAEs (RR 1.07, 95% CI 0.93 to 1.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">FOLFIRI plus targeted agents versus FOLFIRI</HEADING>
<P>Six trials (3335 participants) tested the hypothesis that adding other anticancer agents to the FOLFIRI regimen (conventional chemotherapy drugs only) might increase therapeutic efficacy investigating seven different targeted drugs: conatumumab (<LINK REF="STD-Cohn-2013_x005f_conat" TYPE="STUDY">Cohn 2013_conat</LINK>), ganitumab (<LINK REF="STD-Cohn-2013_x005f_ganit" TYPE="STUDY">Cohn 2013_ganit</LINK>), panitumumab (<LINK REF="STD-Peeters-2010" TYPE="STUDY">Peeters 2010</LINK>), bevacizumab (plus panitumumab) (<LINK REF="STD-Liu-2015" TYPE="STUDY">Liu 2015</LINK>), trebananib (<LINK REF="STD-Peeters-2013" TYPE="STUDY">Peeters 2013</LINK>), ramucirumab (<LINK REF="STD-Tabernero-2015" TYPE="STUDY">Tabernero 2015</LINK>), and aflibercept (<LINK REF="STD-Van-Cutsem-2012" TYPE="STUDY">Van Cutsem 2012</LINK>). Singularly taken, only three RCTs showed a significant improvement in OS (<LINK REF="STD-Liu-2015" TYPE="STUDY">Liu 2015</LINK>; <LINK REF="STD-Tabernero-2015" TYPE="STUDY">Tabernero 2015</LINK>; <LINK REF="STD-Van-Cutsem-2012" TYPE="STUDY">Van Cutsem 2012</LINK>); pooling the data of all six trials, we found that the addition of targeted agents did increase life expectation (HR 0.84, 95% CI 0.77 to 0.91) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). There were similar results when pooling PFS data (HR 0.78, 95% CI 0.71 to 0.87) (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>) and ORR data (RR 2.07, 95% CI 1.31 to 3.28).</P>
<P>Importantly, the addition of targeted agents also significantly increased the incidence of SAEs (RR 1.30, 95% CI 1.17 to 1.45). At subgroup analysis, considering the three trials (2440 participants) that investigated targeted agents blocking exclusively the VEGF pathway (bevacizumab, ramucirumab, aflibercept), findings were even more homogeneous in terms of survival (OS: HR 0.82, 95% CI 0.74 to 0.90; PFS: HR 0.77, 95% CI 0.70 to 0.84).</P>
<P>Based on the GRADE system, we rated the evidence as high.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">FOLFOX plus targeted agents versus FOLFOX</HEADING>
<P>Two RCTs (1432 participants) tested the hypothesis that adding targeted agents (bevacizumab and vatalanib) to the FOLFOX regimen (chemotherapy drugs only) might increase therapeutic efficacy (bevacizumab: <LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>; vatalanib: <LINK REF="STD-Van-Cutsem-2011" TYPE="STUDY">Van Cutsem 2011</LINK>). The meta-analysis of the two trials showed a significantly improved PFS when targeted agents were added to FOLFOX (HR 0.76, 95% CI 0.66 to 0.86) (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>), although there was a high degree of heterogeneity (I<SUP>2</SUP> = 78%). Addition of targeted agents also improved OS, although this result did not reach statistical significance (HR 0.92, 95% CI 0.82 to 1.04).</P>
<P>Finally, the incidence of SAEs was significantly higher among participants receiving the combination regimen (RR 1.2, 95% CI 1.13 to 1.28). Only one study reported ORR, which showed an advantage for the regimen including bevacizumab (<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>).</P>
<P>Based on the GRADE system, we rated the evidence as low (due to high heterogeneity and PFS data not confirmed by OS data).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">FOLFIRI plus bevacizumab versus FOLFIRI plus other targeted agents</HEADING>
<P>Two trials (282 participants) compared the FOLFIRI chemotherapy regimen in combination with either bevacizumab or other targeted agents (axitinib or panitumumab) (<LINK REF="STD-Bendell-2013_x005f_folfiri" TYPE="STUDY">Bendell 2013_folfiri</LINK>; <LINK REF="STD-Hecht-2015" TYPE="STUDY">Hecht 2015</LINK>). Neither study reported a significant OS difference between the two approaches, a result confirmed by data meta-analysis (HR 1.15, 95% CI 0.86 to 1.53). There were similar findings for PFS and ORR both in single studies and meta-analysis (PFS: HR 1.10, 95% CI 0.81 to 1.50; ORR: RR 1.44, 95% CI 0.94 to 2.20).</P>
<P>Toxicity findings favoured the bevacizumab-containing regimen (other agents versus bevacizumab comparison: RR 1.53, 95% CI 1.10 to 2.11). Due to the low number of participants randomized, any result should be interpreted with caution (due to low statistical power considerations).</P>
<P>Using the GRADE system, we rated the evidence as low (due to imprecision and low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">FOLFOX plus bevacizumab versus FOLFOX plus other targeted agents</HEADING>
<P>Two trials (169 participants) compared the FOLFOX chemotherapy regimen in combination with either bevacizumab or other targeted agents (Axitinib or Linifanib) (<LINK REF="STD-Bendell-2013_x005f_folfox" TYPE="STUDY">Bendell 2013_folfox</LINK>; <LINK REF="STD-O_x0027_Neil-2014" TYPE="STUDY">O'Neil 2014</LINK>). Neither study reported a significant OS difference between the two approaches, a result confirmed by data meta-analysis (HR 1.14, 95% CI 0.81 to 1.61). There were similar findings for PFS and ORR both in single studies and meta-analysis (PFS: HR 1.26, 95% CI 0.83 to 1.91; ORR: RR 0.77, 95% CI 0.46 to 1.29).</P>
<P>Toxicity findings favoured the bevacizumab-containing regimen (other agents versus bevacizumab comparison: RR 1.27, 95% CI 1.03 to 1.55). Due to the low number of participants randomized, any result should be interpreted with caution (due to low statistical power considerations).</P>
<P>Using the GRADE system, we rated the evidence as low (due to imprecision and low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other comparisons based on single trials</HEADING>
<P>Single RCTs compared the following regimens (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Irinotecan versus best supportive care</HEADING>
<P>This trial (279 participants) is particularly important because it showed that anticancer therapy (irinotecan) provided a significant OS advantage (HR 0.58, 95% CI 0.43 to 0.80) even in second-line (all enrolled participants were refractory to first-line 5FU) compared to best supportive care, although at the cost of a (predictable) higher incidence of SAEs (RR 1.19, 95% CI 1.01 to 1.40) (<LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as moderate (since there was only one trial).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">IRIS versus FOLFIRI</HEADING>
<P>This trial (426 participants), which compared IRIS versus FOLFIRI (both contained irinotecan), found that the two regimens were very similar in terms of survival, tumour response and toxicity outcomes (<LINK REF="STD-Muro-2010" TYPE="STUDY">Muro 2010</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as low (due to imprecision and low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">XELOX versus FOLFOX</HEADING>
<P>This study (627 participants), in which the two combination regimens basically differed by using oral (XELOX: capecitabine) instead of intravenous (FOLFOX: 5FU) fluoropyrimidine, suggested that the survival and tumour response results achieved with XELOX were similar to those with FOLFOX, but with the advantage of a lower incidence of SAEs (RR 0.75, 95% CI 0.68 to 0.82) (<LINK REF="STD-Rothenberg-2008" TYPE="STUDY">Rothenberg 2008</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as moderate (since there was only one trial).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">FOLFOX versus irinotecan</HEADING>
<P>This RCT (491 participants), which compared FOLFOX with single-agent irinotecan, found no significant difference in OS; however, participants who received FOLFOX showed better PFS and ORR, which were not associated with a significant increase in toxicity (<LINK REF="STD-Kim-2009" TYPE="STUDY">Kim 2009</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as low (due to imprecision and low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mitomycin plus oxaliplatin versus mitomycin plus irinotecan</HEADING>
<P>The investigators of this trial (64 participants) did not report survival outcomes. There were no statistically significant differences between the two chemotherapy regimens in tumour response and toxicity (<LINK REF="STD-Scheithauer-2002" TYPE="STUDY">Scheithauer 2002</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as very low (due to imprecision and very low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gefitinib plus raltitrexed versus raltitrexed</HEADING>
<P>The addition of targeted agent gefitinib to chemotherapy agent raltitrexed did not improve OS, PFS or ORR (76 participants). There were no toxicity differences reported between the two study arms (<LINK REF="STD-Vi_x00e9_itez-2011" TYPE="STUDY">Viéitez 2011</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as very low (due to imprecision and very low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Different bevacizumab dosages</HEADING>
<P>One trial (369 participants) compared two bevacizumab dosages (used in association with FOLFIRI) (<LINK REF="STD-Iwamoto-2015" TYPE="STUDY">Iwamoto 2015</LINK>). Since there were no statistically significant differences in terms of OS, PFS, ORR or SAEs, the authors concluded that higher-dose bevacizumab did not perform better than lower-dose bevacizumab when associated with FOLFIRI.</P>
<P>Using the GRADE system, we rated the evidence as low (due to imprecision and low statistical power).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Panitumumab versus cetuximab</HEADING>
<P>In this trial (999 participants), the investigators did not detect significant differences between the two targeted agents panitumumab and cetuximab in terms of OS, PFS, ORR or SAEs (<LINK REF="STD-Price-2014" TYPE="STUDY">Price 2014</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as moderate (since there was only one trial available).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Abituzumab plus cetuximab plus irinotecan versus cetuximab plus irinotecan</HEADING>
<P>The results of this RCT (216 participants) suggested that targeted agent abituzumab (both low and high dose) does not add any advantage (in terms of OS, PFS, ORR or SAEs) to the cetuximab plus irinotecan combination (<LINK REF="STD-_x00c9_lez-2015" TYPE="STUDY">Élez 2015</LINK>).</P>
<P>Using the GRADE system, we rated the evidence as low (due to imprecision and low statistical power).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-11-07 11:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>This is the first systematic review and meta-analysis addressing the issue of the performance (efficacy plus toxicity) of second-line systemic therapy in people with metastatic (TNM stage IV) CRC. Our findings are based on the data collected from 34 eligible RCTs enrolling 13,787 participants.</P>
<P>Since the included RCTs tested a variety of drug regimens, it was almost always impossible to pool results from identical comparisons. Nevertheless, we exploited the available evidence in order to answer clinically relevant broad questions, which implied the meta-analysis of RCTs addressing the same issue (e.g. do targeted drugs increase the efficacy of chemotherapy?) though - singularly taken - they tested different drug regimens (e.g. different targeted agents).</P>
<SUMMARY_OF_RESULTS MODIFIED="2016-10-19 10:32:04 +0200" MODIFIED_BY="[Empty name]">
<P>The main findings of our work can be summarized as the answers to the following clinical questions.</P>
<UL>
<LI>Is second-line chemotherapy effective in people with metastatic CRC?</LI>
</UL>
<P>Only one RCT addressed this issue. It demonstrated a significant survival advantage for people undergoing chemotherapy (irinotecan) compared to people treated with best supportive care. Obviously, chemotherapy was accompanied by a higher rate of toxicity. The level of evidence was moderate because this result was based on a single study.</P>
<UL>
<LI>Are modern chemotherapy regimens superior to outdated 5FU?</LI>
</UL>
<P>The results of two RCTs showed that modern chemotherapy regimens (FOLFOX and irinotecan) were more effective than 5FU alone, although at the cost of a higher toxicity rate. The level of evidence was high.</P>
<UL>
<LI>Are irinotecan-based regimens better than irinotecan alone?</LI>
</UL>
<P>In general, irinotecan-based regimens were better than irinotecan alone, although results were heterogeneous, which was probably linked to the variety of treatments included. When we looked at more homogeneous subgroups, two combinations were significantly associated with a better efficacy: irinotecan plus targeted agents (two RCTs testing anti-EGFR agents cetuximab and panitumumab; grade of evidence: moderate, since the PFS finding was not supported by the OS finding) and irinotecan plus oxaliplatin (IROX regimen; one RCT; grade of evidence: moderate, as there was only one RCT). In both cases, improved efficacy was accompanied by a higher rate of SAEs. Of note, the combination regimen, FOLFIRI, was not superior to irinotecan alone.</P>
<UL>
<LI>Does targeted agent bevacizumab increase the efficacy of chemotherapy?</LI>
</UL>
<P>Four RCTs addressed this issue and found that bevacizumab significantly increased the efficacy of chemotherapy (miscellany of regimens); interestingly, this benefit was not paralleled by a significant increase in toxicity rates. The grade of evidence was high.</P>
<UL>
<LI>Do targeted agents increase the efficacy of FOLFIRI or FOLFOX?</LI>
</UL>
<P>The evidence from eight RCTs (FOLFIRI, 6 RCTs; FOLFOX, 2 RCTs) supported the superiority of combination regimens including targeted agents; however, the grade of evidence was high for FOLFIRI and low for FOLFOX (due to results heterogeneity and PFS data not confirmed by OS data). In both cases, improved efficacy was accompanied by a higher rate of SAEs.</P>
<P>Importantly, we would like to underscore that the answers to the last two questions strongly support the use of targeted agents in combination with chemotherapy for the treatment of people with metastatic CRC who did not respond to first-line treatment. Interestingly, the use of bevacizumab was associated with higher efficacy without increased toxicity, a common finding when dealing with regimens that show better anticancer activity (see the comparisons 'Modern chemotherapy regimens versus 5-fluorouracil', 'Irinotecan plus other anticancer agents versus irinotecan', and 'Irinotecan and best supportive care'). In particular, other widely used targeted agents, such as those targeting the EGFR pathway (e.g. cetuximab and panitumumab) which improve people's survival (when added to chemotherapy), are accompanied by a significantly worse tolerability (see comparison 'Irinotecan plus other anticancer agents versus irinotecan').</P>
<P>Regarding secondary endpoints, both response and toxicity rates are usually directly proportional to efficacy (i.e. the higher the efficacy, the higher the rates of both tumour shrinkage and SAEs); this was the case for the regimens compared with the exception of bevacizumab (which appeared to lead to higher response rates when combined with chemotherapy, without increasing toxicity). Another important clue comes from the comparison between oral and intravenous fluoropyrimidines (combined with oxaliplatin), which supports the use of oral administration due to similar efficacy, lower toxicity rates and easier route of administration (<LINK REF="STD-Rothenberg-2008" TYPE="STUDY">Rothenberg 2008</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-10-19 10:32:18 +0200" MODIFIED_BY="[Empty name]">
<P>Although the above findings provide clinicians with some useful information, some unanswered questions remain. For instance, many comparisons showing no statistically significant difference between regimens were based on single trials enrolling a number of participants insufficient to obtain a satisfactory statistical power, which prevents us from drawing any definitive conclusions based on those results. Moreover, not all comparisons were available, which did not enable us to generate a full ranking of the variety of tested regimens. For example, thus far no RCT has investigated irinotecan plus bevacizumab (versus irinotecan alone), which would be a potentially useful combination of two drugs with established efficacy when individually taken as second-line therapy for people with metastatic CRC.</P>
<P>Since they are based on moderate to high quality evidence, the main findings of this review could be helpful to guide clinicians for the routine clinical practice in the choice of second-line therapy for people with metastatic CRC.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-10-19 10:32:23 +0200" MODIFIED_BY="[Empty name]">
<P>The main conclusions of this review (see <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>) are based on moderate to high-quality evidence; the main reason for downgrading being inconsistency due to the fact that PFS findings were not confirmed by OS data. Nevertheless, it should be remembered that PFS is nowadays considered a reliable surrogate of OS (which includes disease-unrelated events and requires longer follow-ups) in the setting of second-line therapy for metastatic CRC (<LINK REF="REF-Buyse-2007" TYPE="REFERENCE">Buyse 2007</LINK>; <LINK REF="REF-Giessen-2015" TYPE="REFERENCE">Giessen 2015</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-10-19 10:32:26 +0200" MODIFIED_BY="[Empty name]">
<P>Although always possible, we believe it is unlikely that a significant bias was introduced in the search for trials. Moreover, we employed the high-quality Cochrane methods to evaluate trials and conducting data analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-10-19 10:32:42 +0200" MODIFIED_BY="[Empty name]">
<P>Only one systematic review has so far been published on this subject (<LINK REF="REF-Giessen-2015" TYPE="REFERENCE">Giessen 2015</LINK>); this work had the specific aim to investigate PFS and ORR as potential surrogate endpoints for OS and found 23 RCTs (our review identified 34 studies). Moreover, only one systematic review and meta-analysis has been published in this field (<LINK REF="REF-Beretta-2013" TYPE="REFERENCE">Beretta 2013</LINK>), but its area of interest was limited to one treatment (FOLFIRI plus bevacizumab); the results of this work (based on both randomized and non-randomized trials) were in line with the findings of this review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-10-19 10:33:13 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-10-19 10:32:53 +0200" MODIFIED_BY="[Empty name]">
<P>Systemic therapy offers a survival benefit to people with metastatic colorectal cancer (CRC) who did not respond to first-line treatment, especially when targeted agents are combined with conventional chemotherapeutic drugs. This review provides clinicians with several clues on the choice of second-line therapy for people with metastatic CRC who have not responded to first-line treatment, such as the superiority of some chemotherapy regimens and the advantage of adding targeted agents to chemotherapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-10-19 10:33:13 +0200" MODIFIED_BY="[Empty name]">
<P>Our findings highlight the need for further research in order to address some issues, such as: </P>
<UL>
<LI>the evidence on some treatments was based on single trials, which precludes any definitive conclusion on those regimens;</LI>
<LI>considering the positive results yielded with targeted agents, then other compounds should be tested in this setting that are being successfully used against other tumour types (e.g. co-inhibitory molecule inhibitors);</LI>
<LI>novel biomarkers predictive of tumour response are needed (besides KRAS mutational status for epidermal growth factor receptor (EGFR) pathway inhibitors) in order to improve our ability to select people with the highest likelihood of benefiting from a given therapy (personalized cancer medicine);</LI>
<LI>data on the quality of life of people with cancer should become a mandatory item while designing and running a cancer trial in order to formally investigate the balance between survival benefits provided by second-line systemic therapy and treatment-related toxicity.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-11-30 09:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>We truly thank Dr Marta Briarava (data manager of the Meta-Analysis Unit of the University of Padova, Padova, Italy) for her invaluable help with the setup and management of the dedicated database we used for the collection and analysis of the literature data.</P>
<P>We would also like to thank Juan-José López and the previous authors for their contribution to the first published version of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-12-09 09:02:30 +0100" MODIFIED_BY="[Empty name]">
<P>None of the authors have any known conflicts of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-11-30 09:42:59 +0100" MODIFIED_BY="[Empty name]">
<P>Previous version: MR wrote the draft protocol; IS designed the search strategy; all authors helped design the review and write the review.</P>
<P>Current version: SM and ZB updated and expanded (including targeted therapies) the previous version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-10-19 10:33:29 +0200" MODIFIED_BY="[Empty name]">
<P>The updated version included targeted therapies (which were excluded in the previous version of the protocol and review): overall, this led to the inclusion of 34 trials instead of the seven trials included in the previous version.</P>
<P>Future updates of this review will include targeted therapies.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-12-09 09:35:50 +0000" MODIFIED_BY="Henning Keinke Andersen">
<STUDIES MODIFIED="2016-11-07 11:48:25 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-11-07 11:48:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bendell-2013_x005f_folfiri" MODIFIED="2015-09-23 11:54:11 +0200" MODIFIED_BY="[Empty name]" NAME="Bendell 2013_folfiri" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:54:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, et al</AU>
<TI>Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2013</YR>
<VL>12</VL>
<PG>239-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942627"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942626"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bendell-2013_x005f_folfox" MODIFIED="2016-10-19 11:21:57 +0200" MODIFIED_BY="[Empty name]" NAME="Bendell 2013_folfox" YEAR="">
<REFERENCE MODIFIED="2016-10-19 11:21:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, et al</AU>
<TI>Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2013</YR>
<VL>12</VL>
<PG>239-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942629"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942628"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennouna-2013" MODIFIED="2015-09-23 11:53:53 +0200" MODIFIED_BY="[Empty name]" NAME="Bennouna 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:53:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al</AU>
<TI>Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial</TI>
<SO>Lancet Oncology</SO>
<YR>2013</YR>
<VL>14</VL>
<PG>29-37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942631"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942630"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2015" MODIFIED="2016-09-23 11:25:45 +0200" MODIFIED_BY="[Empty name]" NAME="Cao 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-09-23 11:25:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao R, Zhang S, Ma D, Hu L</AU>
<TI>A multicenter randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer</TI>
<SO>Medical Oncology</SO>
<YR>2015</YR>
<VL>32</VL>
<PG>325</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942633"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942632"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2011" MODIFIED="2016-10-19 11:22:09 +0200" MODIFIED_BY="[Empty name]" NAME="Clarke 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-19 11:22:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, et al on behalf of the Australasian Gastro-Intestinal Trials Group</AU>
<TI>Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis</TI>
<SO>European Journal of Cancer</SO>
<YR>2011</YR>
<VL>47</VL>
<NO>12</NO>
<PG>1826-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-2013_x005f_conat" MODIFIED="2015-09-23 11:53:20 +0200" MODIFIED_BY="[Empty name]" NAME="Cohn 2013_conat" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:53:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, et al</AU>
<TI>A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>24</VL>
<PG>1777-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-02 10:12:57 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-2013_x005f_ganit" MODIFIED="2016-10-19 11:22:44 +0200" MODIFIED_BY="[Empty name]" NAME="Cohn 2013_ganit" YEAR="">
<REFERENCE MODIFIED="2016-10-19 11:22:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, et al</AU>
<TI>A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>24</VL>
<PG>1777-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942639"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942638"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-1998" MODIFIED="2015-09-23 11:52:33 +0200" MODIFIED_BY="[Empty name]" NAME="Cunningham 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-09-23 11:52:33 +0200" MODIFIED_BY="[Empty name]" NOTES="Cunningham D, Pyrh&amp;#246;nen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-18." NOTES_MODIFIED="2015-09-23 11:52:33 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al</AU>
<TI>Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1413-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942641"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942640"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x00c9_lez-2015" MODIFIED="2016-10-15 18:43:22 +0200" MODIFIED_BY="Anne Lawson" NAME="Élez 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-09-23 11:51:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Élez E, Kocáková I, Höhler T, Martens UM, Bokemeyer C, Van Cutsem E, et al</AU>
<TI>Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial</TI>
<SO>Annals of Oncology</SO>
<YR>2015</YR>
<VL>26</VL>
<PG>132-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942643"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942642"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuchs-2003" MODIFIED="2016-10-19 11:23:28 +0200" MODIFIED_BY="[Empty name]" NAME="Fuchs 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-19 11:23:28 +0200" MODIFIED_BY="[Empty name]" NOTES="10. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two Irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol, 2003; 21:807-14" NOTES_MODIFIED="2016-10-19 11:23:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR</AU>
<TI>Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>5</NO>
<PG>807-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942645"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giantonio-2007" MODIFIED="2016-10-19 11:24:52 +0200" MODIFIED_BY="[Empty name]" NAME="Giantonio 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-19 11:24:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al; Eastern Cooperative Oncology Group Study E3200</AU>
<TI>Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>1539-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942647"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942646"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibbs-2011" MODIFIED="2016-10-19 11:25:37 +0200" MODIFIED_BY="[Empty name]" NAME="Gibbs 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-19 11:25:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, et al</AU>
<TI>Hyaluronan-irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2011</YR>
<VL>67</VL>
<NO>1</NO>
<PG>153-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942649"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942648"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graeven-2007" MODIFIED="2015-09-23 11:50:16 +0200" MODIFIED_BY="[Empty name]" NAME="Graeven 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-23 11:50:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graeven U, Arnold D, Reinacher-Schick A, Heuer T, Nusch A, Porschen R, et al</AU>
<TI>A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma</TI>
<SO>Onkologie</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>4</NO>
<PG>169-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942651"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942650"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haller-2008" MODIFIED="2016-10-19 11:26:02 +0200" MODIFIED_BY="[Empty name]" NAME="Haller 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-19 11:26:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH Jr, Bodoky G, et al</AU>
<TI>Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma</TI>
<SO>Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>28</NO>
<PG>4544-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942653"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942652"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hecht-2015" MODIFIED="2016-10-19 11:28:23 +0200" MODIFIED_BY="[Empty name]" NAME="Hecht 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-19 11:28:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, et al</AU>
<TI>SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2015</YR>
<VL>14</VL>
<PG>72-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942655"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942654"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwamoto-2015" MODIFIED="2016-10-19 11:28:59 +0200" MODIFIED_BY="[Empty name]" NAME="Iwamoto 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-19 11:28:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, et al</AU>
<TI>FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study</TI>
<SO>Annals of Oncology</SO>
<YR>2015</YR>
<VL>26</VL>
<PG>1427-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942657"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942656"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2009" MODIFIED="2016-10-19 11:29:09 +0200" MODIFIED_BY="[Empty name]" NAME="Kim 2009" YEAR="2005 ASCO Annual Meeting Proceedings">
<REFERENCE MODIFIED="2016-10-19 11:29:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, et al</AU>
<TI>Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>17</NO>
<PG>2848-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942659"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942658"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2015" MODIFIED="2016-10-19 11:29:31 +0200" MODIFIED_BY="[Empty name]" NAME="Liu 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-19 11:29:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Luan L, Wang X</AU>
<TI>A randomized phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation</TI>
<SO>Journal of OncoTargets and Therapy</SO>
<YR>2015</YR>
<VL>8</VL>
<PG>1061-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942661"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942660"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masi-2015" MODIFIED="2015-09-23 11:49:22 +0200" MODIFIED_BY="[Empty name]" NAME="Masi 2015" YEAR="2014">
<REFERENCE MODIFIED="2015-09-23 11:49:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, et al; BEBYP Study Investigators</AU>
<TI>Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial</TI>
<SO>Annals of Oncology</SO>
<YR>2015</YR>
<VL>26</VL>
<PG>724-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942663"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942662"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muro-2010" MODIFIED="2016-11-07 11:47:33 +0100" MODIFIED_BY="[Empty name]" NAME="Muro 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-11-07 11:47:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al</AU>
<TI>Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)</TI>
<SO>Lancet Oncology</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>9</NO>
<PG>853-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942665"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942664"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Neil-2014" MODIFIED="2015-09-23 11:48:52 +0200" MODIFIED_BY="[Empty name]" NAME="O'Neil 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-23 11:48:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, et al</AU>
<TI>Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2014</YR>
<VL>13</VL>
<PG>156-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942667"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942666"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peeters-2010" MODIFIED="2015-09-23 11:48:25 +0200" MODIFIED_BY="[Empty name]" NAME="Peeters 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-09-23 11:48:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al</AU>
<TI>Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<PG>4706-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942669"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942668"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peeters-2013" MODIFIED="2015-09-23 11:48:04 +0200" MODIFIED_BY="[Empty name]" NAME="Peeters 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:48:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, et al</AU>
<TI>A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma</TI>
<SO>British Journal of Cancer</SO>
<YR>2013</YR>
<VL>108</VL>
<PG>503-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942671"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-2014" MODIFIED="2015-09-23 11:47:49 +0200" MODIFIED_BY="[Empty name]" NAME="Price 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-23 11:47:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al</AU>
<TI>Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study</TI>
<SO>Lancet Oncology</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>569-79</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942673"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942672"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothenberg-2003_x005f_folfox" MODIFIED="2016-10-19 11:30:18 +0200" MODIFIED_BY="[Empty name]" NAME="Rothenberg 2003_folfox" YEAR="">
<REFERENCE MODIFIED="2016-10-19 11:30:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al</AU>
<TI>Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>11</NO>
<PG>2059-69</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942675"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942674"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothenberg-2003_x005f_oxa" MODIFIED="2016-10-19 11:31:04 +0200" MODIFIED_BY="[Empty name]" NAME="Rothenberg 2003_oxa" YEAR="2003">
<REFERENCE MODIFIED="2016-10-19 11:31:04 +0200" MODIFIED_BY="[Empty name]" NOTES="12. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of Oxaliplatin and Fluorouracil-Leucovorin compared with either therapy alone in patients with progressive colorectal cancer after Irinotecan and Fluorouracil-Leucovorin: interim results of a phase III trial. J Clin Oncol, 2003; 21:2059-69" NOTES_MODIFIED="2016-10-19 11:31:04 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al</AU>
<TI>Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>11</NO>
<PG>2059-69</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942677"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942676"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothenberg-2008" MODIFIED="2015-09-23 11:43:22 +0200" MODIFIED_BY="[Empty name]" NAME="Rothenberg 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-23 11:43:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al</AU>
<TI>Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study</TI>
<SO>Annals of Oncology</SO>
<YR>2008</YR>
<VL>19</VL>
<PG>1720-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942679"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942678"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rougier-1998" MODIFIED="2016-10-19 11:31:28 +0200" MODIFIED_BY="[Empty name]" NAME="Rougier 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-10-19 11:31:28 +0200" MODIFIED_BY="[Empty name]" NOTES="9. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of Irinotecan versus Fluorouracil by continuous infusion after Fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998; 352:1407-12" NOTES_MODIFIED="2016-10-19 11:31:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al</AU>
<TI>Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9138</NO>
<PG>1407-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942681"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942680"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheithauer-2002" MODIFIED="2015-09-23 11:41:32 +0200" MODIFIED_BY="[Empty name]" NAME="Scheithauer 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-23 11:41:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, et al</AU>
<TI>Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer</TI>
<SO>Cancer Investigation</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>1</NO>
<PG>60-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942683"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942682"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seymour-2013" MODIFIED="2015-09-23 11:41:15 +0200" MODIFIED_BY="[Empty name]" NAME="Seymour 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:41:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al</AU>
<TI>Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial</TI>
<SO>Lancet Oncology</SO>
<YR>2013</YR>
<VL>14</VL>
<PG>749-59</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942685"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942684"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoemaker-2004" MODIFIED="2016-10-19 11:31:57 +0200" MODIFIED_BY="[Empty name]" NAME="Shoemaker 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-19 11:31:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoemaker NE, Kuppens IELM, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, et al</AU>
<TI>A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>91</VL>
<PG>1434-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942687"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942686"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobrero-2008" MODIFIED="2015-09-23 11:40:54 +0200" MODIFIED_BY="[Empty name]" NAME="Sobrero 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-23 11:40:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al</AU>
<TI>EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>2311-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942689"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942688"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabernero-2015" MODIFIED="2015-09-23 11:40:25 +0200" MODIFIED_BY="[Empty name]" NAME="Tabernero 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-09-23 11:40:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al; RAISE Study Investigators</AU>
<TI>Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study</TI>
<SO>Lancet Oncology</SO>
<YR>2015</YR>
<VL>16</VL>
<PG>499-508</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942691"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942690"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsavaris-2003" MODIFIED="2016-10-19 11:32:23 +0200" MODIFIED_BY="[Empty name]" NAME="Tsavaris 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-19 11:32:23 +0200" MODIFIED_BY="[Empty name]" NOTES="11. Tsavaris N, Ziras N, Kosmas C, et al. Two different schedules of Irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-Fluorouracil and Leucovorin combination. A randomised study. Cancer Chemother Pharmacol, 2003;52:514-9" NOTES_MODIFIED="2016-10-19 11:32:23 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M</AU>
<TI>Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination: a randomised study</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>6</NO>
<PG>514-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942693"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942692"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Cutsem-2011" MODIFIED="2015-09-23 11:39:51 +0200" MODIFIED_BY="[Empty name]" NAME="Van Cutsem 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-23 11:39:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, et al</AU>
<TI>Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>2004-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942695"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942694"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Cutsem-2012" MODIFIED="2015-09-23 11:39:36 +0200" MODIFIED_BY="[Empty name]" NAME="Van Cutsem 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-23 11:39:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al</AU>
<TI>Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<PG>3499-506</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942697"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942696"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vi_x00e9_itez-2011" MODIFIED="2016-11-07 11:48:06 +0100" MODIFIED_BY="[Empty name]" NAME="Viéitez 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-07 11:48:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viéitez JM, Valladares M, Peláez I, de Sande González L, García-Foncillas J, García-López JL, et al</AU>
<TI>A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer (1839IL/0143)</TI>
<SO>Investigational New Drugs</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>1038-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942699"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942698"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-11-07 11:48:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Amado-2008" MODIFIED="2015-09-23 11:31:07 +0200" MODIFIED_BY="[Empty name]" NAME="Amado 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-23 11:31:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al</AU>
<TI>Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>1626-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942701"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942700"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aranda-1998" MODIFIED="2015-09-23 11:31:28 +0200" MODIFIED_BY="[Empty name]" NAME="Aranda 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-09-23 11:31:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aranda E, Díaz-Rubio E, Cervantes A, Antón-Torres A, Carrato A, Massutí T, et al</AU>
<TI>Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study</TI>
<SO>Annals of Oncology</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>727-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942703"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942702"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chau-2004" MODIFIED="2015-09-23 11:31:38 +0200" MODIFIED_BY="[Empty name]" NAME="Chau 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-09-23 11:31:38 +0200" MODIFIED_BY="[Empty name]" NOTES="Chau I, Norman AR, Cunningham D et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004; 91(8):1453-8." NOTES_MODIFIED="2015-09-23 11:31:38 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, et al</AU>
<TI>Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>8</NO>
<PG>1453-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942705"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942704"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chibaudel-2016" MODIFIED="2016-10-19 11:32:44 +0200" MODIFIED_BY="[Empty name]" NAME="Chibaudel 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-10-19 11:32:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chibaudel B, Maindrault-G&#339;bel F, Bachet JB, Louvet C, Khalil A, Dupuis O, et al</AU>
<TI>PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer</TI>
<SO>Cancer Medicine</SO>
<YR>2016</YR>
<VL>5</VL>
<PG>676-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4486740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4486739"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comella-2000" MODIFIED="2015-09-23 11:31:46 +0200" MODIFIED_BY="[Empty name]" NAME="Comella 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-09-23 11:31:46 +0200" MODIFIED_BY="[Empty name]" NOTES="Comella P, De Vita F, Mancarella S et al. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 2000; 11(10):1323-33." NOTES_MODIFIED="2015-09-23 11:31:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, et al</AU>
<TI>Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial</TI>
<SO>Annals of Oncology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1323-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942707"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942706"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comella-2002" MODIFIED="2015-09-23 11:31:54 +0200" MODIFIED_BY="[Empty name]" NAME="Comella 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-23 11:31:54 +0200" MODIFIED_BY="[Empty name]" NOTES="Comella P, Crucitta E, De Vita F et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13(6):866-73." NOTES_MODIFIED="2015-09-23 11:31:54 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comella P, Crucitta E, De Vita F, De Lucia L, Farris A, Del Gaizo F, et al</AU>
<TI>Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>6</NO>
<PG>866-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942709"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942708"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-2004" MODIFIED="2015-09-23 11:32:10 +0200" MODIFIED_BY="[Empty name]" NAME="Cunningham 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-09-23 11:32:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al</AU>
<TI>Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<PG>337-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942711"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942710"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ducreux-2011" MODIFIED="2016-11-07 11:48:25 +0100" MODIFIED_BY="[Empty name]" NAME="Ducreux 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-07 11:48:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, et al; Fédération Francophone de Cancérologie Digestive (FFCD) 2000-05 Collaborative Group</AU>
<TI>Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial</TI>
<SO>Lancet Oncology</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>1032-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942713"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942712"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrett-2013" MODIFIED="2015-09-23 11:32:33 +0200" MODIFIED_BY="[Empty name]" NAME="Garrett 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:32:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, et al</AU>
<TI>Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer</TI>
<SO>Cancer</SO>
<YR>2013</YR>
<VL>119</VL>
<PG>4223-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942715"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942714"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grothey-2013" MODIFIED="2015-09-23 11:32:47 +0200" MODIFIED_BY="[Empty name]" NAME="Grothey 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:32:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al; CORRECT Study Group</AU>
<TI>Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial</TI>
<SO>Lancet Oncology</SO>
<YR>2013</YR>
<VL>381</VL>
<PG>303-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942717"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942716"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hendlisz-2010" MODIFIED="2015-09-23 11:33:08 +0200" MODIFIED_BY="[Empty name]" NAME="Hendlisz 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-09-23 11:33:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al</AU>
<TI>Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<PG>3687-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942719"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942718"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurwitz-2004" MODIFIED="2015-09-23 11:33:22 +0200" MODIFIED_BY="[Empty name]" NAME="Hurwitz 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-09-23 11:33:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al</AU>
<TI>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<PG>2335-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942721"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942720"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonker-2007" MODIFIED="2015-09-23 11:33:38 +0200" MODIFIED_BY="[Empty name]" NAME="Jonker 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-23 11:33:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al</AU>
<TI>Cetuximab for the treatment of colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<PG>2040-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942723"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942722"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabbinavar-2003" MODIFIED="2016-10-15 19:12:33 +0200" MODIFIED_BY="Anne Lawson" NAME="Kabbinavar 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-15 19:12:33 +0200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al</AU>
<TI>Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>60-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942725"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942724"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemeny-1993" MODIFIED="2015-09-23 11:34:12 +0200" MODIFIED_BY="[Empty name]" NAME="Kemeny 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-09-23 11:34:12 +0200" MODIFIED_BY="[Empty name]" NOTES="Kemeny N, Cohen A, Seiter K et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993; 11(2):330-5." NOTES_MODIFIED="2015-09-23 11:34:12 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, et al</AU>
<TI>Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>2</NO>
<PG>330-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942727"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942726"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koopman-2007" MODIFIED="2015-09-23 11:34:22 +0200" MODIFIED_BY="[Empty name]" NAME="Koopman 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-23 11:34:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al</AU>
<TI>Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<PG>135-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942729"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942728"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labianca-2011" MODIFIED="2015-09-23 11:34:40 +0200" MODIFIED_BY="[Empty name]" NAME="Labianca 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-23 11:34:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, et al; Italian Group for the Study of Gastrointestinal Cancer-GISCAD</AU>
<TI>Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<PG>1236-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942731"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942730"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacouture-2010" MODIFIED="2016-10-19 11:33:22 +0200" MODIFIED_BY="[Empty name]" NAME="Lacouture 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-19 11:33:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al</AU>
<TI>Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<PG>1351-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942732"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lal-2004" MODIFIED="2016-10-19 11:33:41 +0200" MODIFIED_BY="[Empty name]" NAME="Lal 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-19 11:33:41 +0200" MODIFIED_BY="[Empty name]" NOTES="13. Lal R, Dickson J, Cunningham D, et al. A randomised trial comparing defined-duration with continuous Irinotecan until disease progression in Fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol, 2004; 22:3023-31" NOTES_MODIFIED="2016-10-19 11:33:41 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, et al</AU>
<TI>A randomised trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>15</NO>
<PG>3023-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942734"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-1997" MODIFIED="2016-10-19 11:33:57 +0200" MODIFIED_BY="[Empty name]" NAME="Levi 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-19 11:33:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lévi F, Zidani R, Misset JL</AU>
<TI>Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>681-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942736"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2014" MODIFIED="2015-09-23 11:30:07 +0200" MODIFIED_BY="[Empty name]" NAME="Lin 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-23 11:30:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, et al</AU>
<TI>A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer</TI>
<SO>Cancer Medicine</SO>
<YR>2014</YR>
<VL>3</VL>
<PG>988-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942739"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942738"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandal_x00e1_-2009" MODIFIED="2016-10-19 11:35:08 +0200" MODIFIED_BY="[Empty name]" NAME="Mandalá 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-19 11:34:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labianca R, Floriani I, Cortesi L, Zaniboni A, Marangolo M, et al</AU>
<TI>Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): a randomized "GISCAD" trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24 (Suppl)</VL>
<PG>3505</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942741"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-19 11:35:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandalá M, Barni S, Floriani I, Isa L, Fornarini G, Marangolo M, et al</AU>
<TI>Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings</TI>
<SO>European Journal of Cancer</SO>
<YR>2009</YR>
<VL>45</VL>
<NO>1</NO>
<PG>65-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942740"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maughan-2003" MODIFIED="2015-09-23 11:29:58 +0200" MODIFIED_BY="[Empty name]" NAME="Maughan 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-09-23 11:29:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al; Medical Research Council Colorectal Cancer Group</AU>
<TI>Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<PG>457-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942744"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayer-2015" MODIFIED="2015-09-23 11:29:42 +0200" MODIFIED_BY="[Empty name]" NAME="Mayer 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-09-23 11:29:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al; RECOURSE Study Group</AU>
<TI>Randomized trial of TAS-102 for refractory metastatic colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2015</YR>
<VL>372</VL>
<PG>1909-19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942746"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942745"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muro-2016" MODIFIED="2016-10-19 11:35:24 +0200" MODIFIED_BY="[Empty name]" NAME="Muro 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-10-19 11:35:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muro K, Kim T, Park Y, Uetake H, Nishina T, Nozawa H, et al</AU>
<TI>A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2016</YR>
<VL>Suppl 4S</VL>
<PG>TPS780</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4486742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4486741"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-2004" MODIFIED="2015-09-23 11:29:49 +0200" MODIFIED_BY="[Empty name]" NAME="Rao 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-09-23 11:29:49 +0200" MODIFIED_BY="[Empty name]" NOTES="Rao S, Cunningham D, de Gramont A et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004; 22(19):3950-7." NOTES_MODIFIED="2015-09-23 11:29:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, et al</AU>
<TI>Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>19</NO>
<PG>3950-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942748"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942747"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reidy-2010" MODIFIED="2015-09-23 11:29:16 +0200" MODIFIED_BY="[Empty name]" NAME="Reidy 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-09-23 11:29:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, et al</AU>
<TI>Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology.</SO>
<YR>2010</YR>
<VL>28</VL>
<PG>4240-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942749"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rougier-2002" MODIFIED="2016-10-16 20:07:41 +0200" MODIFIED_BY="Anne Lawson" NAME="Rougier 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-10-16 20:07:41 +0200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, et al</AU>
<TI>Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>1558-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942752"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltz-2000" MODIFIED="2015-09-23 11:28:45 +0200" MODIFIED_BY="[Empty name]" NAME="Saltz 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-09-23 11:28:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al</AU>
<TI>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<PG>905-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942754"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942753"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltz-2007" MODIFIED="2015-09-23 11:28:29 +0200" MODIFIED_BY="[Empty name]" NAME="Saltz 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-23 11:28:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al</AU>
<TI>Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>4557-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942756"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942755"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seymour-2007" MODIFIED="2016-10-19 11:36:03 +0200" MODIFIED_BY="[Empty name]" NAME="Seymour 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-19 11:36:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al for the FOCUS Trial Investigators and the National Cancer Research Institute Colorectal Clinical Studies Group</AU>
<TI>Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<PG>143-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942758"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942757"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siu-2013" MODIFIED="2015-09-23 11:28:08 +0200" MODIFIED_BY="[Empty name]" NAME="Siu 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-23 11:28:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, et al</AU>
<TI>Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<PG>2477-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942760"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942759"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tournigand-2004" MODIFIED="2015-09-23 11:27:54 +0200" MODIFIED_BY="[Empty name]" NAME="Tournigand 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-09-23 11:27:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al</AU>
<TI>FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>229-37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942762"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942761"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tournigand-2006" MODIFIED="2015-09-23 11:27:42 +0200" MODIFIED_BY="[Empty name]" NAME="Tournigand 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-23 11:27:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al</AU>
<TI>OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>394-400</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942764"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942763"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsavaris-2007" MODIFIED="2016-10-19 11:36:22 +0200" MODIFIED_BY="[Empty name]" NAME="Tsavaris 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-19 11:36:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, et al</AU>
<TI>Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study</TI>
<SO>Chemotherapy</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>4</NO>
<PG>282-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942766"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942765"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Cutsem-2005" MODIFIED="2015-09-23 11:27:17 +0200" MODIFIED_BY="[Empty name]" NAME="Van Cutsem 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-09-23 11:27:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, et al</AU>
<TI>Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study</TI>
<SO>British Journal of Cancer</SO>
<YR>2005</YR>
<VL>92</VL>
<PG>1055-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942768"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942767"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Cutsem-2007" MODIFIED="2015-09-23 11:27:00 +0200" MODIFIED_BY="[Empty name]" NAME="Van Cutsem 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-23 11:27:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al</AU>
<TI>Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>1658-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942770"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942769"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Cutsem-2012_x005f_bis" MODIFIED="2015-09-23 11:26:30 +0200" MODIFIED_BY="[Empty name]" NAME="Van Cutsem 2012_bis" YEAR="2012">
<REFERENCE MODIFIED="2015-09-23 11:26:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, et al</AU>
<TI>Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>23</NO>
<PG>2861-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942772"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942771"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Cutsem-2014" MODIFIED="2015-09-23 11:26:19 +0200" MODIFIED_BY="[Empty name]" NAME="Van Cutsem 2014" YEAR="">
<REFERENCE MODIFIED="2015-09-23 11:26:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, et al</AU>
<TI>Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer</TI>
<SO>Clinical Cancer Research</SO>
<YR>2014</YR>
<VL>20</VL>
<PG>4240-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942774"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942773"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasui-2015" MODIFIED="2015-09-23 11:25:55 +0200" MODIFIED_BY="[Empty name]" NAME="Yasui 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-09-23 11:25:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasui H, Muro K, Shimada Y, Tsuji A, Sameshima S, Baba H, et al</AU>
<TI>A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study</TI>
<SO>Journal of Cancer Research in Clinical Oncology</SO>
<YR>2015</YR>
<VL>141</VL>
<PG>153-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942776"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942775"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshino-2012" MODIFIED="2015-09-23 11:26:05 +0200" MODIFIED_BY="[Empty name]" NAME="Yoshino 2012" YEAR="">
<REFERENCE MODIFIED="2015-09-23 11:26:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al</AU>
<TI>TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial</TI>
<SO>Lancet Oncology</SO>
<YR>2012</YR>
<VL>13</VL>
<PG>993-1001</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2942778"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2942777"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-06-13 17:07:22 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-12-09 09:05:56 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-12-09 09:05:56 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adam-2012" MODIFIED="2015-09-23 11:25:11 +0200" MODIFIED_BY="[Empty name]" NAME="Adam 2012" TYPE="JOURNAL_ARTICLE">
<AU>Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al</AU>
<TI>The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus</TI>
<SO>Oncologist</SO>
<YR>2012</YR>
<VL>17</VL>
<PG>1225-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1999" MODIFIED="2016-10-19 11:36:46 +0200" MODIFIED_BY="[Empty name]" NAME="Altman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Andersen PK</AU>
<TI>Calculating the number needed to treat for trials where the outcome is time to an event</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>1492-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnold-2013" MODIFIED="2015-08-22 14:48:34 +0200" MODIFIED_BY="[Empty name]" NAME="Arnold 2013" TYPE="JOURNAL_ARTICLE">
<AU>Arnold D, Stein A</AU>
<TI>New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy</TI>
<SO>Drugs</SO>
<YR>2013</YR>
<VL>73</VL>
<PG>883-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beretta-2013" MODIFIED="2015-09-23 11:24:53 +0200" MODIFIED_BY="[Empty name]" NAME="Beretta 2013" TYPE="JOURNAL_ARTICLE">
<AU>Beretta GD, Petrelli F, Stinco S, Cabiddu M, Ghilardi M, Squadroni M, et al</AU>
<TI>FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials</TI>
<SO>Medical Oncology</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>1</NO>
<PG>486</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Best-2000" MODIFIED="2016-10-19 11:37:02 +0200" MODIFIED_BY="[Empty name]" NAME="Best 2000" TYPE="COCHRANE_REVIEW">
<AU>Best P, Simmonds C, Baughan R, Buchanan R, Davis C, Fentiman I, et al</AU>
<TI>Palliative chemotherapy for advanced or metastatic colorectal cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-10-17 16:35:34 +0200" MODIFIED_BY="Anne Lawson"><IDENTIFIER MODIFIED="2016-10-17 16:35:34 +0200" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD001545"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Buyse-2007" MODIFIED="2015-09-23 11:24:44 +0200" MODIFIED_BY="[Empty name]" NAME="Buyse 2007" TYPE="JOURNAL_ARTICLE">
<AU>Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al</AU>
<TI>Progression-free survival is a surrogate for survival in advanced colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>5218-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTCAE" MODIFIED="2016-10-19 11:37:14 +0200" MODIFIED_BY="[Empty name]" NAME="CTCAE" TYPE="OTHER">
<TI>Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</TI>
<SO>ctep.cancer.gov/reporting/ctc.html</SO>
<YR>(accessed 16 October 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cunningham-2010" MODIFIED="2015-09-23 11:24:25 +0200" MODIFIED_BY="[Empty name]" NAME="Cunningham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al</AU>
<TI>Colorectal cancer</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<PG>1030-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2015" MODIFIED="2015-09-23 11:24:02 +0200" MODIFIED_BY="[Empty name]" NAME="Ferlay 2015" TYPE="JOURNAL_ARTICLE">
<AU>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al</AU>
<TI>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</TI>
<SO>International Journal of Cancer</SO>
<YR>2015</YR>
<VL>136</VL>
<PG>E359-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giessen-2015" MODIFIED="2015-09-23 11:23:53 +0200" MODIFIED_BY="[Empty name]" NAME="Giessen 2015" TYPE="JOURNAL_ARTICLE">
<AU>Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Schulz C, et al</AU>
<TI>Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials</TI>
<SO>Acta Oncologica</SO>
<YR>2015</YR>
<VL>54</VL>
<PG>187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2006" MODIFIED="2016-10-19 11:37:25 +0200" MODIFIED_BY="[Empty name]" NAME="Goldberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg M</AU>
<TI>Therapy for metastatic colorectal cancer</TI>
<SO>Oncologist</SO>
<YR>2006</YR>
<VL>11</VL>
<PG>981-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-2006" MODIFIED="2016-10-19 11:37:34 +0200" MODIFIED_BY="[Empty name]" NAME="Grothey 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A</AU>
<TI>Is there a third-line therapy for metastatic colorectal cancer?</TI>
<SO>Seminars in Oncology</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>6 Suppl 11</NO>
<PG>S36-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gustavsson-2015" MODIFIED="2015-09-23 11:23:16 +0200" MODIFIED_BY="[Empty name]" NAME="Gustavsson 2015" TYPE="JOURNAL_ARTICLE">
<AU>Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, et al</AU>
<TI>A review of the evolution of systemic chemotherapy in the management of colorectal cancer</TI>
<SO>Clinical Colorectal Cancer</SO>
<YR>2015</YR>
<VL>14</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2016-10-16 21:07:27 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A</AU>
<TI>GRADE guidelines: a new series of articles in the <I>Journal of Clinical Epidemiology</I>
</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<PG>380-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-10-19 11:37:49 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-10-19 11:38:00 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirstein-2014" MODIFIED="2015-05-19 18:26:27 +0200" MODIFIED_BY="[Empty name]" NAME="Kirstein 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A</AU>
<TI>Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data</TI>
<SO>Oncologist</SO>
<YR>2014</YR>
<VL>11</VL>
<PG>1156-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marques-2014" MODIFIED="2015-09-23 11:22:23 +0200" MODIFIED_BY="[Empty name]" NAME="Marques 2014" TYPE="JOURNAL_ARTICLE">
<AU>Marques AM, Turner A, de Mello RA</AU>
<TI>Personalizing medicine for metastatic colorectal cancer: current developments</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2014</YR>
<VL>20</VL>
<PG>10425-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2005" MODIFIED="2016-10-19 11:38:13 +0200" MODIFIED_BY="[Empty name]" NAME="NICE 2005" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review)</TI>
<SO>www.nice.org.uk/TA093.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2015-09-23 11:22:12 +0200" MODIFIED_BY="[Empty name]" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-12-09 09:04:06 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rougier-2005" MODIFIED="2015-09-23 11:21:39 +0200" MODIFIED_BY="[Empty name]" NAME="Rougier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rougier P, Lepere C</AU>
<TI>Second-line treatment of patients with metastatic colorectal cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>6 Suppl 9</NO>
<PG>S48-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saunders-2006" MODIFIED="2015-09-23 11:21:31 +0200" MODIFIED_BY="[Empty name]" NAME="Saunders 2006" TYPE="JOURNAL_ARTICLE">
<AU>Saunders M, Ivanson T</AU>
<TI>Management of advanced colorectal cancer: state of the art</TI>
<SO>British Journal of Cancer</SO>
<YR>2006</YR>
<VL>95</VL>
<PG>131-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmoll-2012" MODIFIED="2016-10-19 11:38:34 +0200" MODIFIED_BY="[Empty name]" NAME="Schmoll 2012" TYPE="JOURNAL_ARTICLE">
<AU>Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al</AU>
<TI>ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making</TI>
<SO>Annals Oncology</SO>
<YR>2012</YR>
<VL>23</VL>
<PG>2479-516</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2000" MODIFIED="2015-09-23 11:20:37 +0200" MODIFIED_BY="[Empty name]" NAME="Sterne 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Gavaghan D, Egger M</AU>
<TI>Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<PG>1119-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Therasse-2000" MODIFIED="2016-10-19 11:38:45 +0200" MODIFIED_BY="[Empty name]" NAME="Therasse 2000" TYPE="JOURNAL_ARTICLE">
<AU>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al</AU>
<TI>New guidelines to evaluate the response to treatment in solid tumors</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>3</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torre-2015" MODIFIED="2015-09-23 11:20:13 +0200" MODIFIED_BY="[Empty name]" NAME="Torre 2015" TYPE="JOURNAL_ARTICLE">
<AU>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A</AU>
<TI>Global cancer statistics, 2012</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2015</YR>
<VL>65</VL>
<PG>87-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1979" MODIFIED="2016-10-19 11:38:57 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 1979" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Handbook for Reporting Results of Cancer Treatment</SO>
<YR>1979</YR>
<PG>15-22</PG>
<PB>World Health Organization</PB>
<CY>Geneva, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2003" MODIFIED="2016-10-19 11:39:06 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 2003" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization/International Agency for Research on Cancer</AU>
<TI>The World Cancer Report - the major findings</TI>
<SO>Central European Journal of Public Health</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2016-10-19 14:01:47 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACS-2001" MODIFIED="2016-10-19 14:01:22 +0200" MODIFIED_BY="[Empty name]" NAME="ACS 2001" TYPE="OTHER">
<AU>American Cancer Society</AU>
<TI>Cancer facts and figures 2001</TI>
<SO>www.cancer.org/docroot/STT/content/STT_1x_2001_Facts_and_Figures.pdf.asp</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GLOBOCAN-2002" MODIFIED="2016-10-19 14:01:28 +0200" MODIFIED_BY="[Empty name]" NAME="GLOBOCAN 2002" TYPE="OTHER">
<AU>GLOBOCAN 2002</AU>
<TI>www.dep.iarc.fr</TI>
<SO>www.dep.iarc.fr</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karnofsky-1949" MODIFIED="2016-10-19 14:01:37 +0200" MODIFIED_BY="[Empty name]" NAME="Karnofsky 1949" TYPE="BOOK_SECTION">
<AU>Karnofsky DA, Burchenal JH</AU>
<TI>The clinical evaluation of chemotherapeutic agents in cancer</TI>
<SO>Evaluation of Chemotherapeutic Agents</SO>
<YR>1949</YR>
<PG>196</PG>
<ED>MacLeod CM</ED>
<PB>Columbia University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michael-2003" MODIFIED="2016-10-19 14:01:41 +0200" MODIFIED_BY="[Empty name]" NAME="Michael 2003" TYPE="BOOK_SECTION">
<AU>Michael M, Zalcberg JR</AU>
<TI>The treatment of carcinoma of the colon and rectum</TI>
<SO>Evidence-Based Oncology</SO>
<YR>2003</YR>
<PG>48-52</PG>
<ED>Williams C</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS><IDENTIFIER TYPE="OTHER" VALUE="ISBN: 0727914391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCCN" MODIFIED="2016-10-19 14:01:47 +0200" MODIFIED_BY="[Empty name]" NAME="NCCN" TYPE="OTHER">
<AU>NCCN</AU>
<TI>National Comprehensive Cancer Network</TI>
<SO>www.nccn.org</SO>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-11-07 11:19:07 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-11-07 11:19:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-10-19 10:34:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<CHAR_METHODS MODIFIED="2016-10-19 10:33:39 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (4-arm), open label, multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:33:48 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with oxaliplatin-containing regimen</P>
<P>Mean age (years): 59</P>
<P>Males (%): 47</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> axitinib + FOLFIRI (n = 49)</P>
<P>Axitinib (small molecule tyrosine kinase inhibitor targeting VEGFR1-3, c-KIT and PDGFR): 5 mg to 10 mg twice daily, oral</P>
<P>
<B>Control group:</B> bevacizumab + FOLFIRI (n = 51)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 5 mg/kg every 2 weeks, i.v.</P>
<P>
<B>Co-intervention:</B> FOLFIRI (every 2 weeks, i.v.): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-06 18:29:24 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>Same publication as <LINK REF="STD-Bendell-2013_x005f_folfox" TYPE="STUDY">Bendell 2013_folfox</LINK> (data split for presentation purposes only)</P>
<P>Country: international (Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:37:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<CHAR_METHODS MODIFIED="2016-10-19 10:36:49 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (4-arm), open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:36:57 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with irinotecan-containing regimen</P>
<P>Mean age (years): 59</P>
<P>Males (%): 47</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:37:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> axitinib + FOLFOX (n = 36)</P>
<P>Axitinib (small molecule tyrosine kinase inhibitor targeting multiple receptors such as VEGFR1-3, c-KIT and PDGFR): 5 mg to 10 mg twice daily, oral</P>
<P>
<B>Control group:</B> bevacizumab + FOLFOX (n = 35)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 5 mg/kg every 2 weeks, i.v.</P>
<P>
<B>Co-intervention:</B> FOLFOX (every 2 weeks, i.v.): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-06 19:02:01 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:37:15 +0200" MODIFIED_BY="[Empty name]">
<P>Same publication as <LINK REF="STD-Bendell-2013_x005f_folfiri" TYPE="STUDY">Bendell 2013_folfiri</LINK> (data split for presentation purposes only)</P>
<P>Country: international (Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:39:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennouna-2013">
<CHAR_METHODS MODIFIED="2016-10-19 10:38:43 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:38:51 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with oxaliplatin- or irinotecan-containing regimen</P>
<P>Mean age (years): 63</P>
<P>Males (%): 64</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:39:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> bevacizumab + chemotherapy (n = 409)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 5 mg/kg every 2 weeks, i.v.</P>
<P>
<B>Control group:</B> chemotherapy (n = 411)</P>
<P>Chemotherapy: irinotecan- or oxaliplatin-containing regimen (switch with first-line regimen)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-06 19:15:48 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:39:05 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>Dropouts: 4 (all in the combination regimen arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:39:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:39:24 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:39:30 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with oxaliplatin-containing regimen</P>
<P>Mean age (years): 62</P>
<P>Males (%): 62</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:39:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> bevacizumab + FOLFIRI (n = 65)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 10 mg/kg, i.v.</P>
<P>
<B>Control group:</B> FOLFIRI (n = 77)</P>
<P>FOLFIRI (i.v.): irinotecan (150 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-06 19:25:27 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:04 +0200" MODIFIED_BY="[Empty name]">
<P>Country: China</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:40:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2011">
<CHAR_METHODS MODIFIED="2016-10-19 10:39:53 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:39:58 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU-containing regimen</P>
<P>Mean age (years): unreported</P>
<P>Males (%): 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:40:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> FOLFIRI (n = 44)</P>
<P>FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (20 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group:</B> irinotecan (n = 45)</P>
<P>Irinotecan: 300 or 350 mg/m<SUP>2</SUP>, i.v., every 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:44:51 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:40:11 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Australia</P>
<P>Dropouts: 4 (2 in each arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:41:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohn-2013_x005f_conat">
<CHAR_METHODS MODIFIED="2016-10-19 10:40:58 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (3-arm), double blind, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:41:03 +0200" MODIFIED_BY="[Empty name]">
<P>People with mutant KRAS metastatic CRC who did not respond to first-line therapy with oxaliplatin (with or without bevacizumab)-containing regimen</P>
<P>Mean age (years): 59</P>
<P>Males (%): 51</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:41:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> conatumumab + FOLFIRI (n = 51)</P>
<P>Conatumumab (agonistic monoclonal antibody targeting DR5 (death receptor 5)): 10 mg/kg, i.v., every 2 weeks</P>
<P>
<B>Control group:</B> placebo + FOLFIRI (n = 52)</P>
<P>FOLFIRI: (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-09 17:08:21 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:41:18 +0200" MODIFIED_BY="[Empty name]">
<P>Same publication as <LINK REF="STD-Cohn-2013_x005f_ganit" TYPE="STUDY">Cohn 2013_ganit</LINK> (data split for presentation purposes only)</P>
<P>Country: international (mainly Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:41:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<CHAR_METHODS MODIFIED="2016-10-19 10:41:29 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (3-arm), double blind, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:41:34 +0200" MODIFIED_BY="[Empty name]">
<P>People with mutant KRAS metastatic CRC who did not respond to first-line therapy with oxaliplatin (with or without bevacizumab)-containing regimen</P>
<P>Mean age (years): 59</P>
<P>Males (%): 51</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:41:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>ganitumab + FOLFIRI (n = 51)</P>
<P>Ganitumab (blocking monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF1R)): 12 mg/kg, i.v., every 2 weeks</P>
<P>
<B>Control group:</B> placebo + FOLFIRI (n = 52)</P>
<P>FOLFIRI: (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-09 17:27:56 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:41:51 +0200" MODIFIED_BY="[Empty name]">
<P>Same publication as <LINK REF="STD-Cohn-2013_x005f_conat" TYPE="STUDY">Cohn 2013_conat</LINK> (data split for presentation purposes only)</P>
<P>Country: international (mainly Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:42:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cunningham-1998">
<CHAR_METHODS MODIFIED="2016-10-19 10:42:13 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:42:22 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU. Some participants (24%) had received &#8805; 2 previous chemotherapy regimens</P>
<P>Mean age (years): 61</P>
<P>Males (%): 66</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:42:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>irinotecan (n = 189)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> i.v. every 21 days</P>
<P>
<B>Control group: </B>best supportive care (n = 90)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:20:00 +0200" MODIFIED_BY="[Empty name]">
<P>OS, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:42:29 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>Dropouts: 10 (5 in each arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:42:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fuchs-2003">
<CHAR_METHODS MODIFIED="2016-10-19 10:42:42 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:42:47 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU</P>
<P>Mean age (years): 62</P>
<P>Males (%): 61</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:42:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> irinotecan schedule-1 (n = 196)</P>
<P>Irinotecan schedule-1 (single dose): 350 mg/m<SUP>2</SUP> i.v. every 3 weeks</P>
<P>
<B>Control group:</B> irinotecan schedule-2 (n = 95)</P>
<P>Irinotecan schedule-2 (fractionated): 125 mg/m<SUP>2</SUP> weekly during 4 weeks every 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:46:48 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:04 +0200" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:43:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giantonio-2007">
<CHAR_METHODS MODIFIED="2016-10-19 10:43:13 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:43:18 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with FOLFIRI</P>
<P>Mean age (years): 60</P>
<P>Males (%): 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:43:30 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> bevacizumab + FOLFOX4 (n = 286)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 10 mg/kg, i.v., every 2 weeks</P>
<P>
<B>Control group: </B>FOLFOX4 (n = 291)</P>
<P>FOLFOX4 (i.v., every 2 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (1000 mg/m<SUP>2</SUP>) + leucovorin (200 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 11:22:44 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:43:31 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (mainly USA)</P>
<P>Dropouts: 6 (number per arm: unreported)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:44:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gibbs-2011">
<CHAR_METHODS MODIFIED="2016-10-19 10:43:47 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open-label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:43:52 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU without oxaliplatin</P>
<P>Mean age (years): 63</P>
<P>Males (%): 59</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:44:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> hyaluronan-irinotecan (n = 41)</P>
<P>Hyaluronan-irinotecan (i.v., every 3 weeks): hyaluronan (1000 mg/m<SUP>2</SUP>) + irinotecan (350 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group:</B> irinotecan (n = 35)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP>, i.v., every 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 11:50:32 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:05 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Australia</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:44:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graeven-2007">
<CHAR_METHODS MODIFIED="2016-10-19 10:44:20 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open-label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:44:26 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU without oxaliplatin</P>
<P>Mean age (years): 66</P>
<P>Males (%): 64</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:44:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> FOLFIRI (n = 28)</P>
<P>FOLFIRI (i.v., every 7 weeks): irinotecan (80 mg/m<SUP>2</SUP>) + leucovorin (500 mg/m<SUP>2</SUP>) + 5FU (2000 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group: </B>irinotecan (n = 27)</P>
<P>Irinotecan: 125 mg/m<SUP>2</SUP>, i.v., every 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 12:00:20 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:44:38 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:45:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haller-2008">
<CHAR_METHODS MODIFIED="2016-10-19 10:45:01 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open-label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:45:08 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU or capecitabine without leucovorin</P>
<P>Mean age (years): 62</P>
<P>Males (%): 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:45:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> IROX (irinotecan + oxaliplatin) (n = 317)</P>
<P>IROX (i.v., every 3 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + irinotecan (200 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group: </B>irinotecan (n = 310)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 12:13:55 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:05 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (mainly Western countries)</P>
<P>Dropouts: 14 (5 in IROX arm; 9 in irinotecan arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:46:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hecht-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:45:49 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open-label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:45:56 +0200" MODIFIED_BY="[Empty name]">
<P>People with wild-type KRAS metastatic CRC who did not respond to first-line therapy with FOLFOX + bevacizumab</P>
<P>Mean age (years): 62</P>
<P>Males (%): 66</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:46:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> panitumumab + FOLFIRI (n = 91)</P>
<P>Panitumumab (blocking monoclonal antibody targeting EGFR): 6 mg/kg, i.v., every 2 weeks</P>
<P>
<B>Control group: </B>bevacizumab + FOLFIRI (n = 91)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 5 mg/kg to 10 mg/kg, i.v., every 2 weeks</P>
<P>
<B>Co-intervention: </B>FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 12:22:46 +0200" MODIFIED_BY="[Empty name]">
<P>OS; PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:05 +0200" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:46:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwamoto-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:46:30 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open-label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:46:35 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with FOLFOX + bevacizumab</P>
<P>Mean age (years): 66</P>
<P>Males (%): 56</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:46:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> bevacizumab (low dose) + FOLFIRI (n = 181)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF) low dose: 5 mg/kg (i.v., every 2 weeks)</P>
<P>
<B>Control group:</B> bevacizumab (high dose) + FOLFIRI (n = 188)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF) high dose: 10 mg/kg (i.v., every 2 weeks)</P>
<P>
<B>Co-intervention: </B>FOLFIRI (i.v., every 2 weeks): irinotecan (150 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (200 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 12:39:24 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:46:54 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Japan</P>
<P>Dropouts: 4 (1 in low-dose arm; 3 in high-dose arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:47:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2009">
<CHAR_METHODS MODIFIED="2016-10-19 10:47:05 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open-label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:47:09 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU</P>
<P>Mean age (years): 63</P>
<P>Males (%): 62</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:47:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> FOLFOX4 (n = 246)</P>
<P>FOLFOX4 (i.v., every 2 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (1000 mg/m<SUP>2</SUP>) + leucovorin (200 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group:</B> irinotecan (n = 245)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP>, i.v., every 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-14 14:03:41 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:47:23 +0200" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>Dropouts: 6 (3 per arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:48:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:47:38 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:47:47 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU- or oxaliplatin-based regimen</P>
<P>Mean age (years): 62</P>
<P>Males (%): 61</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:48:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> panitumumab + bevacizumab + FOLFIRI (n = 65)</P>
<P>Panitumumab (blocking monoclonal antibody targeting EGFR): 4 mg/kg, i.v., every 2 weeks</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 4 mg/kg, i.v., every 2 weeks</P>
<P>FOLFIRI: (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group:</B> FOLFIRI (n = 77)</P>
<P>FOLFIRI: (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-20 09:31:14 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:05 +0200" MODIFIED_BY="[Empty name]">
<P>Country: China</P>
<P>Quality issue: outcome findings (effect size + confidence intervals) do not appear to coincide with Kaplan-Meier curves findings</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:48:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masi-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:48:22 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:48:27 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with bevacizumab-containing regimen</P>
<P>Mean age (years): 64</P>
<P>Males (%): 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:48:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> bevacizumab + chemotherapy (FOLFOX or FOLFIRI) (n = 92)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): schedule unreported</P>
<P>Chemotherapy: FOLFOX or FOLFIRI (based on first-line regimen)</P>
<P>
<B>Control group: </B>chemotherapy (FOLFOX or FOLFIRI) (n = 92)</P>
<P>Chemotherapy: FOLFOX or FOLFIRI (based on first-line regimen)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-20 09:58:22 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:49:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muro-2010">
<CHAR_METHODS MODIFIED="2016-10-19 10:48:46 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:48:51 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy without irinotecan</P>
<P>Mean age (years): 61</P>
<P>Males (%): 54</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:49:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> IRIS (S-1 + irinotecan) (n = 213)</P>
<P>IRIS: irinotecan (125 mg/m<SUP>2</SUP> every 14 days, i.v.) + S-1 (40 mg to 60 mg twice daily for 2 weeks from days 1 to 14 and then a 2-week pause; orally); S-1 is an oral fluoropyrimidine consisting of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in which tegafur is a prodrug of fluorouracil</P>
<P>
<B>Control group:</B> FOLFIRI (n = 213)</P>
<P>FOLFIRI (i.v., every 2 weeks): irinotecan (150 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (200 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-02 11:08:40 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Japan</P>
<P>Trial acronym: FIRIS</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:49:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Neil-2014">
<CHAR_METHODS MODIFIED="2016-10-19 10:49:27 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (3-arm), open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:49:31 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with irinotecan- or 5FU-containing regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 51</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:49:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>linifanib low dose + FOLFOX (n = 49)</P>
<P>Linifanib low dose (small molecule tyrosine kinase inhibitor targeting VEGFR and PDGFR): 7.5 mg/day, oral</P>
<P>
<B>Control group:</B> bevacizumab + FOLFOX (n = 49)</P>
<P>Bevacizumab (blocking monoclonal antibody targeting VEGF): 10 mg/kg (i.v., every 2 weeks)</P>
<P>
<B>Co-intervention:</B> FOLFOX (i.v., every 2 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-20 11:50:19 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:50:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peeters-2010">
<CHAR_METHODS MODIFIED="2016-10-19 10:49:58 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:50:06 +0200" MODIFIED_BY="[Empty name]">
<P>People with KRAS wild-type metastatic CRC who did not respond to first-line therapy with 5FU-containing regimen (neither irinotecan nor anti-EGFR drugs allowed)</P>
<P>Mean age (years): 62</P>
<P>Males (%): 61</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:50:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> panitumumab + FOLFIRI (n = 303)</P>
<P>Panitumumab (blocking monoclonal antibody targeting EGFR): 6 mg/kg (i.v., every 2 weeks)</P>
<P>FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group:</B> FOLFIRI (n = 294)</P>
<P>FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:53:03 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:50:29 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>Note: the trial originally included also 483 participants with KRAS mutated CRC: since no effect is expected in this population (as the authors acknowledge), only the results from participants with KRAS wild-type CRC are presented here (dropouts: none reported)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:51:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peeters-2013">
<CHAR_METHODS MODIFIED="2016-10-19 10:50:45 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, double blind, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:50:49 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with FOLFOX regimen</P>
<P>Mean age (years): 56</P>
<P>Males (%): 62</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:51:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> trebananib + FOLFIRI (n = 95)</P>
<P>Trebananib (anti-angiogenic fusion protein targeting the Tie2 receptor): 10 mg/kg, i.v., weekly</P>
<P>
<B>Control group: </B>placebo + FOLFIRI (n = 49)</P>
<P>
<B>Co-intervention: </B>FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/kg) + 5FU (2800 mg/kg) + leucovorin (400 mg/kg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 09:55:37 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Price-2014">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>People with wild-type KRAS metastatic CRC who did not respond to first-line therapy with FOLFOX + bevacizumab</P>
<P>Mean age (years): 61</P>
<P>Males (%): 63</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> panitumumab (n = 499)</P>
<P>Panitumumab (blocking monoclonal antibody targeting EGFR): 6 mg/kg (i.v., every 2 weeks)</P>
<P>
<B>Control group:</B> cetuximab (n = 500)</P>
<P>Cetuximab (blocking monoclonal antibody targeting EGFR): 400 mg/kg followed by 250 mg/kg (i.v., weekly)</P>
<P>Study design: non-inferiority trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:48:39 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western and Eastern countries)</P>
<P>Dropouts: 11 (7 in experimental arm; 4 in control arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (3-arm), open label (?), multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with irinotecan-based regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 58</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> FOLFOX (n = 152)</P>
<P>FOLFOX (i.v., every 2 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (2000 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
<P>
<B>Control group:</B> 5FU (n = 151)</P>
<P>5FU (i.v., every 2 weeks): 5FU (2000 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 12:06:07 +0200" MODIFIED_BY="[Empty name]">
<P>PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (North America)</P>
<P>Dropouts: 10 (number per arm: unreported)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (3-arm), open label (?), multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with irinotecan-based regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 58</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> oxaliplatin (n = 156)</P>
<P>Oxaliplatin (i.v., every 2 weeks): 85 mg/m<SUP>2</SUP>
</P>
<P>
<B>Control group: </B>5FU (n = 151)</P>
<P>5FU (i.v., every 2 weeks): 5FU (2000 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 12:36:23 +0200" MODIFIED_BY="[Empty name]">
<P>PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (North America)</P>
<P>Dropouts: 10 (number per arm: unreported)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothenberg-2008">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:14 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label (?), multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:18 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with irinotecan-based regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 62</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> XELOX (n = 313)</P>
<P>XELOX (every 3 weeks): oxaliplatin (130 mg/m<SUP>2</SUP>, i.v.) + capecitabine (1000 mg/m<SUP>2</SUP> twice daily for 15 days)</P>
<P>
<B>Control group:</B> FOLFOX (n = 314)</P>
<P>FOLFOX (i.v., every 2 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (2000 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 12:41:24 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>Study design: non-inferiority trial</P>
<P>Dropouts: 8 (2 in XELOX arm; 6 in FOLFOX arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rougier-1998">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:18 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label (?), multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU-based regimen</P>
<P>Mean age (years): 58</P>
<P>Males (%): 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>irinotecan (n = 134)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
<P>
<B>Control group: </B>5FU (n = 133)</P>
<P>5FU (i.v., every 2 weeks): 5FU (2000 mg/m<SUP>2</SUP>) + leucovorin (200 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:56:54 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Europe)</P>
<P>Dropouts: 10 (5 per arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scheithauer-2002">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label (?), multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU-based regimen</P>
<P>Mean age (years): 66</P>
<P>Males (%): 44</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> oxaliplatin + mitomycin (n = 33)</P>
<P>Oxaliplatin (i.v.): 85 mg/m<SUP>2</SUP> on days 1 + 15</P>
<P>
<B>Control group:</B> irinotecan + mitomycin (n = 31)</P>
<P>Irinotecan (i.v.): 120 mg/m<SUP>2</SUP> on days 1 + 15</P>
<P>
<B>Co-intervention:</B> mitomycin-C (i.v.): 8 mg/m<SUP>2</SUP> every 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 15:37:20 +0200" MODIFIED_BY="[Empty name]">
<P>ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Austria</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seymour-2013">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>People with KRAS wild-type metastatic CRC who did not respond to first-line therapy with 5FU-based regimen (without oxaliplatin)</P>
<P>Mean age (years): 64</P>
<P>Males (%): 69</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> irinotecan + panitumumab (n = 230)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
<P>Panitumumab (blocking monoclonal antibody targeting EGFR): 9 mg/kg (i.v., every 3 weeks)</P>
<P>
<B>Control group:</B> irinotecan (n = 230)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 11:58:59 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>Country: UK</P>
<P>Dropouts: 12 (6 per arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoemaker-2004">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:20 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU-based regimen</P>
<P>Mean age (years): 61</P>
<P>Males (%): 58</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:20 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> irinotecan schedule-1 (n = 41)</P>
<P>Irinotecan schedule-1 (single dose): 350 mg/m<SUP>2</SUP>, i.v., every 3 weeks</P>
<P>
<B>Control group:</B> irinotecan schedule-2 (n = 44)</P>
<P>Irinotecan schedule-2 (fractionated): 125 mg/m<SUP>2</SUP>, i.v. weekly for 4 weeks every 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 16:28:05 +0200" MODIFIED_BY="[Empty name]">
<P>ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Europe)</P>
<P>Dropouts: 6 (number per arm: unreported)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sobrero-2008">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:22 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with FOLFOX regimen</P>
<P>Mean age (years): 62</P>
<P>Males (%): 63</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> irinotecan + cetuximab (n = 648)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
<P>Cetuximab (blocking monoclonal antibody targeting EGFR): 400 mg/m<SUP>2</SUP> followed by 250 mg/m<SUP>2</SUP> (i.v., weekly)</P>
<P>
<B>Control group:</B> irinotecan (n = 650)</P>
<P>Irinotecan: 350 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 12:03:04 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>People were not selected based on the KRAS status (which is today mandatory for cetuximab administration because only KRAS wild-type tumours can respond to the drug)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tabernero-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, double blind, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with FOLFOX + bevacizumab regimen</P>
<P>Mean age (years): 62</P>
<P>Males (%): 57</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>ramucirumab + FOLFIRI (n = 536)</P>
<P>Ramucirumab (blocking monoclonal antibody targeting VEGFR2): 8 mg/kg (i.v., every 2 weeks)</P>
<P>
<B>Control group:</B> placebo + FOLFIRI (n = 536)</P>
<P>
<B>Co-intervention: </B>FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-12 12:05:15 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE, QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:07 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (mainly Western countries)</P>
<P>Dropouts: 15 (8 in experimental and 7 in control arm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsavaris-2003">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, open label (?), multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU</P>
<P>Mean age (years): 63</P>
<P>Males (%): 56</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>irinotecan schedule-1 (n = 60)</P>
<P>Irinotecan schedule-1 (single dose): 350 mg/m<SUP>2</SUP> (i.v. every 3 weeks)</P>
<P>
<B>Control group:</B> irinotecan schedule-2 (n=60)</P>
<P>Irinotecan schedule-2: (fractionated):175 mg/m<SUP>2</SUP> (i.v. days 1 and 10 every 3 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-21 17:17:16 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:08 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Greece</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Cutsem-2011">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, double blind, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with FOLFIRI</P>
<P>Mean age (years): 60</P>
<P>Males (%): 58</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>FOLFOX + vatalanib (n = 426)</P>
<P>Vatalanib (also known as PTK787; small molecule tyrosine kinase inhibitor targeting VEGFR): 1250 mg/day, orally</P>
<P>
<B>Control group:</B> FOLFOX + placebo (n = 429)</P>
<P>
<B>Co-intervention: </B>FOLFOX (i.v., every 2 weeks): oxaliplatin (85 mg/m<SUP>2</SUP>) + 5FU (2000 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-22 15:40:06 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:08 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Cutsem-2012">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:25 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, double blind, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:25 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with oxaliplatin-based regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 63</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>FOLFIRI + aflibercept (n = 612)</P>
<P>Aflibercept (also known as VEGF trap; blocking fusion protein targeting VEGF): 4 mg/kg (i.v., every 2 weeks)</P>
<P>
<B>Control group: </B>FOLFIRI + placebo (n = 614)</P>
<P>
<B>Co-intervention:</B> FOLFIRI (i.v., every 2 weeks): irinotecan (180 mg/m<SUP>2</SUP>) + 5FU (2800 mg/m<SUP>2</SUP>) + leucovorin (400 mg/m<SUP>2</SUP>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-22 16:21:27 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:08 +0200" MODIFIED_BY="[Empty name]">
<P>Country: international (mainly Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vi_x00e9_itez-2011">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT, double blind, multicentre, national</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>People with metastatic CRC who did not respond to first-line therapy with 5FU-based regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 58</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group: </B>raltitrexed + gefitinib (n = 38)</P>
<P>Raltitrexed: 3 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
<P>Gefitinib: 250 mg/day (orally)</P>
<P>
<B>Control group:</B> raltitrexed (n = 38)</P>
<P>Raltitrexed: 3 mg/m<SUP>2</SUP> (i.v., every 3 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-02 11:15:59 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-23 10:41:08 +0200" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-07 11:19:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x00c9_lez-2015">
<CHAR_METHODS MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>Parallel-group RCT (3-arm), open label, multicentre, international</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>People with KRAS wild-type metastatic CRC who did not respond to first-line therapy with oxaliplatin-containing regimen</P>
<P>Mean age (years): 60</P>
<P>Males (%): 61</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-07 11:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental group:</B> abituzumab low dose + cetuximab + irinotecan (n = 73)</P>
<P>Abituzumab (blocking monoclonal antibody targeting integrin-alphaV): 500 mg (i.v., every 2 weeks)</P>
<P>
<B>Control group:</B> cetuximab + irinotecan (n = 72)</P>
<P>Irinotecan (i.v., every 2 weeks): 180 mg/m<SUP>2</SUP>
</P>
<P>
<B>Co-intervention: </B>cetuximab (blocking monoclonal antibody targeting EGFR): 400 (first dose) and then 250 mg/m<SUP>2</SUP> (i.v., weekly)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-25 11:24:13 +0200" MODIFIED_BY="[Empty name]">
<P>OS, PFS, ORR, SAE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-15 15:21:20 +0200" MODIFIED_BY="Anne Lawson">
<P>Country: international (Western countries)</P>
<P>Dropouts: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>5FU: 5-fluorouracil; CRC: colorectal cancer; EGFR: epidermal growth factor receptor; FOLFIRI: 5FU plus leucovorin plus irinotecan; FOLFOX: 5FU plus leucovorin plus oxaliplatin; i.v.: intravenous; n: number of participants; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; QoL: quality of life; RCT: randomized controlled trial; SAE: severe adverse effect; VEGF: vascular endothelial growth factor; XELOX: capecitabine + oxaliplatin.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amado-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment (on results described in <LINK REF="STD-Van-Cutsem-2007" TYPE="STUDY">Van Cutsem 2007</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aranda-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chau-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis of <LINK REF="STD-Lal-2004" TYPE="STUDY">Lal 2004</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chibaudel-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>Non-comparative study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comella-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comella-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cunningham-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-13 17:24:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ducreux-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-13 17:24:28 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of first- to second-line sequence of regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garrett-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grothey-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-29 15:55:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hendlisz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-29 15:55:47 +0200" MODIFIED_BY="[Empty name]">
<P>Hepatic arterial infusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hurwitz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jonker-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kabbinavar-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:27 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-06 13:38:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kemeny-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-06 13:38:50 +0200" MODIFIED_BY="[Empty name]">
<P>Hepatic arterial infusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-13 17:24:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koopman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-13 17:24:43 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of first- to second-line sequence of regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Labianca-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment (continuous vs intermittent)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-29 18:27:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacouture-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-29 18:27:39 +0200" MODIFIED_BY="[Empty name]">
<P>Trial focusing on skin toxicity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lal-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]">
<P>Only participants responding to second-line therapy were randomized to 2 different treatments</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:29 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandal_x00e1_-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maughan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Only participants responding (or stable) after first-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mayer-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-07 15:43:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muro-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-07 15:43:13 +0200" MODIFIED_BY="[Empty name]">
<P>No suitable data (abstract only)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rao-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reidy-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rougier-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment; no survival data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltz-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-13 17:25:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seymour-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-13 17:25:00 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of first- to second-line sequence of regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siu-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-13 17:25:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tournigand-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-13 17:25:11 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of first- to second-line sequence of regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tournigand-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment (continuous vs intermittent)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsavaris-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>First-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Cutsem-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of standard dose irinotecan (350 mg/m<SUP>2</SUP>) with a variable dosage (250 or 350 or 500 mg/m<SUP>2</SUP>) according to participant tolerance</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Cutsem-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Cutsem-2012_x005f_bis">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Randomization of a subgroup of participants (those with low toxicity after cetuximab administration)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Cutsem-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment (most participants)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yasui-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Duplicate of <LINK REF="STD-Muro-2010" TYPE="STUDY">Muro 2010</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoshino-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-19 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<P>Third (or higher)-line treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-06-13 17:07:22 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-11-06 17:27:07 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 16:33:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>Permuted block randomization by second-order minimization algorithm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 16:36:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>Randomization by minimization method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 17:18:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>Permutated blocks randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 17:33:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>Permutated blocks randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 10:43:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>Random sequence was generated electronically</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>Random sequence was generated electronically</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:26:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:54:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:04:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:16:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>Central randomization by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:29:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:31:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>Dynamic randomization with minimization method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-29 09:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>"Patients were randomly assigned to treatment through dynamic allocation designed to balance assignment for stratification factors"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-20 09:49:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-20 10:01:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-28 13:41:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>"Randomisation by a computer program, by use of a minimisation method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-20 12:02:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-29 08:19:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 10:02:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>Randomization by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 10:09:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>Randomization by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 11:55:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 11:56:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 12:46:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>"Dynamic randomization was used to assign patients to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 13:08:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>"Randomization stratified by centre and performance status was done with a minimisation procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-28 16:08:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>"Patients were stratified. [...] Balance across strata was attained using the method of Pocock and Simon"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>Computer-generated randomization sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 16:24:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 16:51:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 17:06:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>Computerized randomization system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 17:08:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>"Patients were allocated to the two treatment groups by a simple randomization method (closed envelopes)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-22 15:46:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>Randomization by means of an interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-22 16:22:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>Randomization by means of an interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-02 11:18:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-25 11:41:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-10-19 10:49:14 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 16:32:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>Clinical and statistical teams were masked during the study </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:00:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-19 10:40:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>Participants were randomized centrally by telephone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 17:20:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>Centralized randomization (interactive voice response system)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-09 17:34:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>Centralized randomization (interactive voice response system)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-25 15:21:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:01:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:26:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 11:54:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:05:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:17:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>Central randomization by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:29:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 12:33:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 14:05:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>Remote registration and randomization through a website or by telephone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-20 09:49:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-20 10:01:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-19 10:49:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>"Investigators provided the patient's details to the central registration centre through a web-based registration system. After an eligibility check, patients were randomly assigned to receive FOLFIRI or IRIS at the central. Assignment of patients was concealed from the investigator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-20 12:02:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-29 08:19:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 10:02:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>Randomization by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 10:09:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>Randomization by interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 11:56:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 11:57:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 12:46:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 13:01:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 15:01:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-02 11:33:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>An automated telephonic system was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-18 16:18:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 16:51:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 17:06:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>Randomization by means of a voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 17:08:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>"Patients were allocated to the two treatment groups by a simple randomization method (closed envelopes)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-22 16:21:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>Randomization by means of an interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-22 16:22:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>Randomization by means of an interactive voice response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-02 11:18:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-25 11:41:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>Centralized randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-06-06 18:49:22 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:34:06 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:37:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:39:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:39:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-06-06 19:46:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:41:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:42:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:42:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:42:58 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:43:33 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:44:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:44:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:45:21 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:46:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:46:55 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:47:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:48:09 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:48:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:49:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:49:46 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:50:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:51:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>Double-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:34:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:37:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:39:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:39:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-06 19:46:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-09 17:21:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-09 17:34:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:42:32 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:42:59 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:43:34 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:44:09 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:44:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:45:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:46:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:46:56 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:47:28 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:48:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:48:36 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:49:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:49:47 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:50:32 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-21 10:02:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-21 12:51:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>"Assessment of tumor response was made by an independent response review committee (IRC) that was blinded to treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-21 15:03:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>Treatment efficacy evaluated by personnel blinded to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-21 17:05:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>Open-label trial (?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-22 15:47:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-06-22 16:22:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-07-02 11:19:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>Unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-19 10:52:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-11-06 17:27:07 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Efficacy outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Safety and QoL outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:19:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:19:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:21:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:21:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:21:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:21:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:22:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:22:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-19 10:40:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>Only 1 participant explicitly asking not to be analyzed (irinotecan arm) was excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:22:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:22:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:23:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:23:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:23:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:23:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:24:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>"A total of seven patients, one on the weekly schedule and six on the every-3-weeks regimen, received no irinotecan and were excluded from the tolerability analysis." Reasons for not receiving treatment are described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:24:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:24:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:25:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-06 17:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>"Efficacy analyses were based on an intent-to-treat population". 57 patients were enrolled into this multicentre study. 2 patients were withdrawn prior to the first administration. Therefore, the intent-to-treat population includes 55 patients. Overall survival and PFS are presented for 55 participants. Neither the arm the two patients belonged to, nor the reasons for withdrawal were reported</P>
<P>"39 patients were evaluable for response", therefore the intention-to-treat population includes 16 no evaluable participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:25:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:25:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:26:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:26:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:27:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:27:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:27:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:27:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:28:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:28:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:28:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:28:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:29:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:29:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:29:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:30:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:30:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:30:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:36:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>Intention-to-treat efficacy analysis with 459 eligible participants out of 463 randomized participants. Reasons for ineligibility are described for these 4 participants, but not treatment group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>Safety analysis performed with 445 participants that received treatment during the study out of 463 randomized participants. Group assignment and reasons for not receiving treatment are not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-19 10:52:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>Intention-to-treat efficacy analysis with 459 eligible participants out of 463 randomized participants. Reasons for ineligibility are described for these 4 participants, but not treatment group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-10-19 10:52:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>Safety analysis performed with 445 participants that received treatment during the study out of 463 randomized participants. Group assignment and reasons for not receiving treatment are not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:31:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:31:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>"Of 267 patients randomly allocated treatment, 256 received at least one cycle of treatment." The 11 dropout or withdrawn participants were balanced among treatment arms with regard to number and reason of exclusion</P>
<P>All efficacy results were presented for 256 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-10-19 10:52:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>Safety results are presented for 256 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:32:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:32:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:33:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:33:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-19 10:52:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>174 participants entered the study. 168 received medication and comprised the intention-to-treat population. No information reported on the 6 participants who did not receive medication, and to which group they belonged to</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:33:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:33:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:33:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:34:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:34:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:34:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:34:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:34:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:35:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:35:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:35:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:35:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:35:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-23 16:24:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-10-23 16:24:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>We found no evidence of attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-10-19 10:52:14 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:19:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:21:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:22:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:22:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:22:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:23:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:23:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:23:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:24:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:25:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:25:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:25:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:26:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:26:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:26:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:27:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:27:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:28:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:29:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:29:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:29:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:30:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:31:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-19 10:52:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>OS findings unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-19 10:52:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>OS findings unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:32:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:32:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 15:38:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>No survival data (hazard ratios or survival curves) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:33:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 16:27:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>No survival data (hazard ratios or survival curves) reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:33:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:34:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:34:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-22 15:47:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>Response rates unreported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:35:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:36:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:24:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>We found no evidence of reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2015-10-23 16:36:09 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Other bias?</NAME>
<DESCRIPTION>
<P>See Appendix 5 for explanations</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:21:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfiri">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:21:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bendell-2013_x005f_folfox">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:22:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennouna-2013">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:22:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:22:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2011">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:23:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_conat">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:23:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohn-2013_x005f_ganit">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-14 10:45:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cunningham-1998">
<DESCRIPTION>
<P>"Characteristics were similar for both groups except for performance status (more patients having poor performance status in the supportive-care group) and anaemia."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:24:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuchs-2003">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:25:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giantonio-2007">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:25:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gibbs-2011">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:25:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graeven-2007">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:26:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haller-2008">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:26:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hecht-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:26:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iwamoto-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:27:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2009">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:27:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:28:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Masi-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:29:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muro-2010">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:29:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Neil-2014">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:30:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2010">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:30:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-2013">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:31:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Price-2014">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:31:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_folfox">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:31:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2003_x005f_oxa">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:32:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothenberg-2008">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-21 13:09:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rougier-1998">
<DESCRIPTION>
<P>"A significant difference in baseline was found for the percentage of patients with hyperleukocytosis, but the mean white-blood-cell counts in both groups were similar."</P>
<P>The review authors considered this imbalance as unimportant and not a source of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:32:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheithauer-2002">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:33:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seymour-2013">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:33:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shoemaker-2004">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sobrero-2008">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:34:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabernero-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:34:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsavaris-2003">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:35:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2011">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:35:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Cutsem-2012">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:36:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vi_x00e9_itez-2011">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-23 16:24:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00c9_lez-2015">
<DESCRIPTION>
<P>We found no evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-10-19 11:16:53 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-10-19 11:09:19 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-10-19 11:09:19 +0200" MODIFIED_BY="[Empty name]">Modern chemotherapy regimens compared with 5-flourouracil</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Modern chemotherapy regimens compared with 5-fluorouracil</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention: </B>modern CTX (FOLFOX or irinotecan)</P>
<P>
<B>Comparison: </B>5FU</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks*</P>
<P>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
<P/>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>5FU</P>
</TH>
<TH VALIGN="TOP">
<P>Modern CTX</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>800 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>671 per 1000</P>
<P>(560 to 780)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.69</P>
<P>(0.51 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>167</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial available</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>900 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>749 per 1000</P>
<P>(669 to 818)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.59</P>
<P>(0.49 to 0.73)</P>
</TD>
<TD VALIGN="TOP">
<P>470</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>34 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>99 per 1000</P>
<P>(50 to 197)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.96</P>
<P>(1.66 to 5.27)</P>
</TD>
<TD VALIGN="TOP">
<P>866</P>
<P>(3 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>450 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>621 per 1000</P>
<P>(481 to 801)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.39</P>
<P>(1.22 to 1.58)</P>
</TD>
<TD VALIGN="TOP">
<P>843</P>
<P>(3 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: between-study heterogeneity</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>5FU:</B> 5-fluorouracil; <B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>CTX:</B> chemotherapy; <B>FOLFOX:</B> fluorouracil + oxaliplatin + leucovorin; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 10%; 1-year overall survival rate = 20%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-10-19 11:10:18 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-10-19 11:10:18 +0200" MODIFIED_BY="[Empty name]">Chemotherapy + bevacizumab compared with chemotherapy</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Chemotherapy + bevacizumab compared with chemotherapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> bevacizumab + CTX</P>
<P>
<B>Comparison:</B> CTX</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>CTX</P>
</TH>
<TH VALIGN="TOP">
<P>Bevacizumab + CTX</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>515 per 1000</P>
<P>(474 to 554)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.79</P>
<P>(0.70 to 0.88)</P>
</TD>
<TD VALIGN="TOP">
<P>1723</P>
<P>(4 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>850 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>720 per 1000</P>
<P>(680 to 759)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.67</P>
<P>(0.60 to 0.75)</P>
</TD>
<TD VALIGN="TOP">
<P>1723</P>
<P>(4 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>92 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>158 per 1000</P>
<P>(113 to 223)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.72</P>
<P>(1.23 to 2.43)</P>
</TD>
<TD VALIGN="TOP">
<P>1723</P>
<P>(4 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>585 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>626 per 1000</P>
<P>(544 to 731)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.07</P>
<P>(0.93 to 1.25)</P>
</TD>
<TD VALIGN="TOP">
<P>1708</P>
<P>(4 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + - -</P>
<P>Low</P>
</TD>
<TD VALIGN="TOP">
<P>Reasons for downgrading: 95% CI crossed the null value and between-study heterogeneity</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>CTX:</B> chemotherapy; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 15%; 1-year overall survival rate = 40%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-10-19 11:11:38 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-10-19 11:11:38 +0200" MODIFIED_BY="[Empty name]">Irinotecan-based regimens compared with irinotecan</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Irinotecan-based regimens compared with irinotecan</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> irinotecan-based combination CTX</P>
<P>
<B>Comparison: </B>irinotecan</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Irinotecan</P>
</TH>
<TH VALIGN="TOP">
<P>Irinotecan combination</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>850 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>725 per 1000</P>
<P>(680 to 764)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.68</P>
<P>(0.60 to 0.76)</P>
</TD>
<TD VALIGN="TOP">
<P>2615</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: results inconsistency (progression-free survival findings not supported by overall survival findings)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>565 per 1000</P>
<P>(515 to 614)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.91 (0.79 to 1.04)</P>
</TD>
<TD VALIGN="TOP">
<P>2615</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + - -</P>
<P>Low</P>
</TD>
<TD VALIGN="TOP">
<P>Reasons for downgrading: results imprecision (95% CI crossed the null value) and inconsistency (moderate between-study heterogeneity; overall survival findings not supported by progression-free survival findings)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>67 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>192 per 1000</P>
<P>(141 to 263)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.87</P>
<P>(2.10 to 3.93)</P>
</TD>
<TD VALIGN="TOP">
<P>2577</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>480 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>566 per 1000</P>
<P>(461 to 696)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.18</P>
<P>(0.96 to 1.45)</P>
</TD>
<TD VALIGN="TOP">
<P>2510</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: between-study heterogeneity</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>CTX:</B> chemotherapy; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 15%; 1-year overall survival rate = 40%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2016-10-19 11:13:11 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-10-19 11:13:11 +0200" MODIFIED_BY="[Empty name]">Irinotecan + oxaliplatin compared with irinotecan</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Irinotecan + oxaliplatin compared with irinotecan</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> irinotecan + oxaliplatin (IROX)</P>
<P>
<B>Comparison:</B> irinotecan</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Irinotecan</P>
</TH>
<TH VALIGN="TOP">
<P>IROX</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>511 per 1000</P>
<P>(459 to 562)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.78</P>
<P>(0.67 to 0.90)</P>
</TD>
<TD VALIGN="TOP">
<P>627</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>900 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>749 per 1000</P>
<P>(718 to 781)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.60</P>
<P>(0.55 to 0.66)</P>
</TD>
<TD VALIGN="TOP">
<P>627</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>221 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>658 per 1000</P>
<P>(422 to 1025)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.98</P>
<P>(1.91 to 4.64)</P>
</TD>
<TD VALIGN="TOP">
<P>627</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>594 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>725 per 1000</P>
<P>(647 to 814)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.22</P>
<P>(1.09 to 1.37)</P>
</TD>
<TD VALIGN="TOP">
<P>627</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 10%; 1-year overall survival rate = 40%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2016-10-19 11:13:48 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2016-10-19 11:13:48 +0200" MODIFIED_BY="[Empty name]">Chemotherapy compared with best supportive care</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Chemotherapy compared with best supportive care</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> CTX</P>
<P>
<B>Comparison:</B> BSC</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>BSC</P>
</TH>
<TH VALIGN="TOP">
<P>CTX</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>850 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>667 per 1000</P>
<P>(557 to 780)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.58</P>
<P>(0.43 to 0.80)</P>
</TD>
<TD VALIGN="TOP">
<P>279</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>12 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>14 per 1000</P>
<P>(12 to 17)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.19</P>
<P>(1.01 to 1.40)</P>
</TD>
<TD VALIGN="TOP">
<P>279</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>BSC:</B> best supportive care; <B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>CTX:</B> chemotherapy; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year overall survival rate = 15%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2016-10-19 11:14:41 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2016-10-19 11:14:41 +0200" MODIFIED_BY="[Empty name]">FOLFIRI + targeted therapy compared with FOLFIRI</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>FOLFIRI + targeted therapy compared with FOLFIRI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> FOLFIRI + targeted agents</P>
<P>
<B>Comparison: </B>FOLFIRI</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>FOLFIRI</P>
</TH>
<TH VALIGN="TOP">
<P>FOLFIRI + targeted agents</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>550 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>488 per 1000</P>
<P>(459 to 516)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.84</P>
<P>(0.77 to 0.91)</P>
</TD>
<TD VALIGN="TOP">
<P>3335</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>850 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>772 per 1000</P>
<P>(740 to 808)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.78</P>
<P>(0.71 to 0.87)</P>
</TD>
<TD VALIGN="TOP">
<P>3335</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>112 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>232 per 1000</P>
<P>(147 to 367)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.07</P>
<P>(1.31 to 3.28)</P>
</TD>
<TD VALIGN="TOP">
<P>3192</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: between-study heterogeneity</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>494 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>642 per 1000</P>
<P>(578 to 716)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.30</P>
<P>(1.17 to 1.45)</P>
</TD>
<TD VALIGN="TOP">
<P>3341</P>
<P>(6 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: between-study heterogeneity</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>FOLFIRI:</B> fluorouracil + irinotecan + leucovorin; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 15%; 1-year overall survival rate = 45%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2016-10-19 11:15:59 +0200" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2016-10-19 11:15:59 +0200" MODIFIED_BY="[Empty name]">FOLFOX + targeted therapy compared with FOLFOX</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>FOLFOX + targeted therapy compared with FOLFOX</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> FOLFOX + targeted agents</P>
<P>
<B>Comparison:</B> FOLFOX</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>FOLFOX</P>
</TH>
<TH VALIGN="TOP">
<P>FOLFOX + targeted agents</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>553 per 1000</P>
<P>(453 to 654)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.92 (0.82 to 1.04)</P>
</TD>
<TD VALIGN="TOP">
<P>1432</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ - - -</P>
<P>Very low</P>
</TD>
<TD VALIGN="TOP">
<P>Reasons for downgrading: results imprecision (95% CI crosses the null value) and inconsistency (high between-study heterogeneity; overall survival findings not supported by progression-free survival findings)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>900 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>809 per 1000</P>
<P>(705 to 892)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.76</P>
<P>(0.66 to 0.86)</P>
</TD>
<TD VALIGN="TOP">
<P>1432</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + - -</P>
<P>Low</P>
</TD>
<TD VALIGN="TOP">
<P>Reasons for downgrading: results inconsistency (between-study heterogeneity and progression-free survival findings not conformed by overall survival data)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>86 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>227 per 1000</P>
<P>(147 to 349)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.64</P>
<P>(1.71 to 4.06)</P>
</TD>
<TD VALIGN="TOP">
<P>578</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: only 1 trial available</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>669 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>803 per 1000</P>
<P>(756 to 856)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.20</P>
<P>(1.13 to 1.28)</P>
</TD>
<TD VALIGN="TOP">
<P>1414</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>FOLFIRI:</B> fluorouracil + irinotecan + leucovorin; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 10%; 1-year overall survival rate = 40%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2016-10-19 11:16:53 +0200" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2016-10-19 11:16:53 +0200" MODIFIED_BY="[Empty name]">Irinotecan + targeted therapy compared with irinotecan</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Irinotecan + targeted therapy compared with irinotecan</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with metastatic CRC</P>
<P>
<B>Settings:</B> second-line treatment</P>
<P>
<B>Intervention:</B> irinotecan + targeted therapy</P>
<P>
<B>Comparison:</B> irinotecan</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Irinotecan</P>
</TH>
<TH VALIGN="TOP">
<P>Irinotecan + targeted therapy</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
<TD VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>596 per 1000</P>
<P>(553 to 603)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.99</P>
<P>(0.88 to 1.10)</P>
</TD>
<TD VALIGN="TOP">
<P>1758</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + - -</P>
<P>Low</P>
</TD>
<TD VALIGN="TOP">
<P>Reasons for downgrading: results imprecision (95% CI crosses the null value) and inconsistency (overall survival findings not conformed by progression-free survival data)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
<TD VALIGN="TOP">
<P>900 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>805 per 1000</P>
<P>(771 to 838)</P>
</TD>
<TD VALIGN="TOP">
<P>HR 0.71 </P>
<P>(0.64 to 0.79)</P>
</TD>
<TD VALIGN="TOP">
<P>1758</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + -</P>
<P>Moderate</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for downgrading: results inconsistency (progression-free survival findings not conformed by overall survival data)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall tumour response</P>
</TD>
<TD VALIGN="TOP">
<P>61 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>206 per 1000</P>
<P>(154 to 276)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 3.38</P>
<P>(2.53 to 4.52)</P>
</TD>
<TD VALIGN="TOP">
<P>1758</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Severe adverse effects</P>
</TD>
<TD VALIGN="TOP">
<P>425 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>612 per 1000</P>
<P>(557 to 676)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.44</P>
<P>(1.31 to 1.59)</P>
</TD>
<TD VALIGN="TOP">
<P>1704</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>+ + + +</P>
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (median control group risk across studies) for survival outcomes is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>CRC:</B> colorectal cancer; <B>HR:</B> hazard ratio; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Assumed risk in controls: 1-year progression-free survival rate = 10%; 1-year overall survival rate = 40%.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-11-07 11:20:18 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-11-07 11:20:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-08-20 16:32:23 +0200" MODIFIED_BY="[Empty name]">List of abbreviations</TITLE>
<TABLE COLS="2" ROWS="26">
<TR>
<TH VALIGN="TOP">
<P>
<B>Acronym</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Full name</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5FU</P>
</TD>
<TD VALIGN="TOP">
<P>5-fluorouracil</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Ang1</P>
</TD>
<TD VALIGN="TOP">
<P>Angiopoietin-1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Ang2</P>
</TD>
<TD VALIGN="TOP">
<P>Angiopoietin-2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CRC</P>
</TD>
<TD VALIGN="TOP">
<P>Colorectal cancer</P>
</TD>
</TR>
<TR>
<TD>
<P>CTX</P>
</TD>
<TD>
<P>Chemotherapy</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DR5</P>
</TD>
<TD VALIGN="TOP">
<P>Death receptor 5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EGFR</P>
</TD>
<TD VALIGN="TOP">
<P>Epithelial growth factor receptor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>Fluorouracil + irinotecan + leucovorin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>FOLFOX</P>
</TD>
<TD VALIGN="TOP">
<P>Fluorouracil + oxaliplatin + leucovorin</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>HR</P>
</TD>
<TD VALIGN="TOP">
<P>Hazard ratio</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IGF1R</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin-like growth factor 1 receptor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IRIS</P>
</TD>
<TD VALIGN="TOP">
<P>S-1 + irinotecan</P>
</TD>
</TR>
<TR>
<TD>
<P>i.v.</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>KRAS</P>
</TD>
<TD>
<P>Name of a gene whose product acts downstream of EGFR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ORR</P>
</TD>
<TD VALIGN="TOP">
<P>Overall response rate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>OS</P>
</TD>
<TD VALIGN="TOP">
<P>Overall survival</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PDGFR</P>
</TD>
<TD VALIGN="TOP">
<P>Platelet derived growth factor receptor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PFS</P>
</TD>
<TD VALIGN="TOP">
<P>Progression-free survival</P>
</TD>
</TR>
<TR>
<TD>
<P>QoL</P>
</TD>
<TD>
<P>Quality of life</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>RCT</P>
</TD>
<TD VALIGN="TOP">
<P>Randomized controlled trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>Risk ratio</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>SAE</P>
</TD>
<TD VALIGN="TOP">
<P>Severe adverse event</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>VEGF</P>
</TD>
<TD VALIGN="TOP">
<P>Vascular endothelium growth factor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>VEGFR</P>
</TD>
<TD VALIGN="TOP">
<P>VEGF receptor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>XELOX</P>
</TD>
<TD VALIGN="TOP">
<P>Capecitabine + oxaliplatin</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-10-19 10:52:31 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-08-19 13:37:56 +0200" MODIFIED_BY="[Empty name]">Main features of anticancer agents</TITLE>
<TABLE COLS="4" ROWS="19">
<TR>
<TH VALIGN="TOP">
<P>
<B>Name (abbreviation)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Class</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Mechanism of action</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Route of administration</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5-fluorouracil (5FU)</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>Antimetabolite (pyrimidine analogue) inhibiting RNA synthesis and the enzyme thymidylate synthase (which converts dUMP to dTMP which in turn is needed for the synthesis of DNA)</P>
</TD>
<TD VALIGN="TOP">
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Oxaliplatin</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>Alkylating agent binding covalently to DNA, which in turn inhibits DNA replication or causes DNA breaks</P>
</TD>
<TD VALIGN="TOP">
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>Inhibits the enzyme topoisomerase-I, which is involved in DNA replication or transcription</P>
</TD>
<TD VALIGN="TOP">
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Mitomycin-C</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>Alkylating agent binding covalently to DNA, which in turn inhibits DNA replication or causes DNA breaks</P>
</TD>
<TD VALIGN="TOP">
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Raltitrexed</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>Antimetabolite that inhibits the enzyme thymidylate synthase (which converts dUMP to dTMP which in turn is needed for the synthesis of DNA)</P>
</TD>
<TD VALIGN="TOP">
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Capecitabine</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>It is a prodrug of 5FU: one within the cells, it is transformed into the active drug</P>
</TD>
<TD VALIGN="TOP">
<P>Oral</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S-1</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy agent</P>
</TD>
<TD VALIGN="TOP">
<P>Antimetabolite (pyrimidine analogue) inhibiting RNA synthesis and the enzyme thymidylate synthase (which converts dUMP to dTMP which in turn is needed for the synthesis of DNA)</P>
</TD>
<TD VALIGN="TOP">
<P>Oral</P>
</TD>
</TR>
<TR>
<TD>
<P>Bevacizumab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody blocking VEGF (a ligand of VEGFR, a receptor involved in angiogenesis)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Cetuximab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody blocking EGFR (a receptor involved in cell proliferation); best works against KRAS wild-type tumours</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Panituzumab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody blocking EGFR (a receptor involved in cell proliferation); best works against KRAS wild-type tumours</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Conatumumab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody activating DR5 (a receptor involved in cell apoptosis)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Ganitumab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody blocking IGF1R (a receptor involved in cell proliferation)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Ramucirumab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody blocking VEGFR (a receptor involved in angiogenesis)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Abituzumab</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Monoclonal antibody blocking integrin-alphaV (a molecule involved in cell adhesion)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Trebananib</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Recombinant protein blocking Ang1 and Ang2 (ligands of Tie2, a receptor involved in angiogenesis)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD>
<P>Aflibercept</P>
</TD>
<TD>
<P>Targeted drug</P>
</TD>
<TD>
<P>Recombinant protein blocking VEGF (a ligand of VEGFR, a receptor involved in angiogenesis)</P>
</TD>
<TD>
<P>Intravenous</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vatalanib</P>
</TD>
<TD VALIGN="TOP">
<P>Targeted drug</P>
</TD>
<TD VALIGN="TOP">
<P>Small molecule inhibitor of multiple tyrosine kinases such as VEGFR (a receptor involved in angiogenesis) and PDGFR (a receptor involved in cell proliferation)</P>
</TD>
<TD VALIGN="TOP">
<P>Oral</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gefitinib</P>
</TD>
<TD VALIGN="TOP">
<P>Targeted drug</P>
</TD>
<TD VALIGN="TOP">
<P>Small molecule inhibitor of tyrosine kinase EGFR (a receptor involved in cell proliferation); best works against EGFR mutated/KRAS wild-type tumours</P>
</TD>
<TD VALIGN="TOP">
<P>Oral</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Ang1: angiopoietin-1, Ang2: angiopoietin-2; DR5: death receptor 5; dTMP: deoxythymidine monophosphate; dUMP: deoxyuridine monophosphate; IGF1R: insulin-like growth factor 1 receptor; PDGFR: platelet-derived growth factor receptor; RNA: ribonucleic acid; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-10-19 10:52:31 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-08-19 14:59:13 +0200" MODIFIED_BY="[Empty name]">Summary of studies' results</TITLE>
<TABLE COLS="6" ROWS="38">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>OS (HR, 95% CI)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>PFS (HR, 95% CI)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>ORR (RR, 95% CI)</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>SAE (RR, 95% CI)</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bendell-2013_x005f_folfiri" TYPE="STUDY">Bendell 2013_folfiri</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Axitinib + FOLFIRI vs bevacizumab + FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>1.36 (0.82 to 2.26)</P>
</TD>
<TD VALIGN="TOP">
<P>1.27 (0.77 to 2.09)</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 (0.55 to 2.22)</P>
</TD>
<TD VALIGN="TOP">
<P>2.09 (1.04 to 4.23)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bendell-2013_x005f_folfox" TYPE="STUDY">Bendell 2013_folfox</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Axitinib + FOLFOX vs bevacizumab + FOLFOX</P>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.37 to 1.29)</P>
</TD>
<TD VALIGN="TOP">
<P>1.04 (0.55 to 1.97)</P>
</TD>
<TD VALIGN="TOP">
<P>0.97 (0.38 to 2.49)</P>
</TD>
<TD VALIGN="TOP">
<P>1.94 (0.74 to 5.12)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bennouna-2013" TYPE="STUDY">Bennouna 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bevacizumab + chemotherapy vs chemotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>0.81 (0.69 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>0.68 (0.58 to 0.80)</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (0.74 to 2.59)</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 (0.99 to 1.24)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cao-2015" TYPE="STUDY">Cao 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bevacizumab + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.55 to 1.11)</P>
</TD>
<TD VALIGN="TOP">
<P>0.71 (0.52 to 0.97)</P>
</TD>
<TD VALIGN="TOP">
<P>1.67 (1.08 to 2.58)</P>
</TD>
<TD VALIGN="TOP">
<P>0.84 (0.67 to 1.05)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Clarke-2011" TYPE="STUDY">Clarke 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>FOLFIRI vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.72 (0.46 to 1.13)</P>
</TD>
<TD VALIGN="TOP">
<P>0.81 (0.52 to 1.26)</P>
</TD>
<TD VALIGN="TOP">
<P>1.02 (0.32 to 3.28)</P>
</TD>
<TD VALIGN="TOP">
<P>0.98 (0.63 to 1.52)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cohn-2013_x005f_conat" TYPE="STUDY">Cohn 2013_conat</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Conatumumab + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.89 (0.54 to 1.47)</P>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.41 to 1.16)</P>
</TD>
<TD VALIGN="TOP">
<P>7.14 (0.91 to 55.96)</P>
</TD>
<TD VALIGN="TOP">
<P>1.53 (1.09 to 2.15)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cohn-2013_x005f_ganit" TYPE="STUDY">Cohn 2013_ganit</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ganitumab + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>1.27 (0.76 to 2.12)</P>
</TD>
<TD VALIGN="TOP">
<P>1.01 (0.61 to 1.67)</P>
</TD>
<TD VALIGN="TOP">
<P>4.00 (0.46 to 34.59)</P>
</TD>
<TD VALIGN="TOP">
<P>1.17 (0.80 to 1.71)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cunningham-1998" TYPE="STUDY">Cunningham 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Irinotecan vs best supportive care</P>
</TD>
<TD VALIGN="TOP">
<P>0.58 (0.43 to 0.80)</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>1.19 (1.01 to 1.40)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x00c9_lez-2015" TYPE="STUDY">Élez 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Abituzumab + cetuximab + irinotecan vs cetuximab + irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.83 (0.54 to 1.28)</P>
</TD>
<TD VALIGN="TOP">
<P>1.13 (0.78 to 1.64)</P>
</TD>
<TD VALIGN="TOP">
<P>1.04 (0.61 to 1.78)</P>
</TD>
<TD VALIGN="TOP">
<P>0.91 (0.60 to 1.38)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Fuchs-2003" TYPE="STUDY">Fuchs 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Irinotecan schedule 1 vs irinotecan schedule 2</P>
</TD>
<TD VALIGN="TOP">
<P>0.99 (0.73 to 1.34)</P>
</TD>
<TD VALIGN="TOP">
<P>1.06 (0.76 to 1.47)</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>0.97 (0.81 to 1.17)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Giantonio-2007" TYPE="STUDY">Giantonio 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bevacizumab + FOLFOX vs FOLFOX</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.60 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>0.61 (0.48 to 0.78)</P>
</TD>
<TD VALIGN="TOP">
<P>2.64 (1.71 to 4.06)</P>
</TD>
<TD VALIGN="TOP">
<P>1.23 (1.10 to 1.38)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gibbs-2011" TYPE="STUDY">Gibbs 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Hyaluronan + irinotecan vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.93 (0.49 to 1.76)</P>
</TD>
<TD VALIGN="TOP">
<P>0.56 (0.33 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>3.00 (0.33 to 26.99)</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (0.87 to 2.20)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Graeven-2007" TYPE="STUDY">Graeven 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>FOLFIRI vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>1.31 (0.68 to 2.52)</P>
</TD>
<TD VALIGN="TOP">
<P>0.87 (0.48 to 1.58)</P>
</TD>
<TD VALIGN="TOP">
<P>0.96 (0.21 to 4.37)</P>
</TD>
<TD VALIGN="TOP">
<P>0.34 (0.18 to 0.62)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Haller-2008" TYPE="STUDY">Haller 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Oxaliplatin + irinotecan vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.67 to 0.90)</P>
</TD>
<TD VALIGN="TOP">
<P>0.60 (0.55 to 0.66)</P>
</TD>
<TD VALIGN="TOP">
<P>2.98 (1.91 to 4.64)</P>
</TD>
<TD VALIGN="TOP">
<P>1.22 (1.09 to 1.37)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hecht-2015" TYPE="STUDY">Hecht 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Panitumumab + FOLFIRI vs bevacizumab + FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>1.06 (0.75 to 1.50)</P>
</TD>
<TD VALIGN="TOP">
<P>1.01 (0.68 to 1.50)</P>
</TD>
<TD VALIGN="TOP">
<P>1.67 (0.98 to 2.85)</P>
</TD>
<TD VALIGN="TOP">
<P>1.40 (0.97 to 2.02)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Iwamoto-2015" TYPE="STUDY">Iwamoto 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bevacizumab schedule 1 + FOLFIRI vs bevacizumab schedule 2 + FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>1.08 (0.75 to 1.56)</P>
</TD>
<TD VALIGN="TOP">
<P>0.95 (0.75 to 1.20)</P>
</TD>
<TD VALIGN="TOP">
<P>1.04 (0.58 to 1.86)</P>
</TD>
<TD VALIGN="TOP">
<P>1.07 (0.92 to 1.26)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kim-2009" TYPE="STUDY">Kim 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>FOLFOX vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.92 (0.79 to 1.07)</P>
</TD>
<TD VALIGN="TOP">
<P>0.72 (0.60 to 0.88)</P>
</TD>
<TD VALIGN="TOP">
<P>1.80 (1.26 to 2.56)</P>
</TD>
<TD VALIGN="TOP">
<P>1.13 (0.99 to 1.29)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Liu-2015" TYPE="STUDY">Liu 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Panitumumab + bevacizumab + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.67 (0.47 to 0.96)</P>
</TD>
<TD VALIGN="TOP">
<P>0.58 (0.35 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>1.66 (1.03 to 2.67)</P>
</TD>
<TD VALIGN="TOP">
<P>1.60 (1.30 to 1.99)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Masi-2015" TYPE="STUDY">Masi 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bevacizumab + chemotherapy vs chemotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>0.77 (0.56 to 1.06)</P>
</TD>
<TD VALIGN="TOP">
<P>0.70 (0.52 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>1.24 (0.70 to 2.19)</P>
</TD>
<TD VALIGN="TOP">
<P>1.05 (0.75 to 1.47)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Muro-2010" TYPE="STUDY">Muro 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>IRIS vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.91 (0.71 to 1.16)</P>
</TD>
<TD VALIGN="TOP">
<P>1.08 (0.86 to 1.34)</P>
</TD>
<TD VALIGN="TOP">
<P>1.13 (0.72 to 1.77)</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 (0.84 to 1.18)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-O_x0027_Neil-2014" TYPE="STUDY">O'Neil 2014</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Linifanib + FOLFOX vs bevacizumab + FOLFOX</P>
</TD>
<TD VALIGN="TOP">
<P>1.42 (0.94 to 2.15)</P>
</TD>
<TD VALIGN="TOP">
<P>1.45 (0.83 to 2.53)</P>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.37 to 1.29)</P>
</TD>
<TD VALIGN="TOP">
<P>1.24 (1.01 to 1.53)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Peeters-2010" TYPE="STUDY">Peeters 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Panitumumab + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.85 (0.70 to 1.03)</P>
</TD>
<TD VALIGN="TOP">
<P>0.73 (0.59 to 0.90)</P>
</TD>
<TD VALIGN="TOP">
<P>3.44 (2.36 to 5.02)</P>
</TD>
<TD VALIGN="TOP">
<P>1.40 (1.23 to 1.60)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Peeters-2013" TYPE="STUDY">Peeters 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Trebananib + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.90 (0.53 to 1.53)</P>
</TD>
<TD VALIGN="TOP">
<P>1.23 (0.81 to 1.87)</P>
</TD>
<TD VALIGN="TOP">
<P>13.02 (0.79 to 215.40)</P>
</TD>
<TD VALIGN="TOP">
<P>0.94 (0.73 to 1.22)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Price-2014" TYPE="STUDY">Price 2014</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Panitumumab vs cetuximab</P>
</TD>
<TD VALIGN="TOP">
<P>0.97 (0.84 to 1.12)</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 (0.88 to 1.14)</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 (0.87 to 1.42)</P>
</TD>
<TD VALIGN="TOP">
<P>1.06 (0.93 to 1.20)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rothenberg-2003_x005f_folfox" TYPE="STUDY">Rothenberg 2003_folfox</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>FOLFOX vs 5FU</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>0.55 (0.43 to 0.70)</P>
</TD>
<TD VALIGN="TOP">
<P>5.22 (1.83 to 14.83)</P>
</TD>
<TD VALIGN="TOP">
<P>1.78 (1.43 to 2.22)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rothenberg-2003_x005f_oxa" TYPE="STUDY">Rothenberg 2003_oxa</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Oxaliplatin vs 5FU</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 (0.93 to 1.33)</P>
</TD>
<TD VALIGN="TOP">
<P>1.29 (0.35 to 4.72)</P>
</TD>
<TD VALIGN="TOP">
<P>1.14 (0.88 to 1.48)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rothenberg-2008" TYPE="STUDY">Rothenberg 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>XELOX vs FOLFOX</P>
</TD>
<TD VALIGN="TOP">
<P>1.02 (0.86 to 1.22)</P>
</TD>
<TD VALIGN="TOP">
<P>0.97 (0.83 to 1.13)</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 (0.60 to 2.07)</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.68 to 0.82)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rougier-1998" TYPE="STUDY">Rougier 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Irinotecan vs 5FU</P>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.51 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.49 to 0.97)</P>
</TD>
<TD VALIGN="TOP">
<P>2.90 (1.27 to 6.62)</P>
</TD>
<TD VALIGN="TOP">
<P>1.28 (1.05 to 1.55)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Scheithauer-2002" TYPE="STUDY">Scheithauer 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mitomycin + oxaliplatin vs mitomycin + irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>1.32 (0.47 to 3.71)</P>
</TD>
<TD VALIGN="TOP">
<P>1.62 (0.93 to 2.83)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Seymour-2013" TYPE="STUDY">Seymour 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Panitumumab + irinotecan vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>1.01 (0.83 to 1.23)</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.64 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>2.93 (1.97 to 4.35)</P>
</TD>
<TD VALIGN="TOP">
<P>1.51 (1.24 to 1.84)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shoemaker-2004" TYPE="STUDY">Shoemaker 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Single-dose irinotecan vs fractionated irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>0.62 (0.11 to 3.53)</P>
</TD>
<TD VALIGN="TOP">
<P>0.97 (0.72 to 1.30)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sobrero-2008" TYPE="STUDY">Sobrero 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cetuximab + irinotecan vs irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.98 (0.85 to 1.11)</P>
</TD>
<TD VALIGN="TOP">
<P>0.69 (0.62 to 0.78)</P>
</TD>
<TD VALIGN="TOP">
<P>3.94 (2.62 to 5.92)</P>
</TD>
<TD VALIGN="TOP">
<P>1.42 (1.28 to 1.59)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tabernero-2015" TYPE="STUDY">Tabernero 2015</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ramucirumab + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.84 (0.73 to 0.97)</P>
</TD>
<TD VALIGN="TOP">
<P>0.79 (0.70 to 0.90)</P>
</TD>
<TD VALIGN="TOP">
<P>1.07 (0.79 to 1.47)</P>
</TD>
<TD VALIGN="TOP">
<P>1.15 (0.97 to 1.36)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tsavaris-2003" TYPE="STUDY">Tsavaris 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Single-dose irinotecan vs fractionated irinotecan</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 (0.60 to 1.01)</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.53 to 1.06)</P>
</TD>
<TD VALIGN="TOP">
<P>0.87 (0.45 to 1.66)</P>
</TD>
<TD VALIGN="TOP">
<P>0.98 (0.82 to 1.17)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Van-Cutsem-2011" TYPE="STUDY">Van Cutsem 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Vatalanib + FOLFOX vs FOLFOX</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 (0.87 to 1.15)</P>
</TD>
<TD VALIGN="TOP">
<P>0.83 (0.71 to 0.97)</P>
</TD>
<TD VALIGN="TOP">
<P>Not available</P>
</TD>
<TD VALIGN="TOP">
<P>1.19 (1.10 to 1.28)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Van-Cutsem-2012" TYPE="STUDY">Van Cutsem 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Aflibercept + FOLFIRI vs FOLFIRI</P>
</TD>
<TD VALIGN="TOP">
<P>0.82 (0.71 to 0.94)</P>
</TD>
<TD VALIGN="TOP">
<P>0.76 (0.66 to 0.87)</P>
</TD>
<TD VALIGN="TOP">
<P>1.78 (1.32 to 2.39)</P>
</TD>
<TD VALIGN="TOP">
<P>1.34 (1.24 to 1.43)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Vi_x00e9_itez-2011" TYPE="STUDY">Viéitez 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Gefitinib + raltitrexed vs raltitrexed</P>
</TD>
<TD VALIGN="TOP">
<P>0.99 (0.55 to 1.78)</P>
</TD>
<TD VALIGN="TOP">
<P>1.23 (0.81 to 1.87)</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 (0.15 to 6.74)</P>
</TD>
<TD VALIGN="TOP">
<P>1.67 (0.43 to 6.49)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval; FOLFIRI: fluorouracil + irinotecan + leucovorin; FOLFOX: fluorouracil + oxaliplatin + leucovorin; HR: hazard ratio; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; RR: risk ratio; SAE: severe adverse effects.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-10-19 14:00:10 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-10-19 14:00:10 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>All</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.9356778454290848" CI_START="0.506224032341476" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.6882315103841843" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.028873653436311895" LOG_CI_START="-0.29565724111071207" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.162265447273512" MODIFIED="2016-10-19 11:40:37 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.01711569832970791" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.3842128772892606">
<NAME>Overall survival (OS)_modern chemotherapy (CTX) vs 5-fluorouracil (5FU)</NAME>
<GROUP_LABEL_1>Modern CTX</GROUP_LABEL_1>
<GROUP_LABEL_2>5FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors 
modern CTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5FU</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9356778454290848" CI_START="0.506224032341476" EFFECT_SIZE="0.6882315103841843" ESTIMABLE="YES" ESTIMATE="-0.37363" LOG_CI_END="-0.028873653436311895" LOG_CI_START="-0.29565724111071207" LOG_EFFECT_SIZE="-0.162265447273512" MODIFIED="2015-09-13 14:57:29 +0200" MODIFIED_BY="[Empty name]" ORDER="1102" SE="0.15671" STUDY_ID="STD-Rougier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="21.66660587838256" CI_END="0.9569516678560812" CI_START="0.7309992284204561" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.8363796571165896" ESTIMABLE="YES" I2="90.76920487119092" I2_Q="95.13260101256051" ID="CMP-001.02" LOG_CI_END="-0.01910999630201482" LOG_CI_START="-0.1360830814455802" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07759653887379751" MODIFIED="2016-10-19 14:00:10 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.973143682731937E-5" P_Q="5.825066364262277E-6" P_Z="0.009312435835898995" Q="20.544853680179862" RANDOM="NO" SCALE="2.9" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.600366081324505">
<NAME>Progression-free survival (PFS)_modern CTX vs 5FU</NAME>
<GROUP_LABEL_1>Other CTX</GROUP_LABEL_1>
<GROUP_LABEL_2>5FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours modern CTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5FU</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.1217521982027008" CI_END="0.7259455609194807" CI_START="0.4867741600994795" DF="1" EFFECT_SIZE="0.5944506209051562" ESTIMABLE="YES" I2="10.853751692911784" ID="CMP-001.02.01" LOG_CI_END="-0.13909594607502082" LOG_CI_START="-0.3126724839014245" LOG_EFFECT_SIZE="-0.22588421498822264" MODIFIED="2016-10-19 14:00:10 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28954151026343034" P_Z="3.374941651523833E-7" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="45.414009420650906" Z="5.101207013309534">
<NAME>FOLFOX irinotecan (irino)</NAME>
<IV_DATA CI_END="0.7035414225156914" CI_START="0.42999939535003334" EFFECT_SIZE="0.5500203507920862" ESTIMABLE="YES" ESTIMATE="-0.5978" LOG_CI_END="-0.15271032745397806" LOG_CI_START="-0.36653215510954984" LOG_EFFECT_SIZE="-0.259621241281764" MODIFIED="2015-08-22 15:39:52 +0200" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.1256" STUDY_ID="STD-Rothenberg-2003_x005f_folfox" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.927319092609643"/>
<IV_DATA CI_END="0.9725923094032108" CI_START="0.49055900494812127" EFFECT_SIZE="0.6907343306373547" ESTIMABLE="YES" ESTIMATE="-0.37" LOG_CI_END="-0.012069168858889333" LOG_CI_START="-0.309308747749517" LOG_EFFECT_SIZE="-0.16068895830420316" MODIFIED="2015-08-22 15:39:52 +0200" MODIFIED_BY="[Empty name]" ORDER="136" SE="0.1746" STUDY_ID="STD-Rougier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.486690328041263"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.3333261041668567" CI_START="0.9260040686434148" DF="0" EFFECT_SIZE="1.111154983468545" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.12493638191158435" LOG_CI_START="-0.033387105126378845" LOG_EFFECT_SIZE="0.04577463839260271" MODIFIED="2015-09-13 15:10:17 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25707431745457476" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="54.5859905793491" Z="1.1333333333333333">
<NAME>Oxaliplatin</NAME>
<IV_DATA CI_END="1.3333261041668567" CI_START="0.9260040686434148" EFFECT_SIZE="1.111154983468545" ESTIMABLE="YES" ESTIMATE="0.1054" LOG_CI_END="0.12493638191158435" LOG_CI_START="-0.033387105126378845" LOG_EFFECT_SIZE="0.04577463839260271" MODIFIED="2015-09-01 12:17:30 +0200" MODIFIED_BY="[Empty name]" ORDER="76" SE="0.093" STUDY_ID="STD-Rothenberg-2003_x005f_oxa" TOTAL_1="0" TOTAL_2="0" WEIGHT="54.5859905793491"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.7048068546345445" CI_END="5.274662663899811" CI_START="1.6558398074870144" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.955333553078367" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="15" I2="26.057566862006983" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.7221946899618636" LOG_CI_START="0.21901831910973255" LOG_EFFECT_SIZE="0.4706065045357981" METHOD="IV" MODIFIED="2016-10-19 11:47:10 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2586181455430342" P_Q="1.0" P_Z="2.4618449735820317E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="436" WEIGHT="100.0" Z="3.666196797828204">
<NAME>Overall response rate (ORR)_modern CTX vs 5FU</NAME>
<GROUP_LABEL_1>Modern CTX</GROUP_LABEL_1>
<GROUP_LABEL_2>5FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours modern CTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5FU</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.833559695724595" CI_START="1.8337492186314648" EFFECT_SIZE="5.215460526315789" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="1.1712453837121006" LOG_CI_START="0.26333994179660675" LOG_EFFECT_SIZE="0.7172926627543538" MODIFIED="2015-09-13 15:03:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1379" O_E="0.0" SE="0.5333081507855802" STUDY_ID="STD-Rothenberg-2003_x005f_folfox" TOTAL_1="152" TOTAL_2="151" VAR="0.2844175836943352" WEIGHT="30.71561663345711"/>
<DICH_DATA CI_END="4.717714417582243" CI_START="0.3534953297259059" EFFECT_SIZE="1.2913907284768211" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6737316477360943" LOG_CI_START="-0.45161631959739706" LOG_EFFECT_SIZE="0.11105766406934856" MODIFIED="2015-09-13 15:03:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1380" O_E="0.0" SE="0.661034966573972" STUDY_ID="STD-Rothenberg-2003_x005f_oxa" TOTAL_1="151" TOTAL_2="156" VAR="0.43696722703345225" WEIGHT="19.992486676582285"/>
<DICH_DATA CI_END="6.623139103182154" CI_START="1.2716629361179803" EFFECT_SIZE="2.9021372328458943" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.8210638764586379" LOG_CI_START="0.1043720135273951" LOG_EFFECT_SIZE="0.4627179449930165" MODIFIED="2015-09-13 15:03:20 +0200" MODIFIED_BY="[Empty name]" ORDER="1381" O_E="0.0" SE="0.4209883479677498" STUDY_ID="STD-Rougier-1998" TOTAL_1="127" TOTAL_2="129" VAR="0.17723118912461522" WEIGHT="49.291896689960595"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.80238637400124" CI_END="1.5769350945360034" CI_START="1.2210020729928575" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3876026158103218" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="186" I2="74.36681671309807" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.19781381846209797" LOG_CI_START="0.08671640128197892" LOG_EFFECT_SIZE="0.14226510987203844" METHOD="IV" MODIFIED="2016-10-19 11:45:11 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.020217808657671754" P_Q="1.0" P_Z="5.176854069371863E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="413" WEIGHT="100.00000000000001" Z="5.019639496276729">
<NAME>Serious adverse events (SAE)_modern CTX vs 5FU</NAME>
<GROUP_LABEL_1>Modern CTX</GROUP_LABEL_1>
<GROUP_LABEL_2>5FU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
modern CTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5FU</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2189458294912354" CI_START="1.4264103432671678" EFFECT_SIZE="1.7790804597701149" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" LOG_CI_END="0.3461467000507545" LOG_CI_START="0.1542444793593687" LOG_EFFECT_SIZE="0.25019558970506156" MODIFIED="2015-09-13 15:06:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1382" O_E="0.0" SE="0.11272431436543273" STUDY_ID="STD-Rothenberg-2003_x005f_folfox" TOTAL_1="150" TOTAL_2="142" VAR="0.012706771049156903" WEIGHT="33.51567142518283"/>
<DICH_DATA CI_END="1.4751110326356653" CI_START="0.8750438689710447" EFFECT_SIZE="1.1361280144241606" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="58" LOG_CI_END="0.16882471119291143" LOG_CI_START="-0.05797017374971999" LOG_EFFECT_SIZE="0.055427268721595715" MODIFIED="2015-09-13 15:06:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1383" O_E="0.0" SE="0.13322043806808806" STUDY_ID="STD-Rothenberg-2003_x005f_oxa" TOTAL_1="153" TOTAL_2="142" VAR="0.017747685119053287" WEIGHT="23.996141496862766"/>
<DICH_DATA CI_END="1.5537827480456075" CI_START="1.049423893004437" EFFECT_SIZE="1.2769403824521934" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="70" LOG_CI_END="0.1913902950821211" LOG_CI_START="0.020950947876286586" LOG_EFFECT_SIZE="0.10617062147920388" MODIFIED="2015-09-13 15:06:11 +0200" MODIFIED_BY="[Empty name]" ORDER="1384" O_E="0.0" SE="0.10011691623708269" STUDY_ID="STD-Rougier-1998" TOTAL_1="127" TOTAL_2="129" VAR="0.010023396916823031" WEIGHT="42.488187077954414"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="8.684733566941324" CI_END="1.0369145644828086" CI_START="0.7941772198826837" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.9074656611006395" ESTIMABLE="YES" I2="42.427709941124306" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.01574297461255779" LOG_CI_START="-0.10008257436245972" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04216979987495096" MODIFIED="2016-10-19 11:45:29 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.12231941777562783" P_Q="1.0" P_Z="0.1535313243050398" Q="0.0" RANDOM="YES" SCALE="14.29" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.010000523767696435" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.4271685257972357">
<NAME>OS_irino combination (combo)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
ombo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i
rinotecan</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1269870754219715" CI_START="0.4599912704940761" EFFECT_SIZE="0.7200029282258205" ESTIMABLE="YES" ESTIMATE="-0.3285" LOG_CI_END="0.051918935473697796" LOG_CI_START="-0.3372504100841343" LOG_EFFECT_SIZE="-0.14266573730521823" MODIFIED="2015-09-13 15:13:56 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.2286" STUDY_ID="STD-Clarke-2011" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.435075772542601"/>
<IV_DATA CI_END="1.7649321126295725" CI_START="0.4900184543998537" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.24672800509076034" LOG_CI_START="-0.3097875638631125" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2015-09-13 15:13:57 +0200" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.3269" STUDY_ID="STD-Gibbs-2011" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.9609804083824933"/>
<IV_DATA CI_END="2.5234019034446" CI_START="0.6800370800396096" EFFECT_SIZE="1.3099644507332475" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.4019864263192473" LOG_CI_START="-0.16746740609149127" LOG_EFFECT_SIZE="0.11725951011387804" MODIFIED="2015-09-13 15:13:58 +0200" MODIFIED_BY="[Empty name]" ORDER="31" SE="0.3345" STUDY_ID="STD-Graeven-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.797633979899418"/>
<IV_DATA CI_END="0.9017104093322665" CI_START="0.6747195637313265" EFFECT_SIZE="0.7800010602535503" ESTIMABLE="YES" ESTIMATE="-0.24846" LOG_CI_END="-0.044932916806646885" LOG_CI_START="-0.17087669714071696" LOG_EFFECT_SIZE="-0.10790480697368195" MODIFIED="2015-09-13 15:13:58 +0200" MODIFIED_BY="[Empty name]" ORDER="12" SE="0.07398" STUDY_ID="STD-Haller-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.915314873790223"/>
<IV_DATA CI_END="1.2289896325297909" CI_START="0.8301138699817519" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.08954821929483958" LOG_CI_START="-0.08086232965677453" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2015-09-13 12:53:49 +0200" MODIFIED_BY="[Empty name]" ORDER="152" SE="0.1001" STUDY_ID="STD-Seymour-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.121089061238226"/>
<IV_DATA CI_END="1.113149700844086" CI_START="0.854026064339953" EFFECT_SIZE="0.9750173629392817" ESTIMABLE="YES" ESTIMATE="-0.0253" LOG_CI_END="0.046553573929171956" LOG_CI_START="-0.0685288747134765" LOG_EFFECT_SIZE="-0.010987650392152269" MODIFIED="2015-09-13 12:53:49 +0200" MODIFIED_BY="[Empty name]" ORDER="133" SE="0.0676" STUDY_ID="STD-Sobrero-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.769905904147034"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.244903138850068" CI_END="0.7641757036475679" CI_START="0.6047971782726324" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.6798318242554937" ESTIMABLE="YES" I2="45.91614509200875" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.11680677447217475" LOG_CI_START="-0.21839024373615534" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.16759850910416502" MODIFIED="2016-10-19 11:45:47 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.09968560712296248" P_Q="1.0" P_Z="9.974793587148072E-11" Q="0.0" RANDOM="YES" SCALE="2.42" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.007884919234934291" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="6.467332610055808">
<NAME>PFS_irino combo</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
ombo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i
rinotecan</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2616846565002309" CI_START="0.520040879067863" EFFECT_SIZE="0.810017035544818" ESTIMABLE="YES" ESTIMATE="-0.2107" LOG_CI_END="0.10095082158386376" LOG_CI_START="-0.2839625162578941" LOG_EFFECT_SIZE="-0.09150584733701515" MODIFIED="2015-09-13 13:22:17 +0200" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.2261" STUDY_ID="STD-Clarke-2011" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.03426195214475"/>
<IV_DATA CI_END="0.9502770389328197" CI_START="0.3300212333756787" EFFECT_SIZE="0.560010357437429" ESTIMABLE="YES" ESTIMATE="-0.5798" LOG_CI_END="-0.022149764248137287" LOG_CI_START="-0.4814581169668736" LOG_EFFECT_SIZE="-0.25180394060750544" MODIFIED="2015-09-13 13:22:17 +0200" MODIFIED_BY="[Empty name]" ORDER="58" SE="0.2698" STUDY_ID="STD-Gibbs-2011" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.413384489973707"/>
<IV_DATA CI_END="1.5767299854109686" CI_START="0.48000772910418654" EFFECT_SIZE="0.8699669992060597" ESTIMABLE="YES" ESTIMATE="-0.1393" LOG_CI_END="0.19775732688226433" LOG_CI_START="-0.31875176954051027" LOG_EFFECT_SIZE="-0.06049722132912297" MODIFIED="2015-09-13 13:22:16 +0200" MODIFIED_BY="[Empty name]" ORDER="32" SE="0.3034" STUDY_ID="STD-Graeven-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.5628475538813498"/>
<IV_DATA CI_END="0.6597920656348899" CI_START="0.5456216706378434" EFFECT_SIZE="0.5999973742653398" ESTIMABLE="YES" ESTIMATE="-0.51083" LOG_CI_END="-0.18059291139101408" LOG_CI_START="-0.26310838899026223" LOG_EFFECT_SIZE="-0.22185065019063813" MODIFIED="2015-09-13 13:22:15 +0200" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.04847" STUDY_ID="STD-Haller-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="34.79083352301227"/>
<IV_DATA CI_END="0.9505261230395736" CI_START="0.6400171116452824" EFFECT_SIZE="0.7799698608351326" ESTIMABLE="YES" ESTIMATE="-0.2485" LOG_CI_END="-0.022035943042579123" LOG_CI_START="-0.19380841446333705" LOG_EFFECT_SIZE="-0.1079221787529581" MODIFIED="2015-08-29 16:30:34 +0200" MODIFIED_BY="[Empty name]" ORDER="153" SE="0.1009" STUDY_ID="STD-Seymour-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.709054417641674"/>
<IV_DATA CI_END="0.7760470672974868" CI_START="0.6170174995905336" EFFECT_SIZE="0.6919787720938135" ESTIMABLE="YES" ESTIMATE="-0.3682" LOG_CI_END="-0.11011193795870826" LOG_CI_START="-0.2097025185148464" LOG_EFFECT_SIZE="-0.15990722823677733" MODIFIED="2015-08-29 16:30:34 +0200" MODIFIED_BY="[Empty name]" ORDER="134" SE="0.0585" STUDY_ID="STD-Sobrero-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.489618063346256"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="7.162107422967009" CI_END="3.9268054625925117" CI_START="2.100497818903977" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8719760287014573" ESTIMABLE="YES" EVENTS_1="266" EVENTS_2="86" I2="30.1881456850772" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.5940393864715057" LOG_CI_START="0.322322234915449" LOG_EFFECT_SIZE="0.4581808106934773" METHOD="IV" MODIFIED="2016-10-19 11:47:31 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.208860767988307" P_Q="1.0" P_Z="3.8445951506598406E-11" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04221702301269553" TOTALS="YES" TOTAL_1="1291" TOTAL_2="1286" WEIGHT="100.0" Z="6.6099462785021466">
<NAME>ORR_irino combo</NAME>
<GROUP_LABEL_1>Combo</GROUP_LABEL_1>
<GROUP_LABEL_2>Irinotecan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
ombo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i
rinotecan</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.28022450250642" CI_START="0.3195470127859128" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5159035683650693" LOG_CI_START="-0.49546523800169745" LOG_EFFECT_SIZE="0.010219165181686028" MODIFIED="2016-07-05 17:34:06 +0200" MODIFIED_BY="[Empty name]" ORDER="1385" O_E="0.0" SE="0.5940830432161718" STUDY_ID="STD-Clarke-2011" TOTAL_1="42" TOTAL_2="43" VAR="0.35293466223698783" WEIGHT="6.446818921858533"/>
<DICH_DATA CI_END="26.991720997190598" CI_START="0.33343557459477147" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4312305761369144" LOG_CI_START="-0.47698806669758925" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2016-07-05 17:34:10 +0200" MODIFIED_BY="[Empty name]" ORDER="1386" O_E="0.0" SE="1.12089707663561" STUDY_ID="STD-Gibbs-2011" TOTAL_1="26" TOTAL_2="26" VAR="1.2564102564102562" WEIGHT="1.9616647531106242"/>
<DICH_DATA CI_END="4.367087466659317" CI_START="0.21292152856439428" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.640191890320031" LOG_CI_START="-0.6717804246864949" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2016-07-05 17:34:08 +0200" MODIFIED_BY="[Empty name]" ORDER="1387" O_E="0.0" SE="0.7706590322025324" STUDY_ID="STD-Graeven-2007" TOTAL_1="28" TOTAL_2="27" VAR="0.593915343915344" WEIGHT="4.004624656616665"/>
<DICH_DATA CI_END="4.641117606884913" CI_START="1.9086341826741022" EFFECT_SIZE="2.9762721163077765" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="23" LOG_CI_END="0.666622573670917" LOG_CI_START="0.28072269755545326" LOG_EFFECT_SIZE="0.4736726356131851" MODIFIED="2016-07-05 17:34:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1388" O_E="0.0" SE="0.22667949746541807" STUDY_ID="STD-Haller-2008" TOTAL_1="317" TOTAL_2="310" VAR="0.05138359457117448" WEIGHT="27.21639479770854"/>
<DICH_DATA CI_END="4.351286599731287" CI_START="1.9674738328048016" EFFECT_SIZE="2.925925925925926" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="27" LOG_CI_END="0.6386176892643616" LOG_CI_START="0.29390896499854663" LOG_EFFECT_SIZE="0.46626332713145413" MODIFIED="2015-09-13 15:16:27 +0200" MODIFIED_BY="[Empty name]" ORDER="1389" O_E="0.0" SE="0.20248361096944426" STUDY_ID="STD-Seymour-2013" TOTAL_1="230" TOTAL_2="230" VAR="0.04099961271122525" WEIGHT="30.61252523982618"/>
<DICH_DATA CI_END="5.92361232433987" CI_START="2.618027931786224" EFFECT_SIZE="3.938042981252858" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="27" LOG_CI_END="0.7725866280211411" LOG_CI_START="0.4179742757349492" LOG_EFFECT_SIZE="0.5952804518780451" MODIFIED="2015-09-13 15:16:38 +0200" MODIFIED_BY="[Empty name]" ORDER="1390" O_E="0.0" SE="0.20830105109236302" STUDY_ID="STD-Sobrero-2008" TOTAL_1="648" TOTAL_2="650" VAR="0.04338932788618323" WEIGHT="29.757971630879453"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.01925669514185" CI_END="1.4507445038197266" CI_START="0.9575383745642881" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1786193338375268" ESTIMABLE="YES" EVENTS_1="801" EVENTS_2="597" I2="81.49467967821995" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.16159093390464602" LOG_CI_START="-0.018843812108625752" LOG_EFFECT_SIZE="0.0713735608980101" METHOD="IV" MODIFIED="2016-10-19 11:47:50 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="5.6552260157327616E-5" P_Q="1.0" P_Z="0.12100142565595487" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04376017477637667" TOTALS="YES" TOTAL_1="1266" TOTAL_2="1244" WEIGHT="100.00000000000001" Z="1.5505839301947604">
<NAME>SAE_irino combo</NAME>
<GROUP_LABEL_1>Combo</GROUP_LABEL_1>
<GROUP_LABEL_2>Irinotecan</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
ombo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
irinotecan</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5150093611147497" CI_START="0.6275443385589471" EFFECT_SIZE="0.9750566893424036" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.1804153163154988" LOG_CI_START="-0.20235558409200283" LOG_EFFECT_SIZE="-0.010970133888252005" MODIFIED="2016-07-05 17:59:16 +0200" MODIFIED_BY="[Empty name]" ORDER="1391" O_E="0.0" SE="0.2248415216458816" STUDY_ID="STD-Clarke-2011" TOTAL_1="42" TOTAL_2="43" VAR="0.05055370985603544" WEIGHT="11.910772133025931"/>
<DICH_DATA CI_END="2.1976538112805115" CI_START="0.8723665908947388" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.3419592805843622" LOG_CI_START="-0.05930097499142361" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2016-07-05 17:59:17 +0200" MODIFIED_BY="[Empty name]" ORDER="1392" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Gibbs-2011" TOTAL_1="26" TOTAL_2="26" VAR="0.05555555555555555" WEIGHT="11.310909007895342"/>
<DICH_DATA CI_END="0.6150744477589819" CI_START="0.18289763182252433" EFFECT_SIZE="0.33540372670807456" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.2110723146406621" LOG_CI_START="-0.7377919177771003" LOG_EFFECT_SIZE="-0.47443211620888115" MODIFIED="2016-07-05 17:59:17 +0200" MODIFIED_BY="[Empty name]" ORDER="1393" O_E="0.0" SE="0.30939770218642937" STUDY_ID="STD-Graeven-2007" TOTAL_1="28" TOTAL_2="27" VAR="0.09572693811824246" WEIGHT="8.053440676529275"/>
<DICH_DATA CI_END="1.3688965676257057" CI_START="1.0864739903315666" EFFECT_SIZE="1.2195370089421171" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="179" LOG_CI_END="0.1363706345427399" LOG_CI_START="0.03601933397850893" LOG_EFFECT_SIZE="0.0861949842606244" MODIFIED="2016-07-05 17:59:18 +0200" MODIFIED_BY="[Empty name]" ORDER="1394" O_E="0.0" SE="0.058946850698378475" STUDY_ID="STD-Haller-2008" TOTAL_1="313" TOTAL_2="301" VAR="0.0034747312072569226" WEIGHT="23.782225569082033"/>
<DICH_DATA CI_END="1.8358268078035946" CI_START="1.242517194247644" EFFECT_SIZE="1.5103133364824437" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="87" LOG_CI_END="0.2638317073864326" LOG_CI_START="0.0943024073170031" LOG_EFFECT_SIZE="0.17906705735171782" MODIFIED="2015-09-13 15:20:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1395" O_E="0.0" SE="0.09958235004435244" STUDY_ID="STD-Seymour-2013" TOTAL_1="219" TOTAL_2="218" VAR="0.009916644440355941" WEIGHT="20.928050604141905"/>
<DICH_DATA CI_END="1.5868426892368692" CI_START="1.2794263896800921" EFFECT_SIZE="1.424867858041782" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="274" LOG_CI_END="0.20053387534800984" LOG_CI_START="0.10701530431045207" LOG_EFFECT_SIZE="0.15377458982923092" MODIFIED="2015-09-13 15:20:43 +0200" MODIFIED_BY="[Empty name]" ORDER="1396" O_E="0.0" SE="0.05493327155185403" STUDY_ID="STD-Sobrero-2008" TOTAL_1="638" TOTAL_2="629" VAR="0.003017664323389735" WEIGHT="24.014602009325532"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.3228226654088415" CI_END="0.8804503336265758" CI_START="0.7010204496578076" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.7856294856866491" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.055295137641374406" LOG_CI_START="-0.15426931292634585" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10478222528386014" MODIFIED="2016-10-19 11:48:07 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9556805346323054" P_Q="1.0" P_Z="3.3253474395533356E-5" Q="0.0" RANDOM="YES" SCALE="2.71" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="4.149959061240332">
<NAME>OS_bevacizumab (beva) combo</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
combo
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CTX</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9508728316271683" CI_START="0.6900266534590387" EFFECT_SIZE="0.810017035544818" ESTIMABLE="YES" ESTIMATE="-0.2107" LOG_CI_END="-0.02187756110203993" LOG_CI_START="-0.16113413357199036" LOG_EFFECT_SIZE="-0.09150584733701515" MODIFIED="2015-08-22 15:25:05 +0200" MODIFIED_BY="[Empty name]" ORDER="43" SE="0.0818" STUDY_ID="STD-Bennouna-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.51407211798954"/>
<IV_DATA CI_END="1.1062341377094593" CI_START="0.5499314865393837" EFFECT_SIZE="0.7799698608351326" ESTIMABLE="YES" ESTIMATE="-0.2485" LOG_CI_END="0.04384705640225073" LOG_CI_START="-0.25969141390816686" LOG_EFFECT_SIZE="-0.1079221787529581" MODIFIED="2015-08-22 15:25:05 +0200" MODIFIED_BY="[Empty name]" ORDER="67" SE="0.1783" STUDY_ID="STD-Cao-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.632032633209588"/>
<IV_DATA CI_END="0.9375735206733109" CI_START="0.599931439473547" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.02799466667139348" LOG_CI_START="-0.22189837821573766" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2015-08-22 15:25:05 +0200" MODIFIED_BY="[Empty name]" ORDER="111" SE="0.1139" STUDY_ID="STD-Giantonio-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.053827843592785"/>
<IV_DATA CI_END="1.0587554848724272" CI_START="0.5599576363509753" EFFECT_SIZE="0.7699728688614912" ESTIMABLE="YES" ESTIMATE="-0.2614" LOG_CI_END="0.024795673202904038" LOG_CI_START="-0.25184482834192407" LOG_EFFECT_SIZE="-0.11352457756951002" MODIFIED="2015-08-22 15:25:05 +0200" MODIFIED_BY="[Empty name]" ORDER="141" SE="0.1625" STUDY_ID="STD-Masi-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="12.800067405208097"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.8379538636582586" CI_END="0.7504650748642485" CI_START="0.5988255702719459" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.6703712974350574" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.12466951414245687" LOG_CI_START="-0.22269966325398982" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.17368458869822334" MODIFIED="2016-10-19 11:48:28 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8403691420510588" P_Q="1.0" P_Z="3.7814072878075446E-12" Q="0.0" RANDOM="YES" SCALE="2.49" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="6.945119263888202">
<NAME>PFS_beva combo</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combo

</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CTX</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7972787402935684" CI_START="0.5799293022493904" EFFECT_SIZE="0.6799744874307581" ESTIMABLE="YES" ESTIMATE="-0.3857" LOG_CI_END="-0.09838981636103791" LOG_CI_START="-0.23662494697913056" LOG_EFFECT_SIZE="-0.1675073816700842" MODIFIED="2015-08-28 16:22:39 +0200" MODIFIED_BY="[Empty name]" ORDER="44" SE="0.0812" STUDY_ID="STD-Bennouna-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.290096852261556"/>
<IV_DATA CI_END="0.9694157361209389" CI_START="0.5199938589731516" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="-0.013489934835023119" LOG_CI_START="-0.2840017852687044" LOG_EFFECT_SIZE="-0.1487458600518638" MODIFIED="2015-08-28 16:22:39 +0200" MODIFIED_BY="[Empty name]" ORDER="68" SE="0.1589" STUDY_ID="STD-Cao-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.132479637563922"/>
<IV_DATA CI_END="0.7752293137459629" CI_START="0.4799834785743941" EFFECT_SIZE="0.6099977563111423" ESTIMABLE="YES" ESTIMATE="-0.4943" LOG_CI_END="-0.11056981366960049" LOG_CI_START="-0.3187737111399543" LOG_EFFECT_SIZE="-0.21467176240477734" MODIFIED="2015-08-28 16:22:39 +0200" MODIFIED_BY="[Empty name]" ORDER="112" SE="0.1223" STUDY_ID="STD-Giantonio-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="22.168770959817948"/>
<IV_DATA CI_END="0.942354768278776" CI_START="0.5199479666985125" EFFECT_SIZE="0.699982460976843" ESTIMABLE="YES" ESTIMATE="-0.3567" LOG_CI_END="-0.02578556758919631" LOG_CI_START="-0.2840401158005836" LOG_EFFECT_SIZE="-0.15491284169488992" MODIFIED="2015-08-28 16:22:39 +0200" MODIFIED_BY="[Empty name]" ORDER="142" SE="0.1517" STUDY_ID="STD-Masi-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.408652550356578"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="5.464210295233959" CI_END="2.4274862532867947" CI_START="1.2255273605432433" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7248045746534801" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="80" I2="45.0972814385148" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.385156779202661" LOG_CI_START="0.08832301154918164" LOG_EFFECT_SIZE="0.23673989537592133" METHOD="IV" MODIFIED="2016-10-19 11:48:49 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.14079506519255902" P_Q="1.0" P_Z="0.001769966746201023" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05443528915212272" TOTALS="YES" TOTAL_1="848" TOTAL_2="866" WEIGHT="100.0" Z="3.1263401890465303">
<NAME>ORR_beva combo</NAME>
<GROUP_LABEL_1>Beva + CTX</GROUP_LABEL_1>
<GROUP_LABEL_2>CTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5920909556635223" CI_START="0.7366216797059253" EFFECT_SIZE="1.3818069306930694" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.41365023672390644" LOG_CI_START="-0.13275550345816522" LOG_EFFECT_SIZE="0.14044736663287063" MODIFIED="2015-09-13 15:32:52 +0200" MODIFIED_BY="[Empty name]" ORDER="1402" O_E="0.0" SE="0.3209614365349845" STUDY_ID="STD-Bennouna-2013" TOTAL_1="404" TOTAL_2="406" VAR="0.10301624374260086" WEIGHT="19.30878380734446"/>
<DICH_DATA CI_END="2.5798373924345768" CI_START="1.0800414666124758" EFFECT_SIZE="1.6692307692307693" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" LOG_CI_END="0.4115923331748915" LOG_CI_START="0.03344042990849395" LOG_EFFECT_SIZE="0.22251638154169276" MODIFIED="2015-09-13 15:33:00 +0200" MODIFIED_BY="[Empty name]" ORDER="1403" O_E="0.0" SE="0.2221282998607924" STUDY_ID="STD-Cao-2015" TOTAL_1="65" TOTAL_2="77" VAR="0.04934098159904611" WEIGHT="29.295691460034096"/>
<DICH_DATA CI_END="4.058563040639227" CI_START="1.712365953548331" EFFECT_SIZE="2.6362369337979095" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="25" LOG_CI_END="0.6083722961425038" LOG_CI_START="0.23359658430296212" LOG_EFFECT_SIZE="0.42098444022273296" MODIFIED="2015-09-13 15:33:10 +0200" MODIFIED_BY="[Empty name]" ORDER="1404" O_E="0.0" SE="0.2201451083042401" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="291" VAR="0.04846386871028561" WEIGHT="29.54540806703593"/>
<DICH_DATA CI_END="2.1852586571901704" CI_START="0.6982933356985351" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.3395028494263431" LOG_CI_START="-0.15596210271505237" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2015-09-13 15:33:20 +0200" MODIFIED_BY="[Empty name]" ORDER="1405" O_E="0.0" SE="0.29103856547892365" STUDY_ID="STD-Masi-2015" TOTAL_1="92" TOTAL_2="92" VAR="0.08470344659602971" WEIGHT="21.8501166655855"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.267944149959288" CI_END="1.2459887510031402" CI_START="0.9266397490429903" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0745151015876597" ESTIMABLE="YES" EVENTS_1="552" EVENTS_2="505" I2="67.63036169123679" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.09551412145692602" LOG_CI_START="-0.033089074282038104" LOG_EFFECT_SIZE="0.031212523587443947" METHOD="IV" MODIFIED="2016-10-19 11:49:07 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.025932655067778976" P_Q="1.0" P_Z="0.3414101958164406" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013992149796980501" TOTALS="YES" TOTAL_1="845" TOTAL_2="863" WEIGHT="99.99999999999999" Z="0.9513826113959034">
<NAME>SAE_beva combo</NAME>
<GROUP_LABEL_1>Beva + CTX</GROUP_LABEL_1>
<GROUP_LABEL_2>CTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2373385496843117" CI_START="0.9899516033565638" EFFECT_SIZE="1.1067543906191968" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="235" LOG_CI_END="0.09248854372236967" LOG_CI_START="-0.004386036623612778" LOG_EFFECT_SIZE="0.04405125354937844" MODIFIED="2015-09-13 15:36:13 +0200" MODIFIED_BY="[Empty name]" ORDER="1406" O_E="0.0" SE="0.056904608032136664" STUDY_ID="STD-Bennouna-2013" TOTAL_1="401" TOTAL_2="409" VAR="0.0032381344152911124" WEIGHT="33.11969162193171"/>
<DICH_DATA CI_END="1.0494236206650687" CI_START="0.6682140888385348" EFFECT_SIZE="0.8374005305039788" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="58" LOG_CI_END="0.0209508351711147" LOG_CI_START="-0.1750843717982657" LOG_EFFECT_SIZE="-0.07706676831357549" MODIFIED="2015-09-13 15:36:13 +0200" MODIFIED_BY="[Empty name]" ORDER="1407" O_E="0.0" SE="0.11515205096373872" STUDY_ID="STD-Cao-2015" TOTAL_1="65" TOTAL_2="77" VAR="0.01325999484115548" WEIGHT="20.940065717620787"/>
<DICH_DATA CI_END="1.3815965359330564" CI_START="1.099901252584043" EFFECT_SIZE="1.2327285834434698" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="174" LOG_CI_END="0.14038123565737243" LOG_CI_START="0.04135369662832558" LOG_EFFECT_SIZE="0.09086746614284902" MODIFIED="2015-09-13 15:36:21 +0200" MODIFIED_BY="[Empty name]" ORDER="1408" O_E="0.0" SE="0.058169266619886036" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.003383663579095388" WEIGHT="32.84230138281741"/>
<DICH_DATA CI_END="1.4745683036991815" CI_START="0.751428901745384" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.16866489437347576" LOG_CI_START="-0.12411210495117134" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2015-09-13 15:36:29 +0200" MODIFIED_BY="[Empty name]" ORDER="1409" O_E="0.0" SE="0.1719786586728179" STUDY_ID="STD-Masi-2015" TOTAL_1="92" TOTAL_2="92" VAR="0.029576659038901602" WEIGHT="13.097941277630083"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="4.22512706762465" CI_END="0.9061989749900012" CI_START="0.7697947145766182" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.8352168468739433" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.0427764333910397" LOG_CI_START="-0.11362507510436558" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.07820075424770263" MODIFIED="2016-10-16 21:33:45 +0200" MODIFIED_BY="Anne Lawson" NO="13" P_CHI2="0.6462401031429716" P_Q="1.0" P_Z="1.5135498504037998E-5" Q="0.0" RANDOM="YES" SCALE="2.46" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.326707137436521">
<NAME>OS_FOLFIRI targeted</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFIRI</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4668171065729427" CI_START="0.5400493149245402" EFFECT_SIZE="0.8900300969766776" ESTIMABLE="YES" ESTIMATE="-0.1165" LOG_CI_END="0.16637596622373796" LOG_CI_START="-0.2675665805071956" LOG_EFFECT_SIZE="-0.05059530714172882" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="35" SE="0.2549" STUDY_ID="STD-Cohn-2013_x005f_conat" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.6656221598529335"/>
<IV_DATA CI_END="2.1223215577750514" CI_START="0.7599439761967359" EFFECT_SIZE="1.2699785365838365" ESTIMABLE="YES" ESTIMATE="0.239" LOG_CI_END="0.3268111854971694" LOG_CI_START="-0.11921842314741504" LOG_EFFECT_SIZE="0.10379638117487718" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="39" SE="0.262" STUDY_ID="STD-Cohn-2013_x005f_ganit" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.5231070577254546"/>
<IV_DATA CI_END="0.9636539743373069" CI_START="0.47001202316252877" EFFECT_SIZE="0.6729999659040773" ESTIMABLE="YES" ESTIMATE="-0.39601" LOG_CI_END="-0.016078883123273744" LOG_CI_START="-0.32789103243373974" LOG_EFFECT_SIZE="-0.17198495777850675" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="27" SE="0.18316" STUDY_ID="STD-Liu-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.162701213004913"/>
<IV_DATA CI_END="1.0322412724497065" CI_START="0.6999597603062084" EFFECT_SIZE="0.8500160902253981" ESTIMABLE="YES" ESTIMATE="-0.1625" LOG_CI_END="0.013781219623313775" LOG_CI_START="-0.15492692624187063" LOG_EFFECT_SIZE="-0.07057285330927841" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="152" SE="0.0991" STUDY_ID="STD-Peeters-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.63562892169853"/>
<IV_DATA CI_END="1.5283401368502507" CI_START="0.5299448848869514" EFFECT_SIZE="0.8999644647935904" ESTIMABLE="YES" ESTIMATE="-0.1054" LOG_CI_END="0.18422001858405126" LOG_CI_START="-0.27576929536925676" LOG_EFFECT_SIZE="-0.045774638392602755" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="47" SE="0.2702" STUDY_ID="STD-Peeters-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.3722888721640265"/>
<IV_DATA CI_END="0.9665071536987954" CI_START="0.729983446376731" EFFECT_SIZE="0.8399608461141577" ESTIMABLE="YES" ESTIMATE="-0.1744" LOG_CI_END="-0.014794927149743438" LOG_CI_START="-0.13668698813811087" LOG_EFFECT_SIZE="-0.07574095764392709" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="91" SE="0.0716" STUDY_ID="STD-Tabernero-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="33.78408930559793"/>
<IV_DATA CI_END="0.9362408632522137" CI_START="0.7129688865298405" EFFECT_SIZE="0.8170132225347809" ESTIMABLE="YES" ESTIMATE="-0.2021" LOG_CI_END="-0.028612407539214707" LOG_CI_START="-0.14692942204607967" LOG_EFFECT_SIZE="-0.08777091479264718" MODIFIED="2015-08-30 16:42:31 +0200" MODIFIED_BY="[Empty name]" ORDER="117" SE="0.0695" STUDY_ID="STD-Van-Cutsem-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="35.85656246995623"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="7.765300812738626" CI_END="0.8700539883207978" CI_START="0.7054419177246485" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.7834363752373275" ESTIMABLE="YES" I2="22.733192896310328" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.060453797838465426" LOG_CI_START="-0.151538737898422" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10599626786844371" MODIFIED="2016-10-16 21:33:32 +0200" MODIFIED_BY="Anne Lawson" NO="14" P_CHI2="0.2558073579160264" P_Q="1.0" P_Z="5.075288481835236E-6" Q="0.0" RANDOM="YES" SCALE="2.56" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.004295161474499937" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.5616512978119">
<NAME>PFS_FOLFIRI targeted</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFIRI</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1612144931733768" CI_START="0.40997199180257854" EFFECT_SIZE="0.6899749406147379" ESTIMABLE="YES" ESTIMATE="-0.3711" LOG_CI_END="0.064912447643569" LOG_CI_START="-0.3872458121121625" LOG_EFFECT_SIZE="-0.16116668223429675" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="36" SE="0.2656" STUDY_ID="STD-Cohn-2013_x005f_conat" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.825103218500775"/>
<IV_DATA CI_END="1.672465246148784" CI_START="0.6099985290432743" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.22335710188821495" LOG_CI_START="-0.21467121225014987" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="40" SE="0.2573" STUDY_ID="STD-Cohn-2013_x005f_ganit" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.060586628111886"/>
<IV_DATA CI_END="0.9522406329082068" CI_START="0.3532700538257249" EFFECT_SIZE="0.5799983617584834" ESTIMABLE="YES" ESTIMATE="-0.54473" LOG_CI_END="-0.021253290755528443" LOG_CI_START="-0.4518931754987884" LOG_EFFECT_SIZE="-0.2365732331271584" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.25296" STUDY_ID="STD-Liu-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.192276255827081"/>
<IV_DATA CI_END="0.9031669027229687" CI_START="0.5900475874021962" EFFECT_SIZE="0.7300078437751212" ESTIMABLE="YES" ESTIMATE="-0.3147" LOG_CI_END="-0.044231985861819985" LOG_CI_START="-0.22911296104808668" LOG_EFFECT_SIZE="-0.13667247345495334" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="153" SE="0.1086" STUDY_ID="STD-Peeters-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.79246118650157"/>
<IV_DATA CI_END="1.8676264099012245" CI_START="0.8100426931553226" EFFECT_SIZE="1.2299825717807527" ESTIMABLE="YES" ESTIMATE="0.207" LOG_CI_END="0.2712900066130589" LOG_CI_START="-0.09149209110511268" LOG_EFFECT_SIZE="0.08989895775397311" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="48" SE="0.2131" STUDY_ID="STD-Peeters-2013" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.759075893850918"/>
<IV_DATA CI_END="0.9021861821825544" CI_START="0.69707265769988" EFFECT_SIZE="0.7930254218838771" ESTIMABLE="YES" ESTIMATE="-0.2319" LOG_CI_END="-0.04470382880982658" LOG_CI_START="-0.15672195189690158" LOG_EFFECT_SIZE="-0.10071289035336409" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="92" SE="0.0658" STUDY_ID="STD-Tabernero-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="33.190916939516754"/>
<IV_DATA CI_END="0.8692725926343958" CI_START="0.660933874627696" EFFECT_SIZE="0.7579786954509434" ESTIMABLE="YES" ESTIMATE="-0.2771" LOG_CI_END="-0.06084401306467263" LOG_CI_START="-0.17984198880610952" LOG_EFFECT_SIZE="-0.12034300093539109" MODIFIED="2015-08-30 17:00:30 +0200" MODIFIED_BY="[Empty name]" ORDER="118" SE="0.0699" STUDY_ID="STD-Van-Cutsem-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.17957987769102"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="26.13096630533598" CI_END="3.284642889375919" CI_START="1.3068606892766967" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.071851990475578" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="176" I2="77.0387366089298" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.5164881594044698" LOG_CI_START="0.1162292944642309" LOG_EFFECT_SIZE="0.3163587269343504" METHOD="IV" MODIFIED="2016-10-16 21:33:53 +0200" MODIFIED_BY="Anne Lawson" NO="15" P_CHI2="2.1047612591218456E-4" P_Q="1.0" P_Z="0.0019466484845818606" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.21192110500172207" TOTALS="YES" TOTAL_1="1619" TOTAL_2="1573" WEIGHT="100.0" Z="3.0982534819252328">
<NAME>ORR_FOLFIRI targeted</NAME>
<GROUP_LABEL_1>FOLFIRI + targeted</GROUP_LABEL_1>
<GROUP_LABEL_2>FOLFIRI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFIRI</GRAPH_LABEL_2>
<DICH_DATA CI_END="55.96392015088514" CI_START="0.9102365845391474" EFFECT_SIZE="7.137254901960785" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7479081282691833" LOG_CI_START="-0.040845713166943916" LOG_EFFECT_SIZE="0.8535312075511197" MODIFIED="2015-09-13 15:46:43 +0200" MODIFIED_BY="[Empty name]" ORDER="1410" O_E="0.0" SE="1.0507228609338994" STUDY_ID="STD-Cohn-2013_x005f_conat" TOTAL_1="51" TOTAL_2="52" VAR="1.1040185304891188" WEIGHT="4.200695050606775"/>
<DICH_DATA CI_END="34.592085492615595" CI_START="0.46253354697031884" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.538976745611714" LOG_CI_START="-0.3348567629557893" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2015-09-13 15:46:43 +0200" MODIFIED_BY="[Empty name]" ORDER="1411" O_E="0.0" SE="1.1006990785580142" STUDY_ID="STD-Cohn-2013_x005f_ganit" TOTAL_1="52" TOTAL_2="52" VAR="1.2115384615384617" WEIGHT="3.8833987586591623"/>
<DICH_DATA CI_END="2.6671601868032893" CI_START="1.0288187354361529" EFFECT_SIZE="1.6565096952908587" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.4260490997377213" LOG_CI_START="0.012338864427784504" LOG_EFFECT_SIZE="0.2191939820827529" MODIFIED="2015-09-13 15:46:55 +0200" MODIFIED_BY="[Empty name]" ORDER="1412" O_E="0.0" SE="0.24301544011974974" STUDY_ID="STD-Liu-2015" TOTAL_1="57" TOTAL_2="69" VAR="0.05905650413659567" WEIGHT="20.399696976003717"/>
<DICH_DATA CI_END="5.022811857119655" CI_START="2.357765417402725" EFFECT_SIZE="3.4413096482062" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="29" LOG_CI_END="0.7009469108003921" LOG_CI_START="0.37250059338185215" LOG_EFFECT_SIZE="0.5367237520911221" MODIFIED="2015-09-13 15:47:05 +0200" MODIFIED_BY="[Empty name]" ORDER="1413" O_E="0.0" SE="0.19293099268714278" STUDY_ID="STD-Peeters-2010" TOTAL_1="297" TOTAL_2="285" VAR="0.03722236793924635" WEIGHT="22.187461098021295"/>
<DICH_DATA CI_END="215.40216146245717" CI_START="0.7870956333183969" EFFECT_SIZE="13.020833333333334" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.333250056930896" LOG_CI_START="-0.10397249699392026" LOG_EFFECT_SIZE="1.114638779968488" MODIFIED="2015-09-13 15:47:05 +0200" MODIFIED_BY="[Empty name]" ORDER="1414" O_E="0.0" SE="1.4316365926216519" STUDY_ID="STD-Peeters-2013" TOTAL_1="95" TOTAL_2="49" VAR="2.0495833333333335" WEIGHT="2.444329102344513"/>
<DICH_DATA CI_END="1.465775591790969" CI_START="0.787857914192873" EFFECT_SIZE="1.0746268656716418" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="67" LOG_CI_END="0.1660674855118397" LOG_CI_START="-0.10355209805095565" LOG_EFFECT_SIZE="0.03125769373044202" MODIFIED="2015-09-13 15:47:19 +0200" MODIFIED_BY="[Empty name]" ORDER="1415" O_E="0.0" SE="0.15837587802324937" STUDY_ID="STD-Tabernero-2015" TOTAL_1="536" TOTAL_2="536" VAR="0.02508291873963516" WEIGHT="23.32391250764679"/>
<DICH_DATA CI_END="2.3865654952260886" CI_START="1.32209881069305" EFFECT_SIZE="1.7763094896102654" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="59" LOG_CI_END="0.37777335733833073" LOG_CI_START="0.12126391455589709" LOG_EFFECT_SIZE="0.24951863594711388" MODIFIED="2015-09-13 15:47:36 +0200" MODIFIED_BY="[Empty name]" ORDER="1416" O_E="0.0" SE="0.15067491643262143" STUDY_ID="STD-Van-Cutsem-2012" TOTAL_1="531" TOTAL_2="530" VAR="0.022702930441977454" WEIGHT="23.56050650671775"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.170720042479466" CI_END="1.4474832066100782" CI_START="1.1714293030340737" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.302161373975119" ESTIMABLE="YES" EVENTS_1="1093" EVENTS_2="814" I2="57.6591734081695" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.1606135338372059" LOG_CI_START="0.06871608360420782" LOG_EFFECT_SIZE="0.11466480872070682" METHOD="IV" MODIFIED="2016-10-16 21:34:11 +0200" MODIFIED_BY="Anne Lawson" NO="16" P_CHI2="0.027786225862193148" P_Q="1.0" P_Z="1.0028413655804255E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009969899763663928" TOTALS="YES" TOTAL_1="1694" TOTAL_2="1647" WEIGHT="100.0" Z="4.891080107597188">
<NAME>SAE_FOLFIRI targeted</NAME>
<GROUP_LABEL_1>FOLFIRI + targeted</GROUP_LABEL_1>
<GROUP_LABEL_2>FOLFIRI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFIRI</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.146455109658336" CI_START="1.0905888455187003" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.33172181020118463" LOG_CI_START="0.037661051434012965" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2015-09-13 15:50:51 +0200" MODIFIED_BY="[Empty name]" ORDER="1417" O_E="0.0" SE="0.1727327453240686" STUDY_ID="STD-Cohn-2013_x005f_conat" TOTAL_1="50" TOTAL_2="51" VAR="0.029836601307189542" WEIGHT="7.3202872293441175"/>
<DICH_DATA CI_END="1.7109485461703455" CI_START="0.7955301251798114" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.23323694907920736" LOG_CI_START="-0.0993433698179809" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2015-09-13 15:50:51 +0200" MODIFIED_BY="[Empty name]" ORDER="1418" O_E="0.0" SE="0.1953593256193381" STUDY_ID="STD-Cohn-2013_x005f_ganit" TOTAL_1="51" TOTAL_2="51" VAR="0.03816526610644258" WEIGHT="6.053682711308726"/>
<DICH_DATA CI_END="1.98507474397519" CI_START="1.2959951097423128" EFFECT_SIZE="1.6039473684210526" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="40" LOG_CI_END="0.29777686388747043" LOG_CI_START="0.11260336278771066" LOG_EFFECT_SIZE="0.20519011333759055" MODIFIED="2015-09-13 15:51:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1419" O_E="0.0" SE="0.10877183116961248" STUDY_ID="STD-Liu-2015" TOTAL_1="57" TOTAL_2="69" VAR="0.011831311255990679" WEIGHT="13.366001602898946"/>
<DICH_DATA CI_END="1.5981282399197485" CI_START="1.2310344392810433" EFFECT_SIZE="1.4026228651097943" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="152" LOG_CI_END="0.2036116258258458" LOG_CI_START="0.09027020287485905" LOG_EFFECT_SIZE="0.14694091435035242" MODIFIED="2015-09-13 15:51:12 +0200" MODIFIED_BY="[Empty name]" ORDER="1420" O_E="0.0" SE="0.06657731289050174" STUDY_ID="STD-Peeters-2010" TOTAL_1="302" TOTAL_2="294" VAR="0.00443253859171977" WEIGHT="20.23233943056016"/>
<DICH_DATA CI_END="1.22397421990051" CI_START="0.7293235089786294" EFFECT_SIZE="0.944813829787234" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="32" LOG_CI_END="0.08777227052779338" LOG_CI_START="-0.13707978718410074" LOG_EFFECT_SIZE="-0.02465375832815369" MODIFIED="2015-09-13 15:51:12 +0200" MODIFIED_BY="[Empty name]" ORDER="1421" O_E="0.0" SE="0.1320792117356031" STUDY_ID="STD-Peeters-2013" TOTAL_1="94" TOTAL_2="49" VAR="0.01744491817269828" WEIGHT="10.629106569675367"/>
<DICH_DATA CI_END="1.3646556218886938" CI_START="0.9695480664001759" EFFECT_SIZE="1.150260500714648" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="164" LOG_CI_END="0.13502306867848665" LOG_CI_START="-0.01343065543014115" LOG_EFFECT_SIZE="0.060796206624172774" MODIFIED="2015-09-13 15:51:23 +0200" MODIFIED_BY="[Empty name]" ORDER="1422" O_E="0.0" SE="0.08720245239919394" STUDY_ID="STD-Tabernero-2015" TOTAL_1="529" TOTAL_2="528" VAR="0.007604267704433686" WEIGHT="16.580872007895167"/>
<DICH_DATA CI_END="1.4344319053307975" CI_START="1.244242824577661" EFFECT_SIZE="1.3359571870210167" ESTIMABLE="YES" EVENTS_1="510" EVENTS_2="378" LOG_CI_END="0.1566799364502559" LOG_CI_START="0.09490514489099534" LOG_EFFECT_SIZE="0.12579254067062565" MODIFIED="2015-09-13 15:51:31 +0200" MODIFIED_BY="[Empty name]" ORDER="1423" O_E="0.0" SE="0.03628681835205958" STUDY_ID="STD-Van-Cutsem-2012" TOTAL_1="611" TOTAL_2="605" VAR="0.001316733186115368" WEIGHT="25.81771044831751"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="4.591156074686523" CI_END="1.0382540892017842" CI_START="0.819644957076239" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9224964652387704" ESTIMABLE="YES" I2="78.21899356648906" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.016303650270018833" LOG_CI_START="-0.0863742288034607" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.035035289266720955" MODIFIED="2016-10-16 21:34:26 +0200" MODIFIED_BY="Anne Lawson" NO="17" P_CHI2="0.032137390925679465" P_Q="1.0" P_Z="0.18104630779715675" Q="0.0" RANDOM="NO" SCALE="14.29" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.3375403888421735">
<NAME>OS_FOLFOX targeted</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 
combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFOX</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9375735206733109" CI_START="0.599931439473547" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="-0.02799466667139348" LOG_CI_START="-0.22189837821573766" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2015-09-13 13:05:52 +0200" MODIFIED_BY="[Empty name]" ORDER="111" SE="0.1139" STUDY_ID="STD-Giantonio-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="28.04022759620643"/>
<IV_DATA CI_END="1.1495303174044087" CI_START="0.8699205100200907" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.06052042972257626" LOG_CI_START="-0.060520429722576256" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-13 13:05:52 +0200" MODIFIED_BY="[Empty name]" ORDER="129" SE="0.0711" STUDY_ID="STD-Van-Cutsem-2011" TOTAL_1="0" TOTAL_2="0" WEIGHT="71.95977240379356"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.451748478838898" CI_END="0.8630875294114022" CI_START="0.6643251243539964" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.7572124736853014" ESTIMABLE="YES" I2="77.53691600607185" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-0.06394515838357036" LOG_CI_START="-0.17761932250656295" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12078224044506665" MODIFIED="2016-10-16 21:34:56 +0200" MODIFIED_BY="Anne Lawson" NO="18" P_CHI2="0.03486557268170409" P_Q="1.0" P_Z="3.112950769555795E-5" Q="0.0" RANDOM="NO" SCALE="3.2" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.1650421284515105">
<NAME>PFS_FOLFOX targeted</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFOX</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7752293137459629" CI_START="0.4799834785743941" EFFECT_SIZE="0.6099977563111423" ESTIMABLE="YES" ESTIMATE="-0.4943" LOG_CI_END="-0.11056981366960049" LOG_CI_START="-0.3187737111399543" LOG_EFFECT_SIZE="-0.21467176240477734" MODIFIED="2015-08-30 17:05:05 +0200" MODIFIED_BY="[Empty name]" ORDER="112" SE="0.1223" STUDY_ID="STD-Giantonio-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.808891671179538"/>
<IV_DATA CI_END="0.9703573527500634" CI_START="0.7099866374847887" EFFECT_SIZE="0.8300245502620139" ESTIMABLE="YES" ESTIMATE="-0.1863" LOG_CI_END="-0.013068298984351816" LOG_CI_START="-0.1487498249727998" LOG_EFFECT_SIZE="-0.08090906197857582" MODIFIED="2015-08-30 17:05:05 +0200" MODIFIED_BY="[Empty name]" ORDER="130" SE="0.0797" STUDY_ID="STD-Van-Cutsem-2011" TOTAL_1="0" TOTAL_2="0" WEIGHT="70.19110832882046"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.5433280446020897E-31" CI_END="4.058563040639226" CI_START="1.712365953548331" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.636236933797909" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="25" I2="99.99999999999999" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.6083722961425037" LOG_CI_START="0.23359658430296212" LOG_EFFECT_SIZE="0.42098444022273285" METHOD="IV" MODIFIED="2016-10-16 21:35:11 +0200" MODIFIED_BY="Anne Lawson" NO="19" P_CHI2="0.0" P_Q="1.0" P_Z="1.0664440018039567E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="291" WEIGHT="100.0" Z="4.403243405707041">
<NAME>ORR_FOLFOX targeted</NAME>
<GROUP_LABEL_1>FOLFOX + targted</GROUP_LABEL_1>
<GROUP_LABEL_2>FOLFOX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
ombo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFOX</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.058563040639227" CI_START="1.712365953548331" EFFECT_SIZE="2.6362369337979095" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="25" LOG_CI_END="0.6083722961425038" LOG_CI_START="0.23359658430296212" LOG_EFFECT_SIZE="0.42098444022273296" MODIFIED="2015-09-13 15:55:32 +0200" MODIFIED_BY="[Empty name]" ORDER="1424" O_E="0.0" SE="0.2201451083042401" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="291" VAR="0.04846386871028561" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3157947991670651" CI_END="1.2761123068159663" CI_START="1.127252760844646" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1993753044840167" ESTIMABLE="YES" EVENTS_1="571" EVENTS_2="472" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.10588889702162822" LOG_CI_START="0.052021307645165646" LOG_EFFECT_SIZE="0.07895510233339689" METHOD="IV" MODIFIED="2016-10-16 21:35:27 +0200" MODIFIED_BY="Anne Lawson" NO="20" P_CHI2="0.5741459628934158" P_Q="1.0" P_Z="9.1628851877512E-9" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="709" TOTAL_2="705" WEIGHT="99.99999999999999" Z="5.745538597899465">
<NAME>SAE_FOLFOX targeted</NAME>
<GROUP_LABEL_1>FOLFOX + targted</GROUP_LABEL_1>
<GROUP_LABEL_2>FOLFOX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours c
ombo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours FOLFOX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3815965359330564" CI_START="1.099901252584043" EFFECT_SIZE="1.2327285834434698" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="174" LOG_CI_END="0.14038123565737243" LOG_CI_START="0.04135369662832558" LOG_EFFECT_SIZE="0.09086746614284902" MODIFIED="2015-09-13 15:56:36 +0200" MODIFIED_BY="[Empty name]" ORDER="1426" O_E="0.0" SE="0.058169266619886036" STUDY_ID="STD-Giantonio-2007" TOTAL_1="287" TOTAL_2="285" VAR="0.003383663579095388" WEIGHT="29.589873539190886"/>
<DICH_DATA CI_END="1.2765771807376676" CI_START="1.101160894313623" EFFECT_SIZE="1.1856293139094756" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="298" LOG_CI_END="0.10604707699783908" LOG_CI_START="0.04185077983229187" LOG_EFFECT_SIZE="0.07394892841506549" MODIFIED="2015-09-13 15:56:44 +0200" MODIFIED_BY="[Empty name]" ORDER="1427" O_E="0.0" SE="0.03770922273183846" STUDY_ID="STD-Van-Cutsem-2011" TOTAL_1="422" TOTAL_2="420" VAR="0.0014219854790394025" WEIGHT="70.4101264608091"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="1.374833492008632" CI_END="1.0537948757173554" CI_START="0.7098876407195478" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.8649138443367308" ESTIMABLE="YES" I2="27.263919171840964" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.022756082400475015" LOG_CI_START="-0.1488103849105352" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06302715125503007" MODIFIED="2016-10-19 11:49:25 +0200" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.24098334351286443" P_Q="1.0" P_Z="0.14985720812168368" Q="0.0" RANDOM="NO" SCALE="14.29" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.4400360215389234">
<NAME>OS_irino fraction</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours f
ract</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours s
ingle</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.3363500943744773" CI_START="0.7334160879443968" EFFECT_SIZE="0.9900003324950223" ESTIMABLE="YES" ESTIMATE="-0.01005" LOG_CI_END="0.12592024866133816" LOG_CI_START="-0.13464956774759354" LOG_EFFECT_SIZE="-0.004364659543127671" MODIFIED="2015-09-10 15:15:47 +0200" MODIFIED_BY="[Empty name]" ORDER="25" SE="0.15306" STUDY_ID="STD-Fuchs-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="43.35274525740691"/>
<IV_DATA CI_END="1.0140367808410347" CI_START="0.5999318716098372" EFFECT_SIZE="0.7799698608351326" ESTIMABLE="YES" ESTIMATE="-0.2485" LOG_CI_END="0.006053707883511118" LOG_CI_START="-0.22189806538942733" LOG_EFFECT_SIZE="-0.1079221787529581" MODIFIED="2015-09-10 15:15:47 +0200" MODIFIED_BY="[Empty name]" ORDER="277" SE="0.1339" STUDY_ID="STD-Tsavaris-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="56.64725474259309"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.004501796261938" CI_END="1.1424629432925273" CI_START="0.7081188391154036" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.8994440133419487" ESTIMABLE="YES" I2="50.11229214836158" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.057842122278366354" LOG_CI_START="-0.14989385129183672" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0460258645067352" MODIFIED="2016-10-19 11:49:44 +0200" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.15683317775850258" P_Q="1.0" P_Z="0.38512231313380263" Q="0.0" RANDOM="NO" SCALE="2.49" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.8684970180192293">
<NAME>PFS_irino fraction</NAME>
<GROUP_LABEL_1>Fract</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours f
ract</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours s
ingle</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4744250778457584" CI_START="0.7620598858135821" EFFECT_SIZE="1.0600000973885901" ESTIMABLE="YES" ESTIMATE="0.058269" LOG_CI_END="0.16862270899710585" LOG_CI_START="-0.11801089866506473" LOG_EFFECT_SIZE="0.025305905166020572" MODIFIED="2015-09-10 15:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.16837" STUDY_ID="STD-Fuchs-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="52.52537958447948"/>
<IV_DATA CI_END="1.0612098462631672" CI_START="0.5300363861591355" EFFECT_SIZE="0.7499865544593589" ESTIMABLE="YES" ESTIMATE="-0.2877" LOG_CI_END="0.025801270859785435" LOG_CI_START="-0.2756943157469165" LOG_EFFECT_SIZE="-0.12494652244356551" MODIFIED="2015-09-10 15:19:04 +0200" MODIFIED_BY="[Empty name]" ORDER="278" SE="0.1771" STUDY_ID="STD-Tsavaris-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="47.474620415520526"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.12368135553503669" CI_END="1.530227160952077" CI_START="0.4522481582263349" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8318908673669222" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.18475590625878888" LOG_CI_START="-0.3446231931221418" LOG_EFFECT_SIZE="-0.07993364343167646" METHOD="IV" MODIFIED="2016-10-19 11:50:00 +0200" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.7250756261072826" P_Q="1.0" P_Z="0.5539243428991381" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="101" WEIGHT="100.0" Z="0.5918898666848124">
<NAME>ORR_irino fraction</NAME>
<GROUP_LABEL_1>Irino fraction</GROUP_LABEL_1>
<GROUP_LABEL_2>Irino single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fract</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5317521210612868" CI_START="0.10926715304835702" EFFECT_SIZE="0.6212121212121212" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5479902146583585" LOG_CI_START="-0.9615103723026249" LOG_EFFECT_SIZE="-0.20676007882213318" MODIFIED="2015-09-13 15:25:13 +0200" MODIFIED_BY="[Empty name]" ORDER="1397" O_E="0.0" SE="0.8866881169292964" STUDY_ID="STD-Shoemaker-2004" TOTAL_1="44" TOTAL_2="41" VAR="0.7862158167036215" WEIGHT="12.298920919200537"/>
<DICH_DATA CI_END="1.6614701770967888" CI_START="0.45207619219719236" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.22049255022590053" LOG_CI_START="-0.3447883637235895" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2015-09-13 15:25:29 +0200" MODIFIED_BY="[Empty name]" ORDER="1398" O_E="0.0" SE="0.33204880703958306" STUDY_ID="STD-Tsavaris-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.11025641025641025" WEIGHT="87.70107908079946"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.007662095169557492" CI_END="1.0952577659277165" CI_START="0.8676311575368252" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9748229394372404" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.03951634122715621" LOG_CI_START="-0.061664860411481955" LOG_EFFECT_SIZE="-0.011074259592162898" METHOD="IV" MODIFIED="2016-10-19 11:50:17 +0200" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9961762815246029" P_Q="1.0" P_Z="0.6678975892777417" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="294" TOTAL_2="195" WEIGHT="100.00000000000001" Z="0.4290352279785124">
<NAME>SAE_irino fraction</NAME>
<GROUP_LABEL_1>Irino fract</GROUP_LABEL_1>
<GROUP_LABEL_2>Irino single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fract</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1700117938105437" CI_START="0.8095824553052975" EFFECT_SIZE="0.9732528041415013" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="61" LOG_CI_END="0.06819023949062714" LOG_CI_START="-0.09173891212317219" LOG_EFFECT_SIZE="-0.011774336316272513" MODIFIED="2015-09-13 15:28:51 +0200" MODIFIED_BY="[Empty name]" ORDER="1399" O_E="0.0" SE="0.093943175320014" STUDY_ID="STD-Fuchs-2003" TOTAL_1="190" TOTAL_2="94" VAR="0.008825320189206889" WEIGHT="40.026203476861596"/>
<DICH_DATA CI_END="1.2998260625060618" CI_START="0.7165674111076761" EFFECT_SIZE="0.9650974025974026" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.11388524065466468" LOG_CI_START="-0.1447429470740948" LOG_EFFECT_SIZE="-0.01542885320971506" MODIFIED="2015-09-13 15:29:00 +0200" MODIFIED_BY="[Empty name]" ORDER="1400" O_E="0.0" SE="0.15191947770204983" STUDY_ID="STD-Shoemaker-2004" TOTAL_1="44" TOTAL_2="41" VAR="0.023079527705263614" WEIGHT="15.305515180065289"/>
<DICH_DATA CI_END="1.1661131266836156" CI_START="0.8229048662939933" EFFECT_SIZE="0.9795918367346939" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="49" LOG_CI_END="0.06674068413763086" LOG_CI_START="-0.08465036944348377" LOG_EFFECT_SIZE="-0.008954842652926454" MODIFIED="2015-09-13 15:29:09 +0200" MODIFIED_BY="[Empty name]" ORDER="1401" O_E="0.0" SE="0.08892785427134807" STUDY_ID="STD-Tsavaris-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.00790816326530612" WEIGHT="44.668281343073126"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.6351846097480297" CI_END="1.5269223851984481" CI_START="0.8625634442865322" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.1476355831599945" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.18381696204875325" LOG_CI_START="-0.06420895133851384" LOG_DATA="YES" LOG_EFFECT_SIZE="0.059804005355119726" MODIFIED="2016-10-19 11:50:33 +0200" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.4254601528772485" P_Q="1.0" P_Z="0.34457057981465167" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.9451729863746772">
<NAME>OS_FOLFIRI + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
beva</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.255488782396702" CI_START="0.820069075046725" EFFECT_SIZE="1.3600208085019607" ESTIMABLE="YES" ESTIMATE="0.3075" LOG_CI_END="0.3532406714890043" LOG_CI_START="-0.08614956511850436" LOG_EFFECT_SIZE="0.1335455531852499" MODIFIED="2015-09-13 16:02:01 +0200" MODIFIED_BY="[Empty name]" ORDER="1428" SE="0.2581" STUDY_ID="STD-Bendell-2013_x005f_folfiri" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.863487653304468"/>
<IV_DATA CI_END="1.4981539396572288" CI_START="0.7500363227648799" EFFECT_SIZE="1.0600329579009444" ESTIMABLE="YES" ESTIMATE="0.0583" LOG_CI_END="0.1755564406723816" LOG_CI_START="-0.12491770408246244" LOG_EFFECT_SIZE="0.025319368294959548" MODIFIED="2015-09-13 16:02:11 +0200" MODIFIED_BY="[Empty name]" ORDER="1429" SE="0.1765" STUDY_ID="STD-Hecht-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="68.13651234669553"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.4951873597810339" CI_END="1.5043345868786764" CI_START="0.8087773679915926" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.103028452830867" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.17734444069341393" LOG_CI_START="-0.09217101010484742" LOG_DATA="YES" LOG_EFFECT_SIZE="0.04258671529428331" MODIFIED="2016-10-19 11:50:48 +0200" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.4816224714456857" P_Q="1.0" P_Z="0.5356553621127506" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.6193962383190743">
<NAME>PFS_FOLFIRI + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
beva</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.094633934671998" CI_START="0.7699891884145289" EFFECT_SIZE="1.2699785365838365" ESTIMABLE="YES" ESTIMATE="0.239" LOG_CI_END="0.3211081351576299" LOG_CI_START="-0.11351537280787556" LOG_EFFECT_SIZE="0.10379638117487718" MODIFIED="2015-09-13 16:03:29 +0200" MODIFIED_BY="[Empty name]" ORDER="1428" SE="0.2553" STUDY_ID="STD-Bendell-2013_x005f_folfiri" TOTAL_1="0" TOTAL_2="0" WEIGHT="38.45394576253197"/>
<IV_DATA CI_END="1.5000834382785906" CI_START="0.680096395969467" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.17611541623979046" LOG_CI_START="-0.1674295266017254" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2015-09-13 16:03:39 +0200" MODIFIED_BY="[Empty name]" ORDER="1429" SE="0.2018" STUDY_ID="STD-Hecht-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="61.546054237468034"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.837930062754281" CI_END="2.189487143929492" CI_START="0.9377579760663186" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.432902310946055" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.34034239947704936" LOG_CI_START="-0.027909233285628724" LOG_EFFECT_SIZE="0.15621658309571032" METHOD="IV" MODIFIED="2016-10-19 11:51:05 +0200" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.35998951798183154" P_Q="1.0" P_Z="0.09633674226869947" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.0" Z="1.6628785830954873">
<NAME>ORR_FOLFIRI + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
eva</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2189224836291253" CI_START="0.5539652954162368" EFFECT_SIZE="1.108695652173913" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3461421307492906" LOG_CI_START="-0.256517441916566" LOG_EFFECT_SIZE="0.04481234441636231" MODIFIED="2015-09-13 16:46:42 +0200" MODIFIED_BY="[Empty name]" ORDER="1432" O_E="0.0" SE="0.35400521619692155" STUDY_ID="STD-Bendell-2013_x005f_folfiri" TOTAL_1="46" TOTAL_2="51" VAR="0.12531969309462915" WEIGHT="37.33750068724402"/>
<DICH_DATA CI_END="2.8523150112756177" CI_START="0.9772288713503912" EFFECT_SIZE="1.6695402298850575" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" LOG_CI_END="0.45519748755567035" LOG_CI_START="-0.010003710668170776" LOG_EFFECT_SIZE="0.2225968884437498" MODIFIED="2015-09-13 16:46:56 +0200" MODIFIED_BY="[Empty name]" ORDER="1433" O_E="0.0" SE="0.2732614866197543" STUDY_ID="STD-Hecht-2015" TOTAL_1="87" TOTAL_2="83" VAR="0.07467184006963816" WEIGHT="62.66249931275598"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9903232323830292" CI_END="2.1141280649801653" CI_START="1.1021435845745433" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.526457560427699" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.32513129150008635" LOG_CI_START="0.04223817702603028" LOG_EFFECT_SIZE="0.18368473426305834" METHOD="IV" MODIFIED="2016-10-19 11:51:25 +0200" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.31966362324132025" P_Q="1.0" P_Z="0.010920259106835061" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="142" WEIGHT="100.0" Z="2.545240200241223">
<NAME>SAE_FOLFIRI + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
beva</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.229140961124517" CI_START="1.037015748733075" EFFECT_SIZE="2.0942028985507246" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6262521608192325" LOG_CI_START="0.015785351891390163" LOG_EFFECT_SIZE="0.32101875635531135" MODIFIED="2015-09-13 16:47:20 +0200" MODIFIED_BY="[Empty name]" ORDER="1432" O_E="0.0" SE="0.3585912254236547" STUDY_ID="STD-Bendell-2013_x005f_folfiri" TOTAL_1="46" TOTAL_2="51" VAR="0.12858766695083834" WEIGHT="21.474380367021805"/>
<DICH_DATA CI_END="2.0218447797589096" CI_START="0.9694117073783062" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="30" LOG_CI_END="0.3057478110562903" LOG_CI_START="-0.013491739699814225" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2015-09-13 16:47:31 +0200" MODIFIED_BY="[Empty name]" ORDER="1433" O_E="0.0" SE="0.18752289237539815" STUDY_ID="STD-Hecht-2015" TOTAL_1="91" TOTAL_2="91" VAR="0.03516483516483516" WEIGHT="78.52561963297819"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="3.5823421236744437" CI_END="1.6077141297834137" CI_START="0.807959861046748" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.1397229860377038" ESTIMABLE="YES" I2="72.08530158548089" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.20620882868185422" LOG_CI_START="-0.0926102141745577" LOG_DATA="YES" LOG_EFFECT_SIZE="0.05679930725364822" MODIFIED="2016-10-19 11:51:39 +0200" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.05839692670061358" P_Q="1.0" P_Z="0.45621304650037187" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="0.7450970694492772">
<NAME>OS_FOLFOX + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
eva</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2868129075707866" CI_START="0.36995698121727383" EFFECT_SIZE="0.6899749406147379" ESTIMABLE="YES" ESTIMATE="-0.3711" LOG_CI_END="0.10951540850802743" LOG_CI_START="-0.43184877297662094" LOG_EFFECT_SIZE="-0.16116668223429675" MODIFIED="2015-09-18 14:45:06 +0200" MODIFIED_BY="[Empty name]" ORDER="1440" SE="0.318" STUDY_ID="STD-Bendell-2013_x005f_folfox" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.467548050063854"/>
<IV_DATA CI_END="2.1452850172886153" CI_START="0.9400028058782495" EFFECT_SIZE="1.4200612436299596" ESTIMABLE="YES" ESTIMATE="0.3507" LOG_CI_END="0.3314849996501976" LOG_CI_START="-0.026870850043256737" LOG_EFFECT_SIZE="0.15230707480347044" MODIFIED="2015-09-18 14:45:20 +0200" MODIFIED_BY="[Empty name]" ORDER="1438" SE="0.2105" STUDY_ID="STD-O_x0027_Neil-2014" TOTAL_1="0" TOTAL_2="0" WEIGHT="69.53245194993613"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5920505903478985" CI_END="1.909765387833845" CI_START="0.8250471064162749" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.2552475481618233" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.2809800180186879" LOG_CI_START="-0.08352125451357968" LOG_DATA="YES" LOG_EFFECT_SIZE="0.09872938175255412" MODIFIED="2016-10-19 11:51:53 +0200" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.44162741335017097" P_Q="1.0" P_Z="0.2883456731985682" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.0617577881502835">
<NAME>PFS_FOLFOX + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours b
eva</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.9663682136877783" CI_START="0.5500267888314367" EFFECT_SIZE="1.039978458543684" ESTIMABLE="YES" ESTIMATE="0.0392" LOG_CI_END="0.2936648452354357" LOG_CI_START="-0.2596161578542207" LOG_EFFECT_SIZE="0.017024343690607478" MODIFIED="2015-09-18 14:46:34 +0200" MODIFIED_BY="[Empty name]" ORDER="1440" SE="0.325" STUDY_ID="STD-Bendell-2013_x005f_folfox" TOTAL_1="0" TOTAL_2="0" WEIGHT="43.40168391577935"/>
<IV_DATA CI_END="2.53300349296017" CI_START="0.8301027837624894" EFFECT_SIZE="1.4500528441358083" ESTIMABLE="YES" ESTIMATE="0.3716" LOG_CI_END="0.40363578867419636" LOG_CI_START="-0.08086812972369964" LOG_EFFECT_SIZE="0.1613838294752484" MODIFIED="2015-09-18 14:46:50 +0200" MODIFIED_BY="[Empty name]" ORDER="1438" SE="0.2846" STUDY_ID="STD-O_x0027_Neil-2014" TOTAL_1="0" TOTAL_2="0" WEIGHT="56.598316084220656"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.3498202694673462" CI_END="1.292288129297325" CI_START="0.456454429784541" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.768030364748518" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="0.11135935500040241" LOG_CI_START="-0.3406025738383217" LOG_EFFECT_SIZE="-0.11462160941895964" METHOD="IV" MODIFIED="2016-10-19 11:52:10 +0200" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.5542150939580526" P_Q="1.0" P_Z="0.3201600899772994" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="84" WEIGHT="100.0" Z="0.9941289828920193">
<NAME>ORR_FOLFOX + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
beva</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4855563888010908" CI_START="0.38028348648273536" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3954236202480467" LOG_CI_START="-0.4198925330820699" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2015-09-18 14:49:36 +0200" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.47892074434615933" STUDY_ID="STD-Bendell-2013_x005f_folfox" TOTAL_1="36" TOTAL_2="35" VAR="0.22936507936507933" WEIGHT="30.729225414524894"/>
<DICH_DATA CI_END="1.2926331255696242" CI_START="0.37020435175187155" EFFECT_SIZE="0.691764705882353" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.11147528114549814" LOG_CI_START="-0.4315584804218066" LOG_EFFECT_SIZE="-0.16004159963815423" MODIFIED="2015-09-18 14:49:47 +0200" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.31898071960510704" STUDY_ID="STD-O_x0027_Neil-2014" TOTAL_1="50" TOTAL_2="49" VAR="0.10174869947979191" WEIGHT="69.27077458547511"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.787100528501291" CI_END="1.553636518169163" CI_START="1.033700510073067" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2672785255418824" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="0.19134942075971048" LOG_CI_START="0.01439473057349026" LOG_EFFECT_SIZE="0.10287207566660035" METHOD="IV" MODIFIED="2016-10-19 11:52:25 +0200" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.3749783506731762" P_Q="1.0" P_Z="0.022676678819841187" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="83" WEIGHT="100.0" Z="2.278838307243884">
<NAME>SAE_FOLFOX + beva vs other targeted</NAME>
<GROUP_LABEL_1>Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Beva</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours o
ther</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 
beva</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.11631293457492" CI_START="0.7389822018079881" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7089570998415508" LOG_CI_START="-0.13136602134761166" LOG_EFFECT_SIZE="0.28879553924696955" MODIFIED="2015-09-18 14:50:25 +0200" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.49360996105305016" STUDY_ID="STD-Bendell-2013_x005f_folfox" TOTAL_1="36" TOTAL_2="35" VAR="0.24365079365079367" WEIGHT="4.434365940687015"/>
<DICH_DATA CI_END="1.5302126659208897" CI_START="1.0086446575848833" EFFECT_SIZE="1.2423529411764707" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="34" LOG_CI_END="0.1847517923977651" LOG_CI_START="0.0037381925692364084" LOG_EFFECT_SIZE="0.09424499248350074" MODIFIED="2015-09-18 14:50:36 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.10632828457104791" STUDY_ID="STD-O_x0027_Neil-2014" TOTAL_1="50" TOTAL_2="48" VAR="0.011305704099821744" WEIGHT="95.56563405931298"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-11-06 17:27:08 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-11-06 17:27:08 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAo4AAAEZCAMAAAAuW1S0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-11-06 17:27:08 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYwAAAXbCAIAAACjnx5BAABrW0lEQVR42u2dvW7jyNZ2CRgwHChw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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-10-19 10:52:32 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoEAAAILCAYAAACXeEYGAABLe0lEQVR42u2df2Qd2f//l7Uqqmqp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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-10-19 14:00:11 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu0AAAEwCAMAAAA0KL85AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-10-19 11:45:49 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.06" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvcAAADQCAMAAAC0l74uAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-10-19 11:48:08 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.09" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAACwCAMAAACGllkuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2016-10-19 11:48:29 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.10" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAACwCAMAAACGllkuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2016-10-19 11:03:26 +0200" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.13" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuUAAADgCAMAAACTtuhWAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2016-10-19 11:03:26 +0200" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.14" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuUAAADgCAMAAACTtuhWAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2016-10-19 11:03:26 +0200" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-001.18" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs0AAACQCAMAAADEHqazAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-11-07 11:21:14 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-10-19 14:20:01 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-08-25 09:02:39 +0200" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 14:20:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL search strategy 2016, Issue 4</B>
</P>
<P>#1 MeSH descriptor: [Colorectal Neoplasms] explode all trees</P>
<P>#2 (colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) near/3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*):ti,ab,kw</P>
<P>#3 #1 or #2</P>
<P>#4 MeSH descriptor: [Chemotherapy, Adjuvant] explode all trees</P>
<P>#5 MeSH descriptor: [Salvage Therapy] explode all trees</P>
<P>#6 MeSH descriptor: [Drug Resistance] explode all trees</P>
<P>#7 chemotherap* or salvage therapy or drug resistance:ti,ab,kw</P>
<P>#8 MeSH descriptor: [Antibodies, Monoclonal, Humanized] explode all trees</P>
<P>#9 MeSH descriptor: [Receptor, Epidermal Growth Factor] explode all trees</P>
<P>#10 MeSH descriptor: [Receptors, Vascular Endothelial Growth Factor] explode all trees</P>
<P>#11 MeSH descriptor: [Protein Kinase Inhibitors] explode all trees</P>
<P>#12 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees</P>
<P>#13 (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or target* therap* or antibod* or tyrosine kinase receptor inhibitor or oxaliplatin or cetuximab or irinotecan or camptothecin or protein kinase inhibitor or capecitabine or fluorouracil or leucovorin or conatumumab or panituzumab or bevacizumab or raltitrexed or aflibercept or sorafenib or cediranib or axitinib)</P>
<P>#14 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13</P>
<P>#15 (second line or second-line)</P>
<P>#16 #14 and #15</P>
<P>#17 ((resistant or refractory) adj5 (cisplatin or carboplatin or anthracycline or doxorubicin or platinum))</P>
<P>#18 #16 or #17</P>
<P>#19 #3 and #18</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-10-19 14:20:20 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-08-25 09:02:50 +0200" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 14:20:20 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Ovid MEDLINE 1950 to 18 May 2016</B>
</P>
<P>1. exp Colorectal Neoplasms/</P>
<P>2. ((colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*)).mp.</P>
<P>3. 1 or 2</P>
<P>4. exp Salvage Therapy/</P>
<P>5. exp Drug Resistance/</P>
<P>6. (chemotherap* or salvage therapy or drug resistance).mp.</P>
<P>7. Antibodies/ or exp Antibodies, Monoclonal, Humanized/</P>
<P>8. exp Epidermal Growth Factor/</P>
<P>9. exp Vascular Endothelial Growth Factors/</P>
<P>10. exp Protein Kinase Inhibitors/</P>
<P>11. exp Antineoplastic Combined Chemotherapy Protocols/</P>
<P>12. (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or epidermal growth factor or EGR or EGFR or ErbB-1 or HER1).mp.</P>
<P>13. (target* therap* or antibod* or tyrosine kinase receptor inhibitor or oxaliplatin or cetuximab or irinotecan or camptothecin or protein kinase inhibitor or capecitabine or fluorouracil or leucovorin or conatumumab or panituzumab or bevacizumab or raltitrexed or aflibercept or sorafenib or cediranib or axitinib).mp.</P>
<P>14. or/4-13</P>
<P>15. (second line or second-line).mp.</P>
<P>16. 14 and 15</P>
<P>17. ((resistant or refractory) adj5 (cisplatin or carboplatin or anthracycline or doxorubicin or platinum)).mp.</P>
<P>18. 16 or 17</P>
<P>19. 3 and 18</P>
<P>20. randomized controlled trial.pt.</P>
<P>21. controlled clinical trial.pt.</P>
<P>22. randomized.ab.</P>
<P>23. placebo.ab.</P>
<P>24. clinical trials as topic.sh.</P>
<P>25. randomly.ab.</P>
<P>26. trial.ti.</P>
<P>27. 20 or 21 or 22 or 23 or 24 or 26</P>
<P>28. exp animals/ not humans.sh.</P>
<P>29. 27 not 28</P>
<P>30. 19 and 29</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-10-19 14:20:37 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-08-25 09:03:10 +0200" MODIFIED_BY="[Empty name]">MEDLINE In-process &amp; Other Non-Indexed Citations search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 14:20:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Ovid MEDLINE In-process &amp; Other Non-indexed Citations 1946 to 18 May 2016</B>
</P>
<P>1. exp Colorectal Neoplasms/</P>
<P>2. ((colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*)).mp.</P>
<P>3. 1 or 2</P>
<P>4. exp Salvage Therapy/</P>
<P>5. exp Drug Resistance/</P>
<P>6. (chemotherap* or salvage therapy or drug resistance).mp.</P>
<P>7. Antibodies/ or exp Antibodies, Monoclonal, Humanized/</P>
<P>8. exp Epidermal Growth Factor/</P>
<P>9. exp Vascular Endothelial Growth Factors/</P>
<P>10. exp Protein Kinase Inhibitors/</P>
<P>11. exp Antineoplastic Combined Chemotherapy Protocols/</P>
<P>12. (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or epidermal growth factor or EGR or EGFR or ErbB-1 or HER1).mp.</P>
<P>13. (target* therap* or antibod* or tyrosine kinase receptor inhibitor or oxaliplatin or cetuximab or irinotecan or camptothecin or protein kinase inhibitor or capecitabine or fluorouracil or leucovorin or conatumumab or panituzumab or bevacizumab or raltitrexed or aflibercept or sorafenib or cediranib or axitinib).mp.</P>
<P>14. or/4-13</P>
<P>15. (second line or second-line).mp.</P>
<P>16. 14 and 15</P>
<P>17. ((resistant or refractory) adj5 (cisplatin or carboplatin or anthracycline or doxorubicin or platinum)).mp.</P>
<P>18. 16 or 17</P>
<P>19. 3 and 18</P>
<P>20. random* or placebo or trial or blind* or meta-analys* or meta analys*</P>
<P>21. 19 and 20</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-10-19 14:20:46 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2015-08-25 09:03:19 +0200" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-19 14:20:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Ovid EMBASE 1974 to 18 May 2016</B>
</P>
<P>1. exp colon tumor/</P>
<P>2. exp rectum tumor/</P>
<P>3. ((colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom*)).mp.</P>
<P>4. 1 or 2 or 3</P>
<P>5. exp CHEMOTHERAPY/</P>
<P>6. exp salvage therapy/</P>
<P>7. exp drug resistance/</P>
<P>8. (chemotherap* or salvage therapy or drug resistance).mp.</P>
<P>9. exp monoclonal antibody/ or antibody/</P>
<P>10. exp epidermal growth factor/</P>
<P>11. (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or epidermal growth factor or EGR or EGFR or ErbB-1 or HER1).mp.</P>
<P>12. exp protein kinase inhibitor/</P>
<P>13. exp antineoplastic agent/</P>
<P>14. (target* therap* or antibod* or tyrosine kinase receptor inhibitor or oxaliplatin or cetuximab or irinotecan or camptothecin or protein kinase inhibitor or capecitabine or fluorouracil or leucovorin or conatumumab or panituzumab or bevacizumab or raltitrexed or aflibercept or sorafenib or cediranib or axitinib).mp.</P>
<P>15. or/5-14</P>
<P>16. (second line or second-line).mp.</P>
<P>17. 15 and 16</P>
<P>18. ((resistant or refractory) adj5 (cisplatin or carboplatin or anthracycline or doxorubicin or platinum)).mp.</P>
<P>19. 17 or 18</P>
<P>20. 4 and 19</P>
<P>21. CROSSOVER PROCEDURE.sh.</P>
<P>22. DOUBLE-BLIND PROCEDURE.sh.</P>
<P>23. SINGLE-BLIND PROCEDURE.sh.</P>
<P>24. (crossover* or cross over*).ti,ab.</P>
<P>25. placebo*.ti,ab.</P>
<P>26. (doubl* adj blind*).ti,ab.</P>
<P>27. allocat*.ti,ab.</P>
<P>28. trial.ti.</P>
<P>29. RANDOMIZED CONTROLLED TRIAL.sh.</P>
<P>30. random*.ti,ab.</P>
<P>31. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30</P>
<P>32. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or women).ti.)</P>
<P>33. 31 not 32</P>
<P>34. 20 and 33</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-11-07 11:21:14 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2015-09-18 15:41:23 +0200" MODIFIED_BY="[Empty name]">Criteria for judging risk of bias in the 'Risk of bias' assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-07 11:21:14 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="28">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a random component in the sequence generation process such as:</P>
<UL>
<LI>referring to a random number table;</LI>
<LI>using a computer random number generator;</LI>
<LI>coin tossing;</LI>
<LI>shuffling cards or envelopes;</LI>
<LI>throwing dice;</LI>
<LI>drawing of lots;</LI>
<LI>minimization*.</LI>
</UL>
<P>*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example:</P>
<UL>
<LI>sequence generated by odd or even date of birth;</LI>
<LI>sequence generated by some rule based on date (or day) of admission;</LI>
<LI>sequence generated by some rule based on hospital or clinic record number;</LI>
<LI>Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non-random categorization of participants, for example:</LI>
<LI>allocation by judgement of the clinician;</LI>
<LI>allocation by preference of the participant;</LI>
<LI>allocation based on the results of a laboratory test or a series of tests;</LI>
<LI>allocation by availability of the intervention.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information about the sequence generation process to permit judgement of 'low risk' or 'high risk'.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Allocation concealment </B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Participants and investigators enrolling participants could not foresee assignment because 1 of the following, or an equivalent method, was used to conceal allocation:</P>
<UL>
<LI>central allocation (including telephone, web-based and pharmacy-controlled randomization);</LI>
<LI>sequentially numbered drug containers of identical appearance;</LI>
<LI>sequentially numbered, opaque, sealed envelopes.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:</P>
<UL>
<LI>using an open random allocation schedule (e.g. a list of random numbers);</LI>
<LI>assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered);</LI>
<LI>alternation or rotation;</LI>
<LI>date of birth;</LI>
<LI>case record number;</LI>
<LI>any other explicitly unconcealed procedure.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of 'low risk' or 'high risk'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement - for example, if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;</LI>
<LI>blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;</LI>
<LI>blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>insufficient information to permit judgement of 'low risk' or 'high risk';</LI>
<LI>the study did not address this outcome.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;</LI>
<LI>blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;</LI>
<LI>blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>insufficient information to permit judgement of 'low risk' or 'high risk';</LI>
<LI>the study did not address this outcome.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Iincomplete outcome data </B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>no missing outcome data;</LI>
<LI>reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</LI>
<LI>missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</LI>
<LI>for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</LI>
<LI>for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</LI>
<LI>missing data have been imputed using appropriate methods.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</LI>
<LI>for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</LI>
<LI>for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</LI>
<LI>'as-treated' analysis done with substantial departure of the intervention received from that assigned at randomization;</LI>
<LI>potentially inappropriate application of simple imputation.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>insufficient reporting of attrition/exclusions to permit judgement of 'low risk' or 'high risk' (e.g. number randomized not stated, no reasons for missing data provided);</LI>
<LI>the study did not address this outcome.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Selective reporting </B>
</P>
<P>Reporting bias due to selective outcome reporting.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any of the following:</P>
<UL>
<LI>the study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way;</LI>
<LI>the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any 1 of the following:</P>
<UL>
<LI>not all of the study's prespecified primary outcomes have been reported;</LI>
<LI>1 or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified;</LI>
<LI>1 or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);</LI>
<LI>1 or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;</LI>
<LI>the study report does not include results for a key outcome that would be expected to have been reported for such a study.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of 'low risk' or 'high risk'. It is likely that the majority of studies will fall into this category.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Other bias </B>
</P>
<P>Bias due to problems not covered elsewhere in the table.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'low risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'high risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>There is at least 1 important risk of bias. For example, the study:</P>
<UL>
<LI>had a potential source of bias related to the specific study design used; or</LI>
<LI>has been claimed to have been fraudulent; or</LI>
<LI>had some other problem.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'unclear risk' of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>There may be a risk of bias, but there is either:</P>
<UL>
<LI>insufficient information to assess whether an important risk of bias exists; or</LI>
<LI>insufficient rationale or evidence that an identified problem will introduce bias.</LI>
</UL>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_3" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="3">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 studies included for qualitative and quantitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;26 articles included for qualitative and quantitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;67 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1035 records identified through database searching&lt;/p&gt;" WIDTH="120">
<OUT TEXT="&lt;p&gt;968 records excluded by abstract reading&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;41 full-text articles excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;8 articles retrieved from reference list screening and included for qualitative and quantitative synthesis&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_FCEB45A182E26AA200DA2AF39360FFBF_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="FCEB45A182E26AA200DA2AF39360FFBF"><ADDRESS><DEPARTMENT>Istituto Oncologico Veneto</DEPARTMENT><ORGANISATION>IOV-IRCCS</ORGANISATION><CITY>Padova</CITY><ZIP>35100</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>